[go: up one dir, main page]

WO2025250969A1 - Anti-cd74 antibodies, conjugates and uses thereof - Google Patents

Anti-cd74 antibodies, conjugates and uses thereof

Info

Publication number
WO2025250969A1
WO2025250969A1 PCT/US2025/031700 US2025031700W WO2025250969A1 WO 2025250969 A1 WO2025250969 A1 WO 2025250969A1 US 2025031700 W US2025031700 W US 2025031700W WO 2025250969 A1 WO2025250969 A1 WO 2025250969A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
seq
acid sequence
substitutions
hcdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/031700
Other languages
French (fr)
Inventor
Caitlin STEIN
Emily RADKE
Bradley R. PEARSE
Anthony Boitano
Kellie LATIMER
Sean MCDONOUGH
Patrick C. Falahee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of WO2025250969A1 publication Critical patent/WO2025250969A1/en
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • Hematologic malignancies and non-malignant disorders are currently treated with high dose or lethal chemotherapy and/or radiation therapy conditioning regimens that are highly toxic to multiple organ systems, hematopoietic and non-hematopoietic cells, and the hematopoietic microenvironment prior to hematopoietic cell transplantation.
  • These harsh conditioning regimens effectively kill the host subject's immune and niche cells and oftentimes adversely affect multiple organ systems, that may lead to life-threatening complications.
  • conditioning regimens that avoid undesirable toxicity, minimize the incidence of serious adverse reactions, and reduce a patient’s risk of relapse.
  • an isolated anti-CD74 antibody is provided. Such isolated anti-CD74 antibody binds to human CD74, wherein the antibody is optionally fully human or humanized. [0007] Accordingly, the following non-limiting embodiments are provided. Embodiment 1.
  • an isolated antibody that binds human CD74 comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105;
  • Embodiment 2 An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions
  • Embodiment 3 The isolated antibody of embodiment 1 or embodiment 2, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a heavy chain variable region (VH) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of embodiment 1.ii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of embodiment 1.iii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of embodiment 1.iv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of embodiment 1.v) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of embodiment 1.vi) and further comprises a VH that is at
  • Embodiment 4 The isolated antibody of any one of claims 1-3, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of embodiment 1.ii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of embodiment 1.iii) and further comprises a comprising the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of embodiment 1.iv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of embodiment 1.v) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 512; or Attorney Docket No.01245-0062-00PCT vi) the CDRs of embodiment 1.vi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 612; or vii) the
  • Embodiment 5 The isolated antibody of any one of embodiments 1-4, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a light chain variable region (VL) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of embodiment 1.ii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or Attorney Docket No.01245-0062-00PCT iii) the CDRs of embodiment 1.iii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of embodiment 1.iv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of embodiment 1.v) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the C
  • Embodiment 6 The isolated antibody of any one of embodiments 1-5, wherein the antibody comprises: Attorney Docket No.01245-0062-00PCT i) the CDRs of embodiment 1.i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of embodiment 1.ii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of embodiment 1.iii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of embodiment 1.iv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of embodiment 1.v) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of embodiment 1.vi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 618; or
  • Embodiment 7 The isolated antibody of any one of embodiments 1-6, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ
  • Embodiment 8 The isolated antibody of any one of embodiments 1-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH comprises the amino acid sequence of SEQ ID NO: 12 and the VL comprises the amino acid sequence of SEQ ID NO: 18; or ii) the VH comprises the amino acid sequence of SEQ ID NO: 112 and the VL comprises the amino acid sequence of SEQ ID NO: 118; or iii) the VH comprises the amino acid sequence of SEQ ID NO: 212 and the VL comprises the amino acid sequence of SEQ ID NO: 218; or iv) the VH comprises the amino acid sequence of SEQ ID NO: 312 and the VL comprises the amino acid sequence of SEQ ID NO: 318; or v) the VH comprises the amino acid sequence of SEQ ID NO: 512 and the VL comprises the amino acid sequence of SEQ ID NO: 518; or vi) the VH comprises the amino acid sequence of SEQ ID NO:
  • Embodiment 9 An isolated antibody that binds human CD74, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID
  • Embodiment 10 The isolated antibody of embodiment 9, wherein the antibody comprises: i) the VH and VL of embodiment 8.i and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) the VH and VL of embodiment 8.ii and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO
  • Embodiment 11 The isolated antibody of embodiment 9 or embodiment 10, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 12, 112, 212, 312, 512, 612, 712, 812, 912, 1012, 1112, 1212, 1312, 1412, 1512, 1612, 1712, or 1812.
  • Embodiment 13 The isolated antibody of any one of the preceding embodiments, wherein the antibody is a monoclonal antibody.
  • Embodiment 14 The isolated antibody of any one of the preceding embodiments, wherein the antibody is an antibody fragment.
  • Embodiment 16 The isolated antibody of any one of embodiments 1-13, wherein the antibody is a full-length antibody.
  • Embodiment 17. The isolated antibody of any one of embodiments 1-13, wherein an Fc region of the antibody comprises IgG1, IgG2, IgG3, or IgG4.
  • Embodiment 18. The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG1 heavy chain constant region.
  • Embodiment 19 The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG4 heavy chain constant region.
  • Embodiment 20 The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG4 heavy chain constant region.
  • the isolated antibody of embodiment 18, wherein the antibody comprises a mutant human IgG1 heavy chain constant region.
  • Embodiment 21 The isolated antibody of embodiment 20, wherein the mutant IgG1 heavy chain constant region comprises a mutation selected from a substitution at L234, a substitution at L235, a substitution at P329, or a combination thereof, according to EU numbering.
  • Embodiment 22 The isolated antibody of embodiment 21, wherein the mutant IgG1 heavy chain constant region comprises an L234A substitution, an L234A substitution, and a P329A substitution or a combination thereof, according to EU numbering.
  • Embodiment 23 The isolated antibody of any one of embodiments 20-22, wherein the mutant IgG1 heavy chain constant region comprises a deletion of K447, according to EU numbering.
  • Embodiment 24 The isolated antibody of any one of embodiments 20-23, wherein the mutant IgG heavy chain constant region comprises a substitution at S239, according to EU numbering. Attorney Docket No.01245-0062-00PCT Embodiment 25. The isolated antibody of any one of embodiments 20-24, wherein the mutant IgG heavy chain constant region comprises an S239C substitution, according to EU numbering.
  • Embodiment 26 The isolated antibody of any one of embodiments 1-13 and 16-25, wherein the antibody comprises a human IgG kappa light chain constant region.
  • Embodiment 27 The isolated antibody of any one of embodiments 1-26, further comprising an effector molecule conjugated to the antibody.
  • Embodiment 28 The isolated antibody of any one of embodiments 1-26, further comprising an effector molecule conjugated to the antibody.
  • the isolated antibody of embodiment 27, wherein the effector molecule comprises a cytotoxic agent.
  • Embodiment 29. The isolated antibody of embodiment 28, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor.
  • DGN549C Monoimine indolinobenzodiazepene
  • Tesirine Tesirine
  • Talirine Duocarmycin
  • Duocarmycin secoDUBA prodrug
  • NMS249 anthracycline
  • PNU anthracycline
  • Dxd exatecan
  • MMAF Monomethyl auristatin F
  • MMAE Monomethyl auristatin E
  • DM4 Ravtansine
  • Embodiment 33 A humanized or fully human version of the antibody of any one of the preceding embodiments.
  • Embodiment 34 A humanized or fully human version of the antibody of any one of the preceding embodiments.
  • Embodiment 35 The conjugate of embodiment 34, wherein the effector molecule comprises a cytotoxic agent.
  • the conjugate of embodiment 35, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor.
  • cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD).
  • DGN549C Monoimine indolinobenzodiazepene
  • Tesirine Tesirine
  • Talirine Duocarmycin
  • Duocarmycin secoDUBA prodrug
  • NMS249 anthracycline
  • PNU anthracycline
  • Dxd exatecan
  • MMAF Monomethyl auristatin F
  • MMAE Monomethyl auristatin E
  • DM4 Ravtansine
  • PPD Pyrrolobenzodiazepine
  • the conjugate of any one of embodiments 34-38, wherein the anti-CD74 antibody comprises the isolated antibody of any one of claims 1, 3-12 and 16-26.
  • Embodiment 40 A composition comprising the antibody of any one of embodiments 1-33 and a pharmaceutically acceptable carrier.
  • Embodiment 41. A method of conditioning a subject to reduce an endogenous population of hematopoietic stem cells in the subject comprising administering an anti-CD74 antibody to the subject, the anti-CD74 antibody comprising the isolated antibody of any one of embodiments 1-13 and 16-26.
  • Embodiment 42 The method of embodiment 41, further comprising an effector molecule conjugated to the antibody.
  • Embodiment 43 The method of embodiment 42, wherein the effector molecule comprises a cytotoxic agent.
  • Embodiment 44 The method of embodiment 43, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor.
  • Embodiment 45 The method of embodiment 43 or embodiment 44, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD).
  • DGN549C Monoimine indolinobenzodiazepene
  • Tesirine Tesirine
  • Talirine Duocarmycin (secoDUBA prodrug)
  • NMS249 anthracycline
  • PNU anthracycl
  • Embodiment 47 The method of any one of embodiments 41-46, wherein the anti-CD74 antibody is internalized by the endogenous population of hematopoietic stem cells. Attorney Docket No.01245-0062-00PCT Embodiment 48. The method of any one of embodiments 41-47, wherein the anti-CD74 antibody comprises an effector silencing modification. Embodiment 49. The method of any one of embodiments 41-48, wherein the hematopoietic stem cells are reduced in bone marrow. Embodiment 50.
  • Embodiment 51 The method of any one of embodiments 41-50, wherein the hematopoietic stem cells are human cells.
  • Embodiment 52 The method of any one of embodiments 41-51, comprising administering a composition comprising cells following the conditioning of the subject to reduce the endogenous population of hematopoietic stem cells.
  • Embodiment 53 The method of any one of embodiments 41-52, comprising administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs).
  • Embodiment 54 The method of any one of embodiments 41-49, wherein the hematopoietic stem cells are CD34+ cells.
  • Embodiment 55 The method of any one of embodiments 41-53, comprising administering a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs) that comprise a genetic modification.
  • Embodiment 55 The method of any one of embodiments 41-54, wherein the subject has a hemoglobinopathy. Examples of a hemoglobinopathy include, for example, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
  • SCD sickle cell disease
  • TDT transfusion-dependent beta thalassemia
  • Embodiment 56 A nucleic acid encoding the antibody of any one of embodiments 1-26.
  • Embodiment 57 A host cell comprising the nucleic acid of embodiment 56.
  • Embodiment 58 The method of any one of embodiments 41-53, comprising administering a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs) that comprise
  • FIG.1 depicts an exemplary anti-CD74 antibody conjugated to an exemplary effector molecule.
  • FIGS.2A-2D show the binding of anti-CD74 antibodies from clone 1 (FIG.2A), clone 22 (FIG.2B), and clone 41 (FIG.2C) to primary human bone marrow CD34+ cells.
  • FIG. 2D shows the antibody EC50 for each of the clones.
  • FIGS.3A-3B show the binding of clone 3 anti-CD74 antibody to all CD34+CD90+ cells (FIG.3A), and FIG.3B shows the antibody EC50 comparison of clone 1 to clone 3.
  • FIGS.4A-4D show binding of anti-CD74 antibody and ADC equivalent binding to primary human bone marrow CD34+ cells for clones 1, 3, 22, and 41.
  • FIGS.5A-5C show the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells for each of clones 1, 22, and 41.
  • FIG.5A shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ CD90+ cells.
  • FIG.5B shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ CD90- cells.
  • FIG.5C shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells.
  • FIGS.6A-6B show the internalization of anti-CD74 antibodies into primary human bone marrow CD34+ cells.
  • FIG.6A shows the internalization of anti-CD74 antibodies into primary human bone marrow CD34+CD90+ cells.
  • FIG.6B shows the internalization of anti- CD74 antibodies into primary human bone marrow CD34+CD90 - cells.
  • FIG.7 shows effector silencing of anti-CD74 antibodies.
  • FIGS.8A-8B show the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells.
  • FIG.8A shows the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells by cell number.
  • FIG.8B shows the cytotoxic effect of anti- CD74 ADCs on primary human bone marrow CD34+ cells by percent.
  • FIG.9 shows the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells for clone 3.
  • FIGS.10A-10B show the cytotoxic effect of anti-CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells.
  • FIG.10A shows the cytotoxic effect of anti- CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells by cell number.
  • FIG. 10B shows the cytotoxic effect of anti-CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells by percent.
  • FIGS.11A-11B show the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line.
  • FIG.11A shows the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line by cell number.
  • FIG.11B shows the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line by percent.
  • FIG.12A-12B show the lack of cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line.
  • FIG.12A shows the cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line by cell number.
  • FIG.12B shows the cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line by percent.
  • FIG.13A-13C show evaluation of anti-CD74 antibody in Fc-dependent functional assays.
  • FIG.13A shows ADCC.
  • FIG.13B shows ADCP.
  • FIG.13C shows CDC.
  • FIG.14A-14B show CD74 copy expression on cryopreserved human (FIG.14A) and NHP (FIG.14B) CD34+ bone marrow cell subsets.
  • FIG.15 shows CD74 expression on peripheral blood leukocyte subsets of human healthy donors, human subjects with SCD, and NHPs.
  • FIGS.16A-16B show bone marrow hematopoietic stem cell and progenitor cell depletion following a single IV administration of anti-CD74-DGN549c in humanized mice.
  • FIG.16A shows administration of V-003-0105-001 and FIG.16B shows administration of anti- CD74 ADC.
  • FIGS.17A-17B show bone marrow hematopoietic stem cell and progenitor cell depletion following a single IV administration of anti-CD74-ADC in nonhuman primates at day 7 (FIG.17A) and day 21 (FIG.17B).
  • FIGS.18A-18B show kinetics of neutrophil (FIG.18A) and platelet (FIG, 18B) depletion following a single IV administration of anti-CD74-ADC in nonhuman primates.
  • FIGS.19A-19B show neutrophil (FIG.19A) and neutrophil (FIG.19B) engraftment following conditioning with a single IV administration of anti-CD74 ADC compared to a 4-day regimen of busulfan in nonhuman primates.
  • FIG.20 shows gene-edited chimerism following conditioning with a single IV administration of anti-CD74 ADC compared to a 4-day regimen of busulfan in nonhuman primates.
  • FIGS.21A-21B show plasma PK profiles of total ADC (FIG.21A) and total antibody (FIG.21B) in cynomolgus monkeys following single IV administration of anti-CD74 ADC.
  • FIG.22A-22B show individual plasma concentration-time profile of total antibody (FIG.22A) and total ADC (FIG.22B) following single IV administration of anti-CD74 ADC in cynomolgus monkeys.
  • FIG.23 shows individual plasma concentration-time profile of free payload FGN849 following single IV administration of anti-CD74 ADC in cynomolgus monkeys.
  • mouse CD74 cynomolgus CD74, etc.
  • the term includes full-length, unprocessed CD74 as well as any form of CD74 that results from processing in a cell.
  • the term encompasses naturally occurring variants of human CD74, e.g., splice variants or allelic variants.
  • External ID’s for CD74 gene include HGNC: 1697, NCBI Gene: 972, Ensembl: ENSG00000019582, OMIM: 142790, and UniProtKB: P04233.
  • “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen).
  • binding affinity refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen).
  • the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K D ). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
  • An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations optionally resulting in an improvement in the affinity of the antibody for antigen.
  • HVRs hypervariable regions
  • antibody herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.
  • An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH, Attorney Docket No.01245-0062-00PCT F(ab') 2 ; diabodies; linear antibodies; single-chain antibody molecules (e.g.
  • scFv multispecific antibodies formed from antibody fragments.
  • block in the context of an interaction between two or more molecules, is used herein to refer to inhibition or prevention of said interaction between the two or more molecules, wherein the inhibition or prevention of said interaction between the two or more molecules is complete or nearly complete under at least one condition.
  • a “nearly complete” inhibition is a percent inhibition of about 70 - 99.9 %, and a “complete” inhibition is 100%.
  • a molecule is said to “block” an interaction between two or more other molecules if it completely or nearly completely inhibits such interaction at certain concentrations in a dose dependent manner.
  • cancer is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth.
  • a cancer may be benign (also referred to as a benign tumor), pre-malignant, or malignant.
  • Cancer cells may be solid cancer cells or leukemic cancer cells.
  • tumor is used herein to refer to a cell or cells that comprise a cancer.
  • tumor growth is used herein to refer to proliferation or growth by a cell or cells that comprise a cancer that leads to a corresponding increase in the size or extent of the cancer.
  • chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
  • the “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG 2 , IgG 3 , IgG 4 , IgA 1 , and IgA 2 .
  • the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
  • Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive (sequential) administration in any order.
  • conjugate refers to the linkage of an antibody or an antigen binding fragment thereof with another effector molecule, such as a cytotoxic agent, an immunotherapeutic agent, an imaging probe, and the like.
  • the linkage can be covalent bonds, or non-covalent interactions such as through electrostatic forces.
  • the conjugate can be provided in the form of a fusion protein that may be expressed from a polynucleotide encoding the conjugate.
  • fusion protein refers to proteins created through the joining of two or more genes or gene fragments which Attorney Docket No.01245-0062-00PCT originally coded for separate proteins (including peptides and polypeptides). Translation of the fusion gene results in a single protein with functional properties derived from each of the original proteins.
  • cytotoxic agent refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction.
  • Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 , Sm 153 , Bi 212 , P 32 , Pb 212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins (e.g., DNA inhibitors, topoisomerase inhibitors, or a tubulin inhibitors) or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments
  • Appector functions refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
  • An “effective amount” of an agent e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
  • Fc region herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region.
  • the term includes native sequence Fc regions and variant Fc regions.
  • a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
  • the C-terminal lysine (Lys447) of the Fc region may or may not be present (numbering in this paragraph is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed.
  • “Framework,” “framework region,” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues.
  • the FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3- H3(L3)-FR4.
  • full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
  • host cell “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells.
  • Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell and may contain mutations.
  • a “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non- human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
  • the term "humanized” refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulins.
  • a humanized form of an antibody some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen.
  • a "humanized” antibody retains an antigenic specificity similar to that of the original antibody.
  • the term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
  • variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs).
  • FRs conserved framework regions
  • HVRs hypervariable regions
  • a single VH or VL domain may be sufficient to confer antigen-binding specificity.
  • antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J.
  • a “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols.1-3.
  • the subgroup is subgroup kappa I as in Kabat et al., supra. In some embodiments, for the VH, the subgroup is subgroup III as in Kabat et al., supra.
  • the term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3).
  • the CDRs are the target protein-binding site of the antibody chains that harbors specificity for such target protein.
  • CDRs can be referred to by their region and order.
  • VHCDR1 or “HCDR1” both refer to the first CDR of the heavy chain variable region.
  • the CDRs are structurally complementary to the epitope of the target protein and are thus directly responsible for the binding specificity.
  • the remaining stretches of the VL or VH, the so-called framework regions exhibit less variation in amino acid sequence (Kuby, Immunology, 4th ed., Chapter 4. W.H.
  • the amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme) and ImMunoGenTics (IMGT) numbering (Lefranc, M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp.
  • An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to an effector molecule, such as a cytotoxic agent.
  • An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.
  • an “isolated” antibody is one which has been separated from a component of its natural environment.
  • an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
  • electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
  • chromatographic e.g., ion exchange or reverse phase HPLC
  • the term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts.
  • polyclonal antibody preparations typically include different antibodies directed against different determinants (epitopes)
  • each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen.
  • the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method.
  • the monoclonal antibodies to be used in accordance with the present disclosure may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.
  • a “naked antibody” refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel.
  • the naked antibody may be present in a pharmaceutical formulation.
  • “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3).
  • VH variable region
  • each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain.
  • VL variable region
  • CL constant light
  • the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
  • ALIGN-2 sequence comparison computer program
  • the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087.
  • the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
  • ALIGN-2 The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. [0062] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total number of amino acid residues in B.
  • a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation or composition, other than an active ingredient, which is nontoxic to a subject.
  • a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
  • treatment and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated and can be performed either for prophylaxis or during the course of clinical pathology.
  • Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis.
  • antibodies of the disclosure are used to delay development of a disease or to slow the progression of a disease.
  • vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”
  • expression vectors Such vectors are referred to herein as “expression vectors.”
  • COMPOSITIONS AND METHODS [0067] Anti-CD74 antibodies, anti-CD74 antibody conjugates, compositions comprising the described antibodies, and methods of their use are provided.
  • A. Exemplary Anti-CD74 Antibodies [0068] The Sequence Table below provides the sequences of certain embodiments of the antibodies disclosed and claimed herein. [0069] In some embodiments, antibodies are provided that bind to CD74. [0070] In some embodiments, the antibodies bind to human CD74. In some embodiments, the antibodies bind to human and/or cynomolgus CD74.
  • an anti-CD74 antibody comprises a heavy chain variable region (“VH”) comprising VH CDR1, CDR2 and/or CDR3 of any of the anti-CD74 antibodies Attorney Docket No.01245-0062-00PCT provided herein (i.e., antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56).
  • VH heavy chain variable region
  • an anti-CD74 antibody comprises a VH comprising VH CDR1, CDR2 and/or CDR3 of any of the anti-CD74 antibodies provided herein and a VL comprising CDR1, CDR2 and/or CDR3 of any of the CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VH comprising VH CDR1, CDR2 and/or CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, and a VL comprising VL CDR1, CDR2, and/or CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, optionally wherein the VH and VL CDRs are from the same antibody clone.
  • antibodies comprising the following are provided: (a) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and
  • antibodies comprising the following are provided: (a) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or (b) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of S
  • an anti-CD74 antibody comprises a VL comprising VL CDR1, CDR2 and CDR3 of any of the anti-CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VL comprising VL CDR1, CDR2 and CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody may comprise: Attorney Docket No.01245-0062-00PCT (a) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 22 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 22; or (b) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 3 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 3; or (c) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 1 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 1; or (d) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of
  • an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any of the CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any one of the antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions.
  • an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions.
  • an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions outside the complementarity determining regions (CDRs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions outside the CDRs.
  • CDRs complementarity determining regions
  • an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions outside the complementarity determining regions (CDRs).
  • an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions.
  • an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, or 5 reversion substitutions in the framework regions of the VH sequence.
  • an anti-CD74 antibody comprises the VH and VL CDRs of any of the anti-CD74 antibodies described herein, wherein each CDR comprises 0, 1, 2 or 3 amino acid additions, substitutions (e.g., conservative substitutions), or deletions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VH of any of the anti-CD74 antibodies provided herein.
  • a CD74 antibody comprises a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of any one of the anti-CD74 antibodies provided herein.
  • an isolated antibody that binds human CD74 comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: a) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or b) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, Attorney Docket No.01245-0062-00PCT 91%, 92%, 93%, 94%, 95%, 96%, 97%,
  • the isolated antibody comprises: a) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL is at least 90%, 91%, 92%, Attorney Docket No.01245-0062-00PCT 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ
  • an anti-CD74 antibody comprises a VH CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VH CDRs of any of the anti-CD74 antibodies provided herein and comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH of any of the anti-CD74 antibodies provided herein.
  • a CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • the VH of the antibody differs from that of the VH sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions.
  • an anti-CD74 antibody comprises a VH consisting of the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH that consists of the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody comprises a VL comprising the amino acid sequence of the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of the corresponding anti-CD74 antibody.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VH of any one of Attorney Docket No.01245-0062-00PCT antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56
  • an anti-CD74 antibody comprises a VH consisting of the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and a VL comprising the amino acid sequence of the VL of the corresponding anti-CD74 antibody.
  • an anti-CD74 antibody comprises a VH that consists of the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL that consists of the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, respectively (i.e., the VH and VL of clone 22, the VH and VL of clone 3, the VH and VL of clone 1, the VH and VL of clone 41, the VH and VL of clone 93, the VH and VL of clone 95, the VH and VL of clone 4, the VH and VL of clone 7, the VH and VL of clone 7,
  • an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions.
  • an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions.
  • an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions outside the complementarity determining regions (CDRs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions outside the CDRs.
  • CDRs complementarity determining regions
  • an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but Attorney Docket No.01245-0062-00PCT with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions outside the complementarity determining regions (CDRs).
  • an anti-CD74 antibody comprises a VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VL CDRs of any of the anti-CD74 antibodies provided herein and comprises a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VL of any of the anti-CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • the VL of the antibody differs from that of the VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VL sequence, such as 1, 2, 3, 4, or 5 conservative substitutions.
  • an anti-CD74 antibody comprises a VL consisting of the amino acid sequence of the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL that consists of the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1,41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and comprises a VL comprising the amino acid sequence of the VL of any of the same anti-CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL comprising the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, or 41, optionally wherein the VH and VL are from the same antibody clone number.
  • the VH of the antibody is that of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, but with 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions, and the VL is that of any one of the same antibody from the list above.
  • the VH of the antibody is that of any one of antibody Attorney Docket No.01245-0062-00PCT clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, but with 1, 2, 3, 4, or 5 substitutions in the framework regions of the VH sequence.
  • an anti-CD74 antibody comprises a VH and a VL comprising the amino acid sequences of the VH and VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody comprises a VH CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VH CDRs of any of the anti-CD74 antibodies provided herein as well as a VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VL CDRs of any of the anti-CD74 antibodies provided herein, and also comprises a VH and a VL that are each at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the corresponding VH and VL of any of the anti-CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VH and a VL consisting of the amino acid sequence of the VH and VL of any of the anti-CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a VH and a VL that each consist of the amino acid sequences of the VH and VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • An anti-CD74 antibody may comprise: (a) a VH comprising the amino acid sequence of the VH of antibody clone number 22 and a VL comprising the amino acid sequence of the VL of antibody clone number 22; or (b) a VH comprising the amino acid sequence of the VH of antibody clone number 3 and a VL comprising the amino acid sequence of the VL of antibody clone number 3; or (c) a VH comprising the amino acid sequence of the VH of antibody clone number 1 and a VL comprising the amino acid sequence of the VL of antibody clone number 1; or (d) a VH comprising the amino acid sequence of the VH of antibody clone number 41 and a VL comprising the amino acid sequence of the VL of antibody clone number 41; or (e) a VH comprising the amino acid sequence of the VH of antibody clone number 93 and a VL comprising the amino acid sequence of the VL of
  • An anti-CD74 antibody may comprise: (a) a VH comprising the VH CDRs of the VH of antibody clone number 22, and a VL comprising the VL CDRs of antibody clone number 22, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 22; or (b) a VH comprising the VH CDRs of the VH of antibody clone number 3, and a VL comprising the VL CDRs of antibody clone number 3, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and
  • An anti-CD74 antibody may comprise: (a) a VH consisting of the amino acid sequence of the VH of antibody clone number 22 and a VL consisting of the VL of antibody clone number 22; or (b) a VH consisting of the amino acid sequence of the VH of antibody clone number 3 and a VL consisting of the VL of antibody clone number 3; or (c) a VH consisting of the amino acid sequence of the VH of antibody clone number 1 and a VL consisting of the VL of antibody clone number 1; or (d) a VH consisting of the amino acid sequence of the VH of antibody clone number 41 and a VL consisting of the VL of antibody clone number 41; or (e) a VH consisting of the amino acid sequence of the VH of antibody clone number 93 and a VL consisting of the VL of antibody clone number 93; or (f) a
  • an anti-CD74 antibody comprises any of the variable regions and/or variable region CDRs 1-3 of the antibodies described above and elsewhere herein, such as in the Sequence Table.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 12 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 18.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the Attorney Docket No.01245-0062-00PCT amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 12 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 22 and a VL comprising an Attorney Docket No.01245-0062-00PCT amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 22.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 22 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 22; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22.
  • an anti-CD74 antibody comprises HCDR1 of clone 22 or HCDR1 of clone 22 with one or two amino acid substitutions, HCDR2 of clone 22 or HCDR2 of clone 22 with one or two amino acid substitutions, HCDR3 of clone 22 or HCDR3 of clone 22 with one or two amino acid substitutions, LCDR1 of clone 22 or LCDR1 of clone 22 with one or two amino acid substitutions, LCDR2 of clone 22 or LCDR2 of clone 22 with one or two amino acid substitutions, and LCDR3 of clone 22 or LCDR3 of clone 22 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 118.
  • an anti- Attorney Docket No.01245-0062-00PCT CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of S
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f)
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 3 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 3.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 3 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 3; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3.
  • an anti-CD74 antibody comprises HCDR1 of clone 3 or HCDR1 of clone 3 with one or two amino acid substitutions, HCDR2 of clone 3 or HCDR2 of clone 3 with one or two amino acid substitutions, HCDR3 of clone 3 or HCDR3 of clone 3 with one or two amino acid substitutions, LCDR1 of clone 3 or LCDR1 of clone 3 with one or two amino acid substitutions, LCDR2 of clone 3 or LCDR2 of clone 3 with one or two amino acid substitutions, and LCDR3 of clone 3 or LCDR3 of clone 3 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% Attorney Docket No.01245-0062-00PCT identical to the amino acid sequence of SEQ ID NO: 218.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 218.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO:
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 1 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 1.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 1 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 1; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1.
  • an anti-CD74 antibody comprises HCDR1 of clone 1 or HCDR1 of clone 1 with one or two amino acid substitutions, HCDR2 of clone 1 or HCDR2 of clone 1 with one or two amino acid substitutions, HCDR3 of clone 1 or HCDR3 of clone 1 with one or two amino acid substitutions, LCDR1 of clone 1 or LCDR1 of clone 1 with one or two amino acid substitutions, LCDR2 of clone 1 or LCDR2 of clone 1 with one or two amino acid substitutions, and LCDR3 of clone 1 or LCDR3 of clone 1 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 318.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 41 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 41.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 41 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 41; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41.
  • an anti-CD74 antibody comprises HCDR1 of clone 41 or HCDR1 of clone Attorney Docket No.01245-0062-00PCT 41 with one or two amino acid substitutions, HCDR2 of clone 41 or HCDR2 of clone 41 with one or two amino acid substitutions, HCDR3 of clone 41 or HCDR3 of clone 41 with one or two amino acid substitutions, LCDR1 of clone 41 or LCDR1 of clone 41 with one or two amino acid substitutions, LCDR2 of clone 41 or LCDR2 of clone 41 with one or two amino acid substitutions, and LCDR3 of clone 41 or LCDR3 of clone 41 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 518.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 93 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 93.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 93 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 93; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93.
  • an anti-CD74 antibody comprises HCDR1 of clone 93 or HCDR1 of clone 93 with one or two amino acid substitutions, HCDR2 of clone 93 or HCDR2 of clone 93 with one or two amino acid substitutions, HCDR3 of clone 93 or HCDR3 of clone 93 with one or two amino acid substitutions, LCDR1 of clone 93 or LCDR1 of clone 93 with one or two amino acid substitutions, LCDR2 of clone 93 or LCDR2 of clone 93 with one or two amino acid substitutions, and LCDR3 of clone 93 or LCDR3 of clone 93 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 618.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 618; and (a) Attorney Docket No.01245-0062-00PCT HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 95 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 95.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 95 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions Attorney Docket No.01245-0062-00PCT compared to the amino acid sequence of clone 95.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 95 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 95; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 95 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 95; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95.
  • an anti-CD74 antibody comprises HCDR1 of clone 95 or HCDR1 of clone 95 with one or two amino acid substitutions, HCDR2 of clone 95 or HCDR2 of clone 95 with one or two amino acid substitutions, HCDR3 of clone 95 or HCDR3 of clone 95 with one or two amino acid substitutions, LCDR1 of clone 95 or LCDR1 of clone 95 with one or two amino acid substitutions, LCDR2 of clone 95 or LCDR2 of clone 95 with one or two amino acid substitutions, and LCDR3 of clone 95 or LCDR3 of clone 95 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 718.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 4 and a VL comprising an amino Attorney Docket No.01245-0062-00PCT acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 4.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 4 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 4; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4.
  • an anti-CD74 antibody comprises HCDR1 of clone 4 or HCDR1 of clone 4 with one or two amino acid substitutions, HCDR2 of clone 4 or HCDR2 of clone 4 with one or two amino acid substitutions, HCDR3 of clone 4 or HCDR3 of clone 4 with one or two amino acid substitutions, LCDR1 of clone 4 or LCDR1 of clone 4 with one or two amino acid substitutions, LCDR2 of clone 4 or LCDR2 of clone 4 with one or two amino acid substitutions, and LCDR3 of clone 4 or LCDR3 of clone 4 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 818.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, Attorney Docket No.01245-0062-00PCT 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 7 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 7.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 7 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 7; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7.
  • an anti-CD74 antibody comprises HCDR1 of clone 7 or HCDR1 of clone 7 with one or two amino acid substitutions, HCDR2 of clone 7 or HCDR2 of clone 7 with one or two amino acid substitutions, HCDR3 of clone 7 or HCDR3 of clone 7 with one or two amino acid substitutions, LCDR1 of clone 7 or LCDR1 of clone 7 with one or two amino acid substitutions, LCDR2 of clone 7 or LCDR2 of clone 7 with one or two amino acid substitutions, and LCDR3 of clone 7 or LCDR3 of clone 7 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% Attorney Docket No.01245-0062-00PCT identical to the amino acid sequence of SEQ ID NO: 918.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 912 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 918.
  • an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 912 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO:
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 53 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 53.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 53 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 53; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53.
  • an anti-CD74 antibody comprises HCDR1 of clone 53 or HCDR1 of clone 53 with one or two amino acid substitutions, HCDR2 of clone 53 or HCDR2 of clone 53 with one or two amino acid substitutions, HCDR3 of clone 53 or HCDR3 of clone 53 with one or two amino acid substitutions, LCDR1 of clone 53 or LCDR1 of clone 53 with one or two amino acid substitutions, LCDR2 of clone 53 or LCDR2 of clone 53 with one or two amino acid substitutions, and LCDR3 of clone 53 or LCDR3 of clone 53 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1012 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1018.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1012 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence Attorney Docket No.01245-0062-00PCT of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 66 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 66.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 66 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 66; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66.
  • an anti-CD74 antibody comprises HCDR1 of clone 66 or HCDR1 of clone Attorney Docket No.01245-0062-00PCT 66 with one or two amino acid substitutions, HCDR2 of clone 66 or HCDR2 of clone 66 with one or two amino acid substitutions, HCDR3 of clone 66 or HCDR3 of clone 66 with one or two amino acid substitutions, LCDR1 of clone 66 or LCDR1 of clone 66 with one or two amino acid substitutions, LCDR2 of clone 66 or LCDR2 of clone 66 with one or two amino acid substitutions, and LCDR3 of clone 66 or LCDR3 of clone 66 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1118.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 68 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 68.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 68 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 68; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68.
  • an anti-CD74 antibody comprises HCDR1 of clone 68 or HCDR1 of clone 68 with one or two amino acid substitutions, HCDR2 of clone 68 or HCDR2 of clone 68 with one or two amino acid substitutions, HCDR3 of clone 68 or HCDR3 of clone 68 with one or two amino acid substitutions, LCDR1 of clone 68 or LCDR1 of clone 68 with one or two amino acid substitutions, LCDR2 of clone 68 or LCDR2 of clone 68 with one or two amino acid substitutions, and LCDR3 of clone 68 or LCDR3 of clone 68 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1218.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of Attorney Docket No.01245-0062-00PCT SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 76 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 76.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 76 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions Attorney Docket No.01245-0062-00PCT compared to the amino acid sequence of clone 76.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 76 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 76; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 76 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 76; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76.
  • an anti-CD74 antibody comprises HCDR1 of clone 76 or HCDR1 of clone 76 with one or two amino acid substitutions, HCDR2 of clone 76 or HCDR2 of clone 76 with one or two amino acid substitutions, HCDR3 of clone 76 or HCDR3 of clone 76 with one or two amino acid substitutions, LCDR1 of clone 76 or LCDR1 of clone 76 with one or two amino acid substitutions, LCDR2 of clone 76 or LCDR2 of clone 76 with one or two amino acid substitutions, and LCDR3 of clone 76 or LCDR3 of clone 76 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1318.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 77 and a VL comprising an Attorney Docket No.01245-0062-00PCT amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 77.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 77 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 77; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77.
  • an anti-CD74 antibody comprises HCDR1 of clone 77 or HCDR1 of clone 77 with one or two amino acid substitutions, HCDR2 of clone 77 or HCDR2 of clone 77 with one or two amino acid substitutions, HCDR3 of clone 77 or HCDR3 of clone 77 with one or two amino acid substitutions, LCDR1 of clone 77 or LCDR1 of clone 77 with one or two amino acid substitutions, LCDR2 of clone 77 or LCDR2 of clone 77 with one or two amino acid substitutions, and LCDR3 of clone 77 or LCDR3 of clone 77 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1412 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1418.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1412 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 60 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 60.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 60 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 60; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60.
  • an anti-CD74 antibody comprises HCDR1 of clone 60 or HCDR1 of clone 60 with one or two amino acid substitutions, HCDR2 of clone 60 or HCDR2 of clone 60 with one or two amino acid substitutions, HCDR3 of clone 60 or HCDR3 of clone 60 with one or two amino acid substitutions, LCDR1 of clone 60 or LCDR1 of clone 60 with one or two amino acid substitutions, LCDR2 of clone 60 or LCDR2 of clone 60 with one or two amino acid substitutions, and LCDR3 of clone 60 or LCDR3 of clone 60 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1518.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO:
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 61 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 61.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 61 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 61; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61.
  • an anti-CD74 antibody comprises HCDR1 of clone 61 or HCDR1 of clone 61 with one or two amino acid substitutions, HCDR2 of clone 61 or HCDR2 of clone 61 with one or two amino acid substitutions, HCDR3 of clone 61 or HCDR3 of clone 61 with one or two amino acid substitutions, LCDR1 of clone 61 or LCDR1 of clone 61 with one or two amino acid substitutions, LCDR2 of clone 61 or LCDR2 of clone 61 with one or two amino acid substitutions, and LCDR3 of clone 61 or LCDR3 of clone 61 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1618.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising Attorney Docket No.01245-0062-00PCT the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 33 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 33.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 33 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 33; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 33.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 33.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 33.
  • an anti-CD74 antibody comprises HCDR1 of clone 33 or HCDR1 of clone 33 with one or two amino acid substitutions, HCDR2 of clone 33 or HCDR2 of clone 33 with one or two amino acid substitutions, HCDR3 of clone 33 or HCDR3 of clone 33 with one or two amino acid substitutions, LCDR1 of clone 33 or LCDR1 of clone 33 with one or two amino acid substitutions, LCDR2 of clone 33 or LCDR2 of clone 33 with one or two amino acid substitutions, and LCDR3 of clone 33 or LCDR3 of clone 33 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1718.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 49 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 49.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 49 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 49; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 49.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 49.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 49.
  • an anti-CD74 antibody comprises HCDR1 of clone 49 or HCDR1 of clone 49 with one or two amino acid substitutions, HCDR2 of clone 49 or HCDR2 of clone 49 with one or two amino acid substitutions, HCDR3 of clone 49 or HCDR3 of clone 49 with one or two amino acid substitutions, LCDR1 of clone 49 or LCDR1 of clone 49 with one or two amino acid substitutions, LCDR2 of clone 49 or LCDR2 of clone 49 with one or two amino acid substitutions, and LCDR3 of clone 49 or LCDR3 of clone 49 with one or two amino acid substitutions.
  • an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818.
  • an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1818.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806.
  • an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (
  • an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 56 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 56.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56 and a VL Attorney Docket No.01245-0062-00PCT comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56.
  • an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 56 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 56; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 56.
  • an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 56.
  • an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 56.
  • an anti-CD74 antibody comprises HCDR1 of clone 56 or HCDR1 of clone 56 with one or two amino acid substitutions, HCDR2 of clone 56 or HCDR2 of clone 56 with one or two amino acid substitutions, HCDR3 of clone 56 or HCDR3 of clone 56 with one or two amino acid substitutions, LCDR1 of clone 56 or LCDR1 of clone 56 with one or two amino acid substitutions, LCDR2 of clone 56 or LCDR2 of clone 56 with one or two amino acid substitutions, and LCDR3 of clone 56 or LCDR3 of clone 56 with one or two amino acid substitutions.
  • the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions.
  • the anti-CD74 antibody is an IgG antibody, such as IgG1, IgG2, IgG3 or IgG4 antibody or a modified form thereof as described in the section below.
  • the constant region has effector function, and in some embodiments, the constant region is effectorless.
  • an anti-CD74 antibody comprises a heavy chain (HC) comprising the amino acid sequence of the heavy chain of any of the anti-CD74 antibodies provided herein.
  • an anti-CD74 antibody comprises a heavy chain comprising the amino acid sequence of the heavy chain of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56.
  • an anti-CD74 antibody may comprise: (a) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 22 and a light chain comprising the light chain amino acid sequence of antibody clone number 22; or Attorney Docket No.01245-0062-00PCT (b) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 3 and a light chain comprising the light chain amino acid sequence of antibody clone number 3; or (c) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 1 and a light chain comprising the light chain amino acid sequence of antibody clone number 1; or (d) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 41 and a light chain comprising the light chain amino acid sequence of antibody clone number 41; or (e) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 93 and a light chain
  • An anti-CD74 antibody may comprise: (a) a heavy chain (HC) comprising the HC CDRs of the HC of antibody clone number 22 and a light chain (LC) comprising the LC CDRs of antibody clone number 22 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 22, respectively; or (b) a HC comprising the HC CDRs of the HC of antibody clone number 3, and a light chain (LC) comprising the LC CDRs of antibody clone number 3 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or
  • the HC and/or LC may differ from the sequence of each of the species by the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, or deletions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions.
  • the HC and/or LC may differ from the sequence of each of the species by the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions.
  • the amino acid substitutions may be conservative amino acid substitutions or non-conservative amino acid substitutions. 1.
  • an antibody provided herein is an antibody fragment.
  • Antibody fragments include, but are not limited to, Fab, Fab’, Fab’-SH, F(ab’) 2 , Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med.9:129-134 (2003).
  • Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific.
  • Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
  • a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S.
  • an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody.
  • Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites.
  • one of the binding specificities is for CD74 and the other is for any other antigen.
  • bispecific antibodies may bind to two different epitopes of CD74.
  • Bispecific antibodies may also be used to localize cytotoxic agents to cells which express CD74.
  • Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.
  • Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO J.10: 3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Patent No.5,731,168).
  • Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross- linking two or more antibodies or fragments (see, e.g., US Patent No.4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using “diabody” technology for making bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci.
  • the antibody or fragment herein also includes a “Dual Acting Fantibody” or “DAF” comprising an antigen binding site that binds to CD74 as well as another, different antigen (see, US 2008/0069820, for example).
  • DAF Double Acting Fantibody
  • amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis.
  • Such modifications include, for example, Attorney Docket No.01245-0062-00PCT deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding. 4. Substitution, Insertion, and Deletion Variants [00157] In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 as are “exemplary substitutions.
  • Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
  • a desired activity e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.
  • Amino acids may be grouped according to common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe.
  • Non-conservative substitutions will entail exchanging a member of one of these classes for another class.
  • Alterations may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol.207:179-196 (2008)), and/or residues that contact antigen, with the resulting variant VH or VL being tested for binding affinity.
  • affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O’Brien et al., ed., Human Press, Totowa, NJ, (2001).)
  • diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis).
  • a secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity.
  • HVR-directed approaches in which several HVR residues (e.g., 4-6 residues at a time) are randomized.
  • HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling.
  • CDR-H3 and CDR-L3 in particular are often targeted.
  • substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen.
  • conservative alterations e.g., conservative substitutions as provided herein
  • that do not substantially reduce binding affinity may be made in HVRs.
  • each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.
  • a residue or group of target residues e.g., charged residues such as arg, asp, his, lys, and glu
  • a neutral or negatively charged amino acid e.g., alanine or polyalanine
  • Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions.
  • a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution.
  • Variants may be screened to determine whether they contain the desired properties.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues.
  • terminal insertions include an antibody with an N-terminal methionyl residue.
  • Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody. 5.
  • Glycosylation variants [00164] In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated.
  • Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed.
  • the carbohydrate attached thereto may be altered.
  • Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997).
  • the oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure.
  • modifications of the oligosaccharide in an antibody of the disclosure may be made in order to create antibody variants with certain improved properties.
  • antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region.
  • the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%.
  • the amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example.
  • Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ⁇ 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd).
  • Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol.336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech.
  • Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys.249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng.87: 614 (2004); Kanda, Y. et al., Biotechnol.
  • Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean- Mairet et al.); US Patent No.6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.).
  • Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.). 6. Fc region variants [00168] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant.
  • the Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
  • a human Fc region sequence e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region
  • an amino acid modification e.g. a substitution
  • the disclosure contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector Attorney Docket No.01245-0062-00PCT functions (such as complement and ADCC) are unnecessary or deleterious.
  • In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
  • Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc ⁇ R binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
  • FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol.9:457-492 (1991).
  • Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Patent No.5,500,362 (see, e.g. Hellstrom, I.
  • non-radioactive assays methods may be employed (see, for example, ACTITM non- radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96 ® non-radioactive cytotoxicity assay (Promega, Madison, WI).
  • PBMC peripheral blood mononuclear cells
  • NK Natural Killer
  • ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. Proc. Nat’l Acad. Sci. USA 95:652-656 (1998).
  • C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
  • a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, M.S. et al., Blood 101:1045-1052 (2003); and Cragg, M.S. and M.J. Glennie, Blood 103:2738-2743 (2004)).
  • FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., Int’l. Immunol.18(12):1759-1769 (2006)).
  • an antibody variant comprises an Fc region with one or more amino acid substitutions which reduce Fc receptor binding, e.g. substitutions at positions 234, 235, and/or 329 of the Fc region (EU numbering of residues).
  • an antibody variant comprises an Fc region with one or more amino acid deletions which reduce heterogeneity, e.g., deletion at 447 of the Fc region (EU numbering of residues).
  • Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No.6,737,056; WO 2004/056312, and Shields et al., J. Biol.
  • an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
  • alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No.6,194,551, WO 99/51642, and Idusogie et al. J. Immunol.164: 4178-4184 (2000).
  • Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 252, 254, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (e.g., US Patent No.7,371,826).
  • substitution of Fc region residue 434 e.g., US Patent No.7,371,826.
  • an antibody is provided according to the Table of Sequences, wherein the isotype is human IgG1. In some embodiments, an antibody is provided according to the Table of Sequences, wherein the isotype is human IgG4. 7. Cysteine engineered antibody variants [00178] In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., “thioMantibodies,” in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody.
  • any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; S239 (EU numbering) of the heavy chain Fc region; and S400 (EU numbering) of the heavy chain Fc region.
  • Cysteine engineered antibodies may be generated as described, e.g., in U.S.
  • an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
  • the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
  • Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof.
  • PEG polyethylene glycol
  • copolymers of ethylene glycol/propylene glycol carboxymethylcellulose
  • dextran polyvinyl alcohol
  • Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
  • the polymer may be of any molecular weight and may be branched or unbranched.
  • the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
  • conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided.
  • the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)).
  • the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody- nonproteinaceous moiety are killed.
  • B. Recombinant Methods [00181] Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No.4,816,567.
  • isolated nucleic acid encoding an anti-CD74 antibody described herein is provided.
  • nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody).
  • one or more vectors comprising such nucleic acid are provided.
  • a host cell comprising such nucleic acid is provided.
  • a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the Attorney Docket No.01245-0062-00PCT antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody.
  • the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell).
  • a method of making an anti-CD74 antibody comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).
  • nucleic acid encoding an antibody e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
  • Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
  • prokaryotic or eukaryotic cells described herein.
  • antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
  • U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C.
  • the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
  • eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech.22:1409-1414 (2004), and Li et al., Nat.
  • Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. [00186] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES TM technology for producing antibodies in transgenic plants).
  • Vertebrate cells may also be used as hosts.
  • mammalian cell lines that are adapted to grow in suspension may be useful.
  • useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol.36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol.
  • monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci.383:44-68 (1982); MRC 5 cells; and FS4 cells.
  • Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub et al., Proc. Natl. Acad. Sci.
  • the disclosure also provides immunoconjugates comprising an anti-CD74 antibody herein conjugated to one or more effector molecules.
  • the effector molecules comprise cytotoxic agents.
  • the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor, but not limited thereto.
  • DNA inhibitors include, but are not limited to, monoimine indolinobenzodiazepenes (e.g., DGN549C), tesirine, talirine, duocarmycins (e.g., seco-DUBA), pyrrolobenzodiazepine (PBD), and anthracyclines (e.g., NMS249, PNU-159682).
  • topoisomerase inhibitors include, but are not limited to, exatecans (e.g., Dxd).
  • tubulin inhibitors include, but are not limited to, auristatins (e.g., monomethyl auristatin F, monomethyl auristatin E) and maytansinoids (e.g., ravtansine).
  • the cytotoxic agent is selected from Table 2.
  • the cytotoxic agent is a monoimine indolinobenzodiazepene (e.g., FGN849). (See, e.g., U.S. Patent No.10,898,579.)
  • the cytotoxic agent is DGN549C.
  • DGN549C may be conjugated to the CD74 antibody at an S239C substitution of an IgG heavy chain constant region.
  • DAR Drug to antibody ratio
  • Methods of measuring DAR are known in the art, and include liquid chromatography mass spectrometry, for example. Any suitable DAR can be used with the disclosures described herein.
  • DAR is from about 2 to about 4.
  • DAR is about 2.
  • the DAR is about 3.
  • the DAR is about 4.
  • Methods of conjugating one or more effector molecules to an antibody are known in the art.
  • an antibody e.g., an antibody described herein
  • an antibody can be directly conjugated to one or more effector molecules, including any of the effector molecules described herein, such as a cytotoxic agent in Table 2, to produce an immunoconjugate.
  • an antibody e.g., an antibody described herein
  • Conjugates of an antibody may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as toluene 2,6-diisocyan
  • a linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell.
  • a linker for example, an acid-labile linker, peptidase- sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Res.52:127-131 (1992); U.S. Patent No.5,208,020) may be used.
  • the immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).
  • cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC
  • compositions or compositions of an anti-CD74 antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers, diluents, and/or excipients (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
  • Pharmaceutically acceptable carriers, diluents, and excipients are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: sterile water, buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as
  • Exemplary pharmaceutically acceptable carriers herein further include insterstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX ® , Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos.2005/0260186 and 2006/0104968.
  • sHASEGP soluble neutral-active hyaluronidase glycoproteins
  • rHuPH20 HYLENEX ® , Baxter International, Inc.
  • a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.
  • additional glycosaminoglycanases such as chondroitinases.
  • exemplary lyophilized antibody formulations are described in US Patent No.6,267,958.
  • Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer.
  • the formulation or composition herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.
  • Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions.
  • colloidal drug delivery systems for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules
  • Sustained-release preparations may be prepared.
  • sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
  • the formulations or compositions to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes.
  • Therapeutic Methods Any of the anti-CD74 antibodies provided herein may be used in therapeutic methods. Throughout, where an “antibody” is discussed, it should also be appreciated that a composition comprising the antibody is also encompassed. [00201] In one aspect, an anti-CD74 antibody for use as a medicament is provided.
  • an anti-CD74 antibody for use in conditioning a subject to reduce an Attorney Docket No.01245-0062-00PCT endogenous population of hematopoietic stem cells in the subject.
  • an effector molecule is conjugated to the antibody.
  • the antibodies or immunoconjugates of the present disclosure are useful in a variety of applications including, but not limited to, for reducing an endogenous population of hematopoietic stem cells in a subject in need thereof, e.g., a hematopoietic stem cell transplantation recipient.
  • methods of reducing an endogenous population hematopoietic stem cells in a subject in need thereof by administering to the subject an effective amount of any of the antibodies and/or immunoconjugates described herein.
  • methods of reducing an endogenous population of hematopoietic stem cells includes reducing a population of cells in bone marrow and/or CD34+ cells but not all immune cells.
  • hematopoietic stem cell transplantation subject e.g., a transplant subject
  • methods of conditioning a hematopoietic stem cell transplantation subject e.g., a transplant subject
  • administering an effective amount of any of the antibodies and/or immunoconjugates described herein, and allowing a sufficient period of time for the antibodies and/or immunoconjugates to clear from the subject’s circulation before performing a hematopoietic stem cell transplantation on the subject.
  • any of the antibodies, immunoconjugates, or pharmaceutical compositions described herein for reducing an endogenous population hematopoietic stem cells in a subject in need thereof.
  • any of the antibodies, immunoconjugates or pharmaceutical compositions described herein in the manufacture of a medicament for reducing an endogenous population hematopoietic stem cells in a subject in need thereof.
  • Provided herein are methods of reducing an endogenous population of hematopoietic stem cells in a pre-treatment/conditioning of the subject before a hematopoietic stem cell transplantation.
  • the antibodies and/or immunoconjugates herein could be used to condition a subject having any non-malignant condition/disorder wherein stem cell transplantation could be beneficial, such as Adrenoleukodystrophy (ALD), Severe aplastic anemia (SAA), Severe immunodeficiency syndrome (SCID), Wiskott Aldrich Syndrome, Hurler Syndrome, familial haemophagocytic lymphohistiocytosis (FHL), Krabbe disease (Globoid-Cell Leukodystrophy), Metachromatic Leukodystrophy (MLD), Sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), Chronic granulomatous disease (CGD), Kostmanns syndrome, other autoimmune disorders such as SLE, Multiple sclerosis, IBD, Crohns Disease, Ulcerative colitis, Sjogrens syndrome, vasculitis, Lupus, Myasthenia Gravis, Wegeners disease, in
  • the antibodies and/or immunoconjugates herein could be used to condition a subject having any malignant condition/disorder wherein stem cell transplantation Attorney Docket No.01245-0062-00PCT could be beneficial, such as hematologic diseases, hematological malignancies or solid tumors (e.g., renal cancer, hepatic cancer, pancreatic cancer).
  • stem cell transplantation Attorney Docket No.01245-0062-00PCT could be beneficial, such as hematologic diseases, hematological malignancies or solid tumors (e.g., renal cancer, hepatic cancer, pancreatic cancer).
  • hematological diseases/malignancies that could be pretreated or conditioned with the claimed methods include, but are not limited to hematologic malignancies derived from either of the two major blood cell lineages, i.e., the myeloid cell line (which produces granulocytes, erythrocytes, thrombocytes, macrophages and mast cells) or lymphoid cell line (which produces B, T, NK and plasma cells), such as all types of leukemias, lymphomas, and myelomas, e.g., acute, chronic, lymphocytic and/or myelogenous leukemias, such as acute leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (Ml), myeloblastic leukemia (M2; with cell maturation), promyelocy
  • the antibodies and/or immunoconjugates described herein can be used to condition a subject in preparation for a transplant of an engineered cell.
  • the antibodies and/or immunoconjugates described herein can be used to condition a subject prior to transplanting an engineered cell for treatment of a disease.
  • the antibodies and/or immunoconjugates described herein can be used to condition a subject in preparation for administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs).
  • the antibodies and/or immunoconjugates described herein can be used to condition a subject in preparation for administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs) that comprise a genetic modification.
  • the subject has a hemoglobinopathy.
  • diseases include sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
  • SCD sickle cell disease
  • TDT transfusion-dependent beta thalassemia
  • the cells, compositions, and/or methods can be used for treatment as described in WO 2019/113149, WO 2020/257325, and/or WO 2022/133246, which are incorporated by reference herein in their entirety for any purpose.
  • Antibodies of the invention can be used either alone or in combination with other agents in a therapy.
  • an antibody or immunoconjugate of the disclosure may be used in combination with at least one additional therapeutic agent (e.g., further comprising administering a second therapy).
  • the antibody or immunoconjugate may be used with a second conditioning therapy such as radiation therapy or chemotherapy.
  • the antibodies or immunoconjugates herein may be provided before, substantially contemporaneous with, or after other modes of treatment, for example, surgery, chemotherapy, radiation therapy, or the administration of a biologic, such as another therapeutic antibody or an engineered cell type.
  • the cancer has recurred or progressed following a therapy selected from surgery, chemotherapy, and radiation therapy, or a combination thereof.
  • the combinations may be administered in conjunction with one or more additional anti-cancer agents, such as a chemotherapeutic agent, growth inhibitory agent, anti-cancer vaccine such as a gene therapy vaccine, anti-angiogenesis agent and/or anti-neoplastic composition.
  • additional anti-cancer agents such as a chemotherapeutic agent, growth inhibitory agent, anti-cancer vaccine such as a gene therapy vaccine, anti-angiogenesis agent and/or anti-neoplastic composition.
  • an anti-inflammatory drug may be administered with the combination, such as a steroid or a non-steroidal anti-inflammatory drug (NSAID).
  • NSAID non-steroidal anti-inflammatory drug
  • hormones and steroids including synthetic analogs, such as 17a-Ethinylestradiol, Diethylstilbestrol,Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyl-testosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, ZOLADEX®, can also be administered to the subject.
  • steroids including synthetic analogs
  • 17a-Ethinylestradiol Diethylstilbestrol,Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisol
  • combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations or compositions), and separate administration, in which case, administration of the antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent or agents.
  • administration of the anti- CD74 antibody and administration of an additional therapeutic agent occur within about one month, or within about one, two or three weeks, or within about one, two, three, four, five, or six days, of each other.
  • An antibody of the disclosure can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
  • Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
  • Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.
  • Antibodies of the disclosure can be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
  • a “split dose” is the division of single unit dose or total daily dose Attorney Docket No.01245-0062-00PCT into two or more doses, e.g., two or more administrations of the single unit dose.
  • the antibody may be administered as “split dose.”
  • the antibody need not be but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question.
  • the effective amount of such other agents depends on the amount of antibody present in the formulation or composition, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
  • the antibody is provided in a formulation for immediate release and the other agent is formulated for extended release or vice versa. G.
  • an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above comprises a container and a label or package insert on or associated with the container.
  • Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
  • the containers may be formed from a variety of materials such as glass or plastic.
  • the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
  • At least one active agent in the composition is an antibody of the disclosure.
  • the label or package insert indicates that the composition is used for treating the condition of choice.
  • the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the disclosure; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
  • the article of manufacture in this embodiment of the disclosure may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
  • the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
  • BWFI bacteriostatic water for injection
  • phosphate-buffered saline such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution.
  • BWFI bacteriostatic water for injection
  • Ringer's solution such as bacterio
  • Anti-CD74 Antibody Generation Materials and methods [00216] Antigen preparation [00217] Antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit (Thermo Scientific, Cat #21425). [00218] The antigens were concentrated to ⁇ 1mg/mL and buffer exchanged into PBS before addition of 1:7.5 molar ration biotinylation reagent. The mixture was held at 4C overnight prior to another buffer exchange to remove free biotin in the solution. Biotinylation was confirmed through streptavidin sensor binding of the labeled proteins on a ForteBio.
  • the cell pellet was resuspended in 20 mL wash buffer, and Streptavidin MicroBeads (500 ⁇ l) were added to the yeast and incubated for 15 min at 4°C. Next the yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL were loaded, the column was washed 3 times with 3 mL wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight.
  • yeast cells ( ⁇ 10 10 cells/library) were incubated with biotinylated human CD74 for 30 min at 30°C in wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)).
  • wash buffer phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)
  • the cell pellet was resuspended in 20 mL wash buffer, and Streptavidin MicroBeads (500 ⁇ l) were added to the yeast and incubated for 15 min at 4°C. Next the yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL were loaded, the column was washed 3 times with 3 mL wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight.
  • Attorney Docket No.01245-0062-00PCT [00222] The following rounds of selection were performed using flow cytometry (FACS).
  • Yeast were pelleted, washed three times with wash buffer, and incubated at 30°C with decreasing concentrations of biotinylated p33 and p41 human CD74 (100 to 1 nM) under equilibrium conditions, 100 nM biotinylated cyno CD74 in order to obtain species cross- reactivity, or with a polyspecificity reagent (PSR) to remove non-specific antibodies from the selection.
  • PSR polyspecificity reagent
  • the libraries were incubated with a 1:10 dilution of biotinylated PSR reagent as previously described (see, e.g., Y.
  • Yeast were then washed twice with wash buffer and stained with goat F(ab’)2 anti-human kappa-FITC (LC-FITC) diluted 1:100 (Southern Biotech, Cat # 2062-02) and either Streptavidin-AF633 (SA- 633) diluted 1:500 (Life Technologies, Cat # S21375) or Extravidin- phycoerthyrin (EA-PE) diluted 1:50 (Sigma-Aldrich, Cat # E4011), secondary reagents for 15 min at 4°C.
  • LC-FITC goat F(ab’)2 anti-human kappa-FITC
  • SA- 633 Streptavidin-AF633
  • EA-PE Extravidin- phycoerthyrin
  • the libraries were evaluated for, e.g., PSR binding, species cross-reactivity, and affinity pressure by antigen titration. Sorting was performed in order to obtain a population with the desired characteristics. Individual colonies from each terminal FACS selection round were picked for sequencing and characterization. [00225] Affinity maturation [00226] Optimization of parent clones was carried out utilizing two maturation strategies: diversification of CDRH1 and CDRH2 and diversification of CDRL1, CDRL2, CDRL3 and CDRH3.
  • CDRH1 and CDRH2 selection The CDRH3s from clones selected from the light chain diversification procedure were recombined into a premade library with CDRH1 and CDRH2 variants of a diversity of 1 x 10 8 and selections were performed using CD74 antigen. Affinity pressures were applied by using decreasing concentrations of biotinylated CD74 antigen (100 to 1 nM) under equilibrium conditions at room temperature and by preincubating the biotinylated antigen with parental IgG for 30 minutes and then applying that precomplexed mixture Attorney Docket No.01245-0062-00PCT to the yeast library for a length of time which would allow the selection to reach an equilibrium.
  • CDRL1, CDRL2, CDRL3 and CDRH3 selection Oligos were ordered from IDT which comprised the CDRL3 or CDRH3 as well as a flanking region on either sides of the CDR. Amino acid positions in the CDRL3 and CDRH3 were variegated via NNK diversity. Clones obtained from CDRH1 and CDRH2 selection procedure were combined into a premade library with CDRL1 and CDRL2 diversity and the CDRL3 and CDRH3 oligo. Selections were performed using biotinylated CD74 as antigen generally as described above.
  • Example 2 Anti-CD74 Antibody Binding [00239] From the analyses in Example 1, 3 sequences (clone 1, clone 22, and clone 41) bound comparably to human and cynomolgus CD74. Clone 3 was a variant identified by affinity maturation of Clone 1 and exhibited improved affinity relative to it’s parental lineage. Table 3 lists the measured avid binding kinetics for Clones 1, 3, 22, and 41 to human and cynomolgus CD74.
  • Antibody binding studies were performed at 25 degrees Celsius in 1xPBS supplemented with 0.1% w/v bovine serum albumin with a Sartorious Octet biolayer interferometry (BLI) instrument.
  • BBI Sartorious Octet biolayer interferometry
  • the indicated antibody was immobilized onto anti-human Fc biosensors (AHC; Sartorious 18-5060) and incubated with 100 nM of purified human or cynomolgus CD74 p33 ectodomain.
  • the apparent affinity KD was determined by global full fitting with a 1:1 binding model as calculated by ForteBio data analysis software. Table 4 lists the measured avid binding kinetics for Clones 1, 3, 22, and 41 to human CD74 p33 and p41.
  • Table 3 Human and Cynomolgus CD74 Binding Attorney Docket No.01245-0062-00PCT Screening for avid binding to human and cynomolgus recombinant CD74 as determined by bio-layer interferometry.
  • Table 4 p33 and p41 Human CD74 Binding
  • Table 5 Epitope Identification [00240] Clone 22 was determined to bind to CD74 in a unique epitope, where it did not cross-block with Clone 1, Clone 41, or any other selected antibody. Table 5 shows epitope binning by bio-layer interferometry. Briefly, antibody in the first column is loaded onto an instrument sensor followed by human CD74. Next, antibody from the first row is loaded on the antigen-loaded sensor.
  • the second antibody does not cross-block the first antibody and will result in a positive binding value. Non-crossblocking interactions are highlighted in bold. Crossblocking interactions are underlined. Self-self blocking is italicized.
  • Antibody binding studies were performed at 25 degrees Celsius in 1xPBS supplemented with 0.1% w/v bovine serum albumin with a Sartorious Octet biolayer interferometry (BLI) instrument. For binning, the indicated antibody was immobilized onto anti- human Fc biosensors (AHC; Sartorious 18-5060). A second binding step was performed with saturating amounts of a non-specific isotype control antibody.
  • Biotinylated antigen was immobilized onto streptavidin biosensors (SA; Sartorious 18-5057) and incubated with 100 nM of indicated Fab.
  • Fab was generated from the indicated antibody using papain digestion and standard methods known in the art.
  • the resulting binding intervals are represented with association and dissociation curves in the sensorgram.
  • the apparent affinity (KD), apparent association rate (kON) and apparent dissociation rate (kOFF) were determined by global full fitting with a 1:1 binding model as calculated by ForteBio data analysis software. Based on response values and corresponding 1:1 kinetics, clones 1, 3, 22, and 41 exhibited comparable binding to both p33 and p41isoforms.
  • Clone 3 is an affinity maturation variant of Clone 1 and exhibits a resultant improvement in monovalent affinity to both human p33 and p41 isoforms as well as the cynomolgus counterparts.
  • a stock 1 mg/ml antibody solution was buffer exchanged to pH 3.7 and incubated for 1 hour at room temperature; 2) a stock 1 mg/ml antibody solution was buffer exchanged into Tris pH 8.0 and incubated for 7 days at 40 o C; 3) a stock 1 mg/ml antibody solution was buffer exchanged into acetate pH 5.0 and incubated for 7 days at 40 o C; 4) a stock 1 mg/ml antibody solution was incubated for 7 or 14 days at 50 o C; 5) a stock 1 mg/ml antibody solution was cycled through 6 freeze/thaw cycles (- 80 o C to room temperature); 6) a stock 1 mg/ml antibody solution was incubated with 0.02% hydrogen peroxide and incubated at room temperature for 2 hours or 16 hours.
  • Samples taken from a zero hour or terminal time point were assessed in a variety of standard analytical methods known in the art, including size exclusion chromatography (SEC) to assess impact of stress on aggregation, capillary electrophoresis SDS- PAGE (CE-SDS) to assess the impact of stress on fragmentation, and reduced peptide mapping by LC-MS to assess the impact of stress on chemical modification (deamidation, oxidation).
  • SEC size exclusion chromatography
  • CE-SDS capillary electrophoresis SDS- PAGE
  • LC-MS reduced peptide mapping by LC-MS
  • Table 8 Forced Degradation of Clone 1 Antibody SEC: % high molecular weight species relative to untreated control Attorney Docket No.01245-0062-00PCT CE-SDS: % total fragments relative to corresponding intact antibody (non-reduced; NR) or HC/LC (reduced; RD) relative to untreated control LC-MS: %Oxidation and %Deamidation detected within CDR peptides relative to untreated control. ⁇ 1.0% isomerization observed.
  • Binding was performed on primary human bone marrow CD34+ cells (AllCells). Cryopreserved cells were rapidly thawed, washed, and incubated with antibody (Clones 1, 3, 22, and 41) at the indicated concentrations on ice for 4 hours in triplicate. Unbound antibody was washed out and cells were stained with fluorescently-labeled anti-human IgG secondary antibody and surface marker antibodies according to methods known in the art. Data were read out by flow cytometry and are expressed as the geometric mean fluorescent intensity (gMFI) of the labeled secondary antibody on viable CD34+ cells. EC50 values were calculated using a four-parameter non-linear regression curve fit with no constraints in GraphPad Prism software.
  • FIGS.2A-2C show the binding of anti-CD74 clone 1, clone 22, and clone 41 antibodies to primary human bone marrow CD34+ cells and the corresponding EC50 values are reported in FIG.2D.
  • the antibodies demonstrated binding to human bone marrow CD34+ cells relative to the isotype control.
  • FIG.3A shows binding to primary human bone marrow CD34+ cells.
  • clone 3 shows marked improvement in EC50 on primary human bone marrow CD34+ cells relative to its parental clone 1 as shown in FIG.3B.
  • linker payload conjugation was performed using clone 1, 3, 22, and 41 conjugated with the linker payload DGN549C.
  • Antibodies and antibody drug conjugates were incubated with primary human bone marrow CD34+ cells prepared as described previously. Unbound antibody and ADC were washed out and cells were stained with fluorescently-labeled Attorney Docket No.01245-0062-00PCT anti-human IgG secondary antibody and surface marker antibodies as previously described. Data was read out by flow cytometry and expressed as gMFI of the labeled secondary antibody on viable CD34+ cells.
  • binding of Anti-CD74 Antibodies to Cyno Bone Marrow CD34+ Cells was performed on primary cynomolgus monkey bone marrow CD34+ cells (Worldwide Primates, Inc.). Cryopreserved cells were rapidly thawed, washed, and expanded in culture for 7 days prior to binding. Cells were incubated with antibody at the indicated concentrations on ice for two hours in technical triplicate. Unbound antibody was washed out and cells were stained with fluorescently-labeled anti-human IgG secondary antibody and surface marker antibodies.
  • FIGS.5A-5C show the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells.
  • Table 11 shows the EC 50 values for clones 1, 22, and 41 binding to CD34+CD90+, CD34+CD90-, and all CD34+ cells.
  • Table 11 EC 50 [nM] Cyno Bone Marrow CD34+ Cells Example 6.
  • Anti-CD74 Antibodies into Human Bone Marrow CD34+ Cells were conjugated to the pH-sensitive fluorophore, pHAb (Promega, catalog # G9835).
  • pHAb pH-sensitive fluorophore
  • AllCells Primary human bone marrow CD34+ cells (AllCells) were incubated in the presence of a fixed 50 nM concentration of the pHAb- conjugated anti-CD74 antibody overnight at 37°C in growth culture media. After overnight incubation, cells were stained with a panel of cell surface markers, and fluorescence was Attorney Docket No.01245-0062-00PCT measured by flow cytometry.
  • FIGS.6A-6B show the internalization of anti-CD74 antibodies into primary human bone marrow CD34+ cells.
  • Table 12 shows the gMFI values for clones 1, 3, 22, and 41 for internalization on bone marrow CD34+ cells. Based on these findings a rank order can be applied based on internalization capability. Amongst these clones, Clone 3 exhibited the greatest capacity to internalize on primary bone marrow CD34+ cells.
  • Table 12 gMFI values for internalization of anti-CD74 antibodies on CD34+ cells.
  • MDM Monocyte-derived macrophages
  • AllCells primary human monocytes
  • R&D Systems recombinant human M-CSF
  • Adherent cells were detached and plated overnight in growth media with M-CSF.
  • Fluorescently-labeled primary human bone marrow CD34+ cells (AllCells) were incubated in the presence of MDM for 2 hours in the presence of effector-silenced or wild-type anti-CD74 antibody. After incubation, a fluorescently labeled cell surface marker specific to MDM cells was added. Cells were then washed, and fluorescence was measured by flow cytometry.
  • FIG.7 shows effector silencing of anti-CD74 antibodies.
  • AllCells Primary human bone marrow CD34+ cells (AllCells) were incubated in the presence of a titration of anti-CD74 antibody or antibody-drug-conjugate (ADC) prepared with DGN549C for 5 days. Cells were stained for cell surface markers and viability, and fluorescence was measured by flow cytometry.
  • FIGS.8A-8B shows the cytotoxic effect of anti-CD74 antibodies and ADCs on primary human bone marrow CD34+ cells. As shown, clone 1, 22, and 41 antibodies had no impact on primary human CD34+ cell viability whereas the ADCs of the corresponding clones were highly potent cytotoxic agents relative to the isotype control ADC. In this assay, the rank order of cytotoxicity was Clone 41>Clone 1>Clone 22.
  • the affinity maturation variant clone 3 showed highly potent cytotoxicity of primary human CD34+ cells relative to isotype control ADC as shown in FIG.9.
  • Example 9 Cytotoxicity of Anti-CD74 ADCs on Cyno Bone Marrow CD34+ Cells.
  • primary cynomolgus monkey bone marrow CD34+ cells (Worldwide Primates, Inc.) were incubated in the presence of a titration of anti-CD74 antibody or antibody-drug-conjugate (ADC) prepared with DGN549C for 5 days. Cells were stained for cells surface markers and fluorescence was measured by flow cytometry.
  • FIGS.10A-10B show the cytotoxic effect of anti-CD74 antibodies and ADCs on primary cynomolgus monkey bone marrow CD34+ cells.
  • clone 1, 22, and 41 antibodies had no impact on primary cynomolgus CD34+ cell viability whereas the ADCs of the corresponding clones were highly potent cytotoxic agents relative to the isotype control ADC.
  • FIGS.11A-11B show the cytotoxic effect of anti-CD74 antibodies and ADCs on CD74 expressing cell line and FIGS.12A-12B show the lack of cytotoxic effect of anti-CD74 ADCs on the CD74 knockout cell line.
  • clone 1, 22, and 41 antibodies had no impact on Raji cell viability whereas the ADCs of the corresponding clones were highly potent cytotoxic agents relative to the isotype control ADC. Cytotoxicity was target dependent, as the ADCs exhibited marked reduction in cytotoxicity in the Raji CD74 knockout cells.
  • Binding curves were generated using non- linear regression, 4-parameter curve fitting.
  • Table 15 Binding Affinity of anti-CD74 Antibody and ADC on Mouse, Rat, and Rabbit Bone Marrow-Derived Hematopoietic Cells in Culture Notes: Binding affinity assessed on primary mouse, rat, and rabbit hematopoietic cells by flow cytometry. Data reflect 3 biological replicates per species.
  • Binding curves were generated using non- linear regression, 4-parameter curve fitting.
  • Example 12 Fc-dependent Functional Testing [00261]
  • Anti-CD74 antibody (clone 22) was engineered with Fc silencing mutations to diminish antibody binding to CD74 negative cells that express Fc receptors.
  • Surface plasmon resonance (SPR) studies showed that the anti-CD74 antibody maintained binding to only the neonatal Fc receptor (FcRn) and the high affinity Fc receptor (FCGRI) amongst a panel of Fc receptors maintaining the ability of cells to recycle anti-CD74 ADC of cells after nonspecific uptake (Table 17).
  • Orthogonal BLI binding studies demonstrate that anti-CD74 ADC maintains the pH-dependent binding to FcRn (Table 18).
  • ADCC antibody-dependent cellular cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • Table 17 Fc Receptor Binding by Surface Plasmon Resonance Anti-CD74 antibody Positive Control Ligand KD (nM) KD (nM) FCGRI, CD64 201.5 a 0.106 FCGRIIA, CD32a (R131) NA 999.3 FCGRIIA, CD32a (H131) NA 802.3 FCGRIIB/C, C32b/c NA 4933.3 FCGRIIIA, CD16a (V158) NA 101.3 FCGRIIIA, CD16a (F158) NA 702.67 FCGRIIB, CD16b (NA1) NA 6300 FCGRIIB, CD16b (NA2) NA 4066.7 FcRn pH 7.4 NA NA FcRn pH 6.0 0.605 a 11 NA: no at applicable Notes: Fit was generated using a bulk shift term
  • CD34+ HSPC subsets was quantified by flow cytometry based on geometric mean fluorescence intensity following staining with a PE-conjugated anti-CD74 antibody and interpolated based on a standard curve produced with PE-conjugated beads.
  • Each symbol represents an individual donor. Bars represent mean values.
  • Analysis of cryopreserved bone marrow-derived CD34+ cell subsets from healthy human donors and NHPs showed the cell surface CD74 copy number was in the same range between human and NHP (FIGS.14A, 14B). The cell surface CD74 copy number was also comparable on peripheral blood cells from healthy human donors, donors with SCD, and NHPs as assessed by flow cytometry.
  • Example 14 Cytotoxicity of anti-CD74 Antibody and ADC, Isotype-DGN549c, and FGN849 on Cells in Culture.
  • the Raji cell line is a lymphoblast-like cell that expresses CD74.
  • anti-CD74 ADC was >90-fold more potent on Raji CD74+ cells compared to Raji CD74- cells (Table 19).
  • Attorney Docket No.01245-0062-00PCT In contrast, the potency of the active catabolite, FGN849, and isotype-DGN549c conjugate were similar between CD74+ and CD74- cells indicating the expression of the target drives increased potency with anti-CD74 ADC. No cytotoxicity was observed with the antibody alone, demonstrating that the anti-CD74 antibody needs to be conjugated to the linker payload to be cytotoxic.
  • anti-CD74 ADC was more cytotoxic to primary human (77-fold) and NHP (150-fold) CD34+ HSPCs compared to isotype-DGN549c conjugate (Table 20 and Table 21), respectively.
  • the cytotoxic activity of anti-CD74 ADC was similar on the phenotypic subset of CD34+ cells that has been reported to be enriched for long-term HSCs, the CD34+ CD90+ population.
  • Pre-incubation with plasma led to a ⁇ 2-fold shift in cytotoxic activity, suggesting the conjugation of anti-CD74 antibody to DGN549c is stable in human, NHP, and mouse plasma for at least up to 48 hours (Table 22).
  • Table 19 Cytotoxicity of anti-CD74 Antibody and ADC, Isotype-DGN549c, and FGN849 on CD74- Expressing and CD74-Knockout Raji Cells in Culture Notes: CD74 dependent cytotoxicity was evaluated on CD74-expressing versus CD74-knockout Raji cell lines. Data reflect 2 independent experiments. Values reported as the geometric mean and range across all experimental replicates. The number of replicates per condition is shown.
  • Table 20 Cytotoxicity of anti-CD74 Antibody and ADC, Isotype-DGN549c, FGN849, and DGN549c on Human CD34 + Versus CD34 + CD90 + HSPCs in Culture HSPCs: hematopoietic stem and progenitor cells Notes: Cytotoxicity was evaluated on primary human HSPCs. Data reflect over 50 experiments and include 23 unique human donors and 17 different batches of anti-CD74 ADC. Values reported as the geometric mean and 95% confidence interval across all experimental replicates. The number of replicates per condition is shown.
  • Table 21 Cytotoxicity of anti-CD74 Antibody and ADC, Isotype- DGN549c, and FGN849 on NHP CD34 + and CD34 + CD90 + HSPCs in Culture Attorney Docket No.01245-0062-00PCT HSPCs: hematopoietic stem and progenitor cells; NHP: non-human primate Notes: Cytotoxicity was evaluated on primary NHP HSPCs. Data reflect 4 independent experiments and include 4 unique NHP donors and 1 batch of anti-CD74 ADC. Values reported as the geometric mean and 95% confidence interval across all experimental replicates. The number of replicates per condition is shown. Table 22: Plasma Stability Analysis N: total sample size; NHP: non-human primate Notes: Data reflect 2 independent experiments.
  • Example 15 Bone Marrow Hematopoietic Stem and Progenitor Cell Depletion in Mice
  • the effect of anti-CD74-DGN549c on HSPC depletion was evaluated in humanized NOD/scid/IL2R ⁇ null (NSG) mice in two independent experiments.
  • humanized mice received a single IV administration of V-003-0105- 001, an anti-CD74 antibody with a different Fc allotype but the same variable domains as clone 22 conjugated to DGN549c, unconjugated CD74 mAb, isotype-DGN549c, or PBS vehicle.
  • the first model monitored HSPC depletion to identify the minimum dose of anti-CD74 ADC that causes myeloablation.
  • the second model was Attorney Docket No.01245-0062-00PCT to determine if the identified myeloablative doses are sufficient to enable autologous gene-edited HSCT.
  • BM bone marrow
  • HSPCs hematopoietic stem and progenitor cells
  • HSCT hematopoietic stem cell transplant
  • NHP non-human primate
  • FIGS.17A and 17B show the results where NHPs received a 4-day regimen of busulfan (6 mg/kg/day) or a single IV administration of anti-CD74 ADC at the doses indicated, and the number of BM HSPCs (defined as CD34+ CD90+ CD45RA- cells) per mL of BM aspirate was quantified at 7 (17A) versus 21 (17B) days post-dose administration. Data reflect 2- 4 NHP per dose cohort and are expressed as the geometric mean. Symbols represent individual animals.
  • Terminal BM aspirates for animals treated with busulfan were collected on day 20 post-final dose administration due to dosing error.
  • Terminal BM aspirates for animal treated with 0.2 mg/kg anti-CD74 ADC collected on day 24 post-dose administration. Calculated values equal to zero are plotted as 10 for visualization on a logarithmic scale.
  • FIGS.18A and 18B show the kinetics of neutrophil and platelet depletion following a 4-day regimen of busulfan (6 mg/kg/day) compared to a single IV administration of 0.05, 0.1, 0.2, 0.3, and 0.4 mg/kg anti-CD74 ADC in Attorney Docket No.01245-0062-00PCT NHPs measured by hematology analyzer. Data reflect 2- 4 NHPs per dose cohort and are expressed as the geometric mean +/- standard deviation. [00268] In the depletion model, single doses of anti-CD74 ADC (0.1, 0.2, 0.3, and 0.4 mg/kg) are myeloablative and comparable to a myeloablative busulfan 4-day QD regimen (FIGS.
  • anti-CD74 ADC 0.05 mg/kg
  • a monitoring duration of 21 days was selected because myelosuppression with 1020 gray total body irradiation, resulting in an absolute neutrophil count ⁇ 500/ ⁇ L for 19 days, is sufficient to enable successful autologous gene-edited hematopoietic stem cell transplant in NHPs.
  • NHPs went through ⁇ 2 cycles of HSPC mobilization, collection via leukapheresis, ex vivo editing with CRISPR/Cas9 at the CCR5 locus, and cryopreservation of the edited HSPCs.
  • Animals that achieved a cumulative dose of ⁇ 2 ⁇ 10 6 CD34 + cells/kg were conditioned with a single administration of anti-CD74 ADC or a 4-day regimen of myeloablative busulfan (6 mg/kg/day) prior to infusion of the edited CD34 + cell product.
  • FIGS.19A and 19B show NHPs transplanted 6 days (0.2 or 0.3 mg/kg) or 10 days (0.1 mg/kg) after anti-CD74 ADC administration versus 2 days after the final administration of busulfan (6 mg/kg/day), and the kinetics of neutrophil (19A) and platelet (19B) engraftment measured by hematology analyzer.
  • Myeloid cells (CD11b+) were isolated from peripheral blood, and genomic DNA was isolated for next-generation sequencing analysis to determine indel frequency at the CCR5 locus.
  • the editing efficiency for each post-transplant sample is expressed relative to the editing efficiency in the drug product.
  • Bone marrow aspirates were collected bi-monthly beginning 4 months post-transplant, and editing efficiency was measured in bone marrow Attorney Docket No.01245-0062-00PCT CD34+ cells (squares). Each colored line represents an individual animal.
  • Example 17 Drug Metabolism and Pharmacokinetics [00272] Pharmacokinetics (PK) and biodistribution of anti-CD74 ADC (clone 22) were evaluated in NHPs using sensitive and selective bioanalytical methods (total ADC/total antibody by ligand binding assays, unconjugated payload by LC-MS/MS). Following a single IV administration, anti-CD74 ADC exhibits a short residence time in circulation (effective T 1/2 2-5 hours) due to rapid target-mediated distribution into CD74-expressing tissues including bone marrow as the pharmacological site of action.
  • Results showing mean plasma pharmacokinetic parameters of total ADC and total antibody following a single intravenous administration of anti-CD74 ADC to cynomolgus monkeys are in Table 24 and FIGS.21A, 21B.
  • FIG.21A shows plasma PK profiles of total ADC
  • FIG.21B shows plasma PK profiles of total antibody with 2-4 NHPs per dose cohort and results are expressed as the arithmetic mean +/- standard deviation.
  • Table 25 shows individual and mean plasma toxicokinetic parameters of total antibody following a single intravenous administration of antiCD74ADC in cynomolgus monkeys.
  • FIGS.22A and 22B show individual plasma concentration-time profile of total ADC and total antibody following a single intravenous administration of anti-CD74ADC in cynomolgus monkeys.
  • Table 26 shows individual and mean plasma toxicokinetic parameters of free FGN849 following a single intravenous administration of anti-CD74 ADC in cynomolgus monkeys.
  • FIG.23 shows the individual plasma concentration-time profile of free FGN849 following a single intravenous administration of anti-CD74 ADC in cynomolgus monkeys.
  • Table 25 Individual and Mean Plasma Toxicokinetic Parameters of Total Antibody Following a Single Intravenous Administration of anti-CD74 ADC in Cynomolgus Monkeys * Animal 3501B showed unexpected TK profiles. Dose proportionality analysis at the 0.4 mg/kg dose only included 3001B.
  • Table 26 Individual and Mean Plasma Toxicokinetic Parameters of Free FGN849 Following a Single Intravenous Administration of BIO-111 in Cynomolgus Monkeys Attorney Docket No.01245-0062-00PCT * Animal 3501B showed unexpected TK profiles. Dose proportionality analysis at the 0.4 mg/kg dose only included 3001B.
  • anti-CD74 ADC Upon internalization with the target, anti-CD74 ADC undergoes linker cleavage via intracellular metabolism and releases FGN849 as the active catabolite that drives HSPC depletion in the bone marrow.
  • Systemic exposure of total ADC, total antibody, and FGN849 increased with escalating doses in an approximately dose-proportional manner.
  • the rapid clearance of anti-CD74 ADC provides the desired candidate profile for this indication so that HSCT can be performed 7-10 days following myeloablative conditioning.
  • Preliminary biodistribution data following a single 0.2 mg/kg IV dose of anti- CD74 ADC indicate that highest exposure to the intact ADC occurred in plasma, followed by spleen (a CD74 expressing tissue), which likely indicates target-mediated uptake of the ADC. Selective ADC distribution into spleen is consistent with this being a target organ for toxicity. In other tissues, including the bone marrow and gonads, the ADC exposure was approximately 4-60 fold and 2-30 fold lower than plasma and spleen, respectively. Comparative exposure data of the payload FGN849 in bone marrow versus other tissues are pending.
  • Anti-CD74 ADC has a low risk of drug interactions via effects on cytochrome P450 enzymes or drug transporters because of the ADC modality and the very low systemic exposure of FGN849.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The disclosure provides anti-CD74 antibodies, anti-CD74 antibody conjugates, compositions, and their use in reducing a population of hematopoietic cells.

Description

Attorney Docket No.01245-0062-00PCT ANTI-CD74 ANTIBODY COMPOSITIONS AND METHODS CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of priority of US Provisional Application Nos. 63/654,412, filed May 31, 2024, and 63/787,525, filed April 11, 2025, each of which is incorporated by reference herein in its entirety for any purpose. REFERENCE TO ELECTRONIC SEQUENCE LISTING [0002] The application contains a Sequence Listing which has been submitted electronically in .XML format and is hereby incorporated by reference in its entirety. Said .XML copy, created on May 27, 2025, is named “01245-0062-61US.xml” and is 678,549 bytes in size. The sequence listing contained in this .XML file is part of the specification and is hereby incorporated by reference herein in its entirety. FIELD [0003] Anti-CD74 antibodies and anti-CD74 antibody conjugates are provided, as well as their use in conditioning hemopoietic stem cells. BACKGROUND [0004] Hematopoietic cell transplantation is the administration of hematopoietic stem and progenitor cells to patients with a variety of acquired and inherited malignant and non- malignant disorders to establish marrow and immune function. Hematologic malignancies and non-malignant disorders are currently treated with high dose or lethal chemotherapy and/or radiation therapy conditioning regimens that are highly toxic to multiple organ systems, hematopoietic and non-hematopoietic cells, and the hematopoietic microenvironment prior to hematopoietic cell transplantation. These harsh conditioning regimens effectively kill the host subject's immune and niche cells and oftentimes adversely affect multiple organ systems, that may lead to life-threatening complications. [0005] There is a need for the development of conditioning regimens that avoid undesirable toxicity, minimize the incidence of serious adverse reactions, and reduce a patient’s risk of relapse. There is also a need for therapies that can selectively reduce an endogenous hematopoietic cell population in a target tissue, while minimizing or eliminating the effects of such therapies on non-targeted cells and tissues.  Attorney Docket No.01245-0062-00PCT SUMMARY [0006] In some embodiments, an isolated anti-CD74 antibody is provided. Such isolated anti-CD74 antibody binds to human CD74, wherein the antibody is optionally fully human or humanized. [0007] Accordingly, the following non-limiting embodiments are provided. Embodiment 1. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. Embodiment 2. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID Attorney Docket No.01245-0062-00PCT NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID Attorney Docket No.01245-0062-00PCT NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID Attorney Docket No.01245-0062-00PCT NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID Attorney Docket No.01245-0062-00PCT NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions. Embodiment 3. The isolated antibody of embodiment 1 or embodiment 2, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a heavy chain variable region (VH) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of embodiment 1.ii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of embodiment 1.iii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of embodiment 1.iv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of embodiment 1.v) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of embodiment 1.vi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of embodiment 1.vii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 712; or Attorney Docket No.01245-0062-00PCT viii) the CDRs of embodiment 1.viii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of embodiment 1.ix) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 912; or x) the CDRs of embodiment 1.x) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1012; or xi) the CDRs of embodiment 1.xi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of embodiment 1.xii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of embodiment 1.xv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of embodiment 1.xviii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1812. Embodiment 4. The isolated antibody of any one of claims 1-3, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of embodiment 1.ii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of embodiment 1.iii) and further comprises a comprising the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of embodiment 1.iv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of embodiment 1.v) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 512; or Attorney Docket No.01245-0062-00PCT vi) the CDRs of embodiment 1.vi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of embodiment 1.vii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 712; or viii) the CDRs of embodiment 1.viii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of embodiment 1.ix) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 912; or x) the CDRs of embodiment 1.x) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1012; or xi) the CDRs of embodiment 1.xi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of embodiment 1.xii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of embodiment 1.xv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of embodiment 1.xviii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1812. Embodiment 5. The isolated antibody of any one of embodiments 1-4, wherein the antibody comprises: i) the CDRs of embodiment 1.i) and further comprises a light chain variable region (VL) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of embodiment 1.ii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or Attorney Docket No.01245-0062-00PCT iii) the CDRs of embodiment 1.iii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of embodiment 1.iv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of embodiment 1.v) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of embodiment 1.vi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of embodiment 1.vii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the CDRs of embodiment 1.viii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the CDRs of embodiment 1.ix) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of embodiment 1.x) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of embodiment 1.xi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of embodiment 1.xii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of embodiment 1.xv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the CDRs of embodiment 1.xviii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 6. The isolated antibody of any one of embodiments 1-5, wherein the antibody comprises: Attorney Docket No.01245-0062-00PCT i) the CDRs of embodiment 1.i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of embodiment 1.ii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of embodiment 1.iii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of embodiment 1.iv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of embodiment 1.v) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of embodiment 1.vi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of embodiment 1.vii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 718; or viii) the CDRs of embodiment 1.viii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 818; or ix) the CDRs of embodiment 1.ix) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of embodiment 1.x) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of embodiment 1.xi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of embodiment 1.xii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of embodiment 1.xiii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of embodiment 1.xiv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of embodiment 1.xv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of embodiment 1.xvi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of embodiment 1.xvii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1718; or Attorney Docket No.01245-0062-00PCT xviii) the CDRs of embodiment 1.xviii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1818. Embodiment 7. The isolated antibody of any one of embodiments 1-6, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is Attorney Docket No.01245-0062-00PCT at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or Attorney Docket No.01245-0062-00PCT xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 8. The isolated antibody of any one of embodiments 1-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH comprises the amino acid sequence of SEQ ID NO: 12 and the VL comprises the amino acid sequence of SEQ ID NO: 18; or ii) the VH comprises the amino acid sequence of SEQ ID NO: 112 and the VL comprises the amino acid sequence of SEQ ID NO: 118; or iii) the VH comprises the amino acid sequence of SEQ ID NO: 212 and the VL comprises the amino acid sequence of SEQ ID NO: 218; or iv) the VH comprises the amino acid sequence of SEQ ID NO: 312 and the VL comprises the amino acid sequence of SEQ ID NO: 318; or v) the VH comprises the amino acid sequence of SEQ ID NO: 512 and the VL comprises the amino acid sequence of SEQ ID NO: 518; or vi) the VH comprises the amino acid sequence of SEQ ID NO: 612 and the VL comprises the amino acid sequence of SEQ ID NO: 618; or vii) the VH comprises the amino acid sequence of SEQ ID NO: 712 and the VL comprises the amino acid sequence of SEQ ID NO: 718; or viii) the VH comprises the amino acid sequence of SEQ ID NO: 812 and the VL comprises the amino acid sequence of SEQ ID NO: 818; or ix) the VH comprises the amino acid sequence of SEQ ID NO: 912 and the VL comprises the amino acid sequence of SEQ ID NO: 918; or x) the VH comprises the amino acid sequence of SEQ ID NO: 1012 and the VL comprises the amino acid sequence of SEQ ID NO: 1018; or xi) the VH comprises the amino acid sequence of SEQ ID NO: 1112 and the VL comprises the amino acid sequence of SEQ ID NO: 1118; or xii) the VH comprises the amino acid sequence of SEQ ID NO: 1212 and the VL comprises the amino acid sequence of SEQ ID NO: 1218; or Attorney Docket No.01245-0062-00PCT xiii) the VH comprises the amino acid sequence of SEQ ID NO: 1312 and the VL comprises the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH comprises the amino acid sequence of SEQ ID NO: 1412 and the VL comprises the amino acid sequence of SEQ ID NO: 1418; or xv) the VH comprises the amino acid sequence of SEQ ID NO: 1512 and the VL comprises the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH comprises the amino acid sequence of SEQ ID NO: 1612 and the VL comprises the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH comprises the amino acid sequence of SEQ ID NO: 1712 and the VL comprises the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH comprises the amino acid sequence of SEQ ID NO: 1812 and the VL comprises the amino acid sequence of SEQ ID NO: 1818. Embodiment 9. An isolated antibody that binds human CD74, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or Attorney Docket No.01245-0062-00PCT vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the Attorney Docket No.01245-0062-00PCT VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 10. The isolated antibody of embodiment 9, wherein the antibody comprises: i) the VH and VL of embodiment 8.i and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) the VH and VL of embodiment 8.ii and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) the VH and VL of embodiment 8.iii and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) Attorney Docket No.01245-0062-00PCT LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) the VH and VL of embodiment 8.iv and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at Attorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Embodiment 11. The isolated antibody of embodiment 9 or embodiment 10, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 12, 112, 212, 312, 512, 612, 712, 812, 912, 1012, 1112, 1212, 1312, 1412, 1512, 1612, 1712, or 1812. Attorney Docket No.01245-0062-00PCT Embodiment 12. The isolated antibody of any one of embodiments 9-11, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 18, 118, 218, 318, 518, 618, 718, 818, 918, 1018, 1118, 1218, 1318, 1418, 1518, 1618, 1718, or 1818. Embodiment 13. The isolated antibody of any one of the preceding embodiments, wherein the antibody is a monoclonal antibody. Embodiment 14. The isolated antibody of any one of the preceding embodiments, wherein the antibody is an antibody fragment. Embodiment 15. The isolated antibody of embodiment 14, wherein the fragment is a Fab, Fab’, Fv, scFv or (Fab’)2. Embodiment 16. The isolated antibody of any one of embodiments 1-13, wherein the antibody is a full-length antibody. Embodiment 17. The isolated antibody of any one of embodiments 1-13, wherein an Fc region of the antibody comprises IgG1, IgG2, IgG3, or IgG4. Embodiment 18. The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG1 heavy chain constant region. Embodiment 19. The isolated antibody of any one of embodiments 1-13, wherein the antibody comprises a human IgG4 heavy chain constant region. Embodiment 20. The isolated antibody of embodiment 18, wherein the antibody comprises a mutant human IgG1 heavy chain constant region. Embodiment 21. The isolated antibody of embodiment 20, wherein the mutant IgG1 heavy chain constant region comprises a mutation selected from a substitution at L234, a substitution at L235, a substitution at P329, or a combination thereof, according to EU numbering. Embodiment 22. The isolated antibody of embodiment 21, wherein the mutant IgG1 heavy chain constant region comprises an L234A substitution, an L234A substitution, and a P329A substitution or a combination thereof, according to EU numbering. Embodiment 23. The isolated antibody of any one of embodiments 20-22, wherein the mutant IgG1 heavy chain constant region comprises a deletion of K447, according to EU numbering. Embodiment 24. The isolated antibody of any one of embodiments 20-23, wherein the mutant IgG heavy chain constant region comprises a substitution at S239, according to EU numbering. Attorney Docket No.01245-0062-00PCT Embodiment 25. The isolated antibody of any one of embodiments 20-24, wherein the mutant IgG heavy chain constant region comprises an S239C substitution, according to EU numbering. Embodiment 26. The isolated antibody of any one of embodiments 1-13 and 16-25, wherein the antibody comprises a human IgG kappa light chain constant region. Embodiment 27. The isolated antibody of any one of embodiments 1-26, further comprising an effector molecule conjugated to the antibody. Embodiment 28. The isolated antibody of embodiment 27, wherein the effector molecule comprises a cytotoxic agent. Embodiment 29. The isolated antibody of embodiment 28, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. Embodiment 30. The isolated antibody of embodiment 28 or embodiment 29, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). Embodiment 31. The isolated antibody of any one of embodiments 28-30, wherein the cytotoxic agent is DGN549C. Embodiment 32. The isolated antibody of embodiment 31, wherein the DGN549C is conjugated to the antibody at an S239C substitution of a IgG heavy chain constant region. Embodiment 33. A humanized or fully human version of the antibody of any one of the preceding embodiments. Embodiment 34. A conjugate comprising an anti-CD74 antibody and an effector molecule conjugated to the antibody, the anti-CD74 antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; Attorney Docket No.01245-0062-00PCT and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 Attorney Docket No.01245-0062-00PCT with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one Attorney Docket No.01245-0062-00PCT or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 Attorney Docket No.01245-0062-00PCT with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with Attorney Docket No.01245-0062-00PCT one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID Attorney Docket No.01245-0062-00PCT NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 Attorney Docket No.01245-0062-00PCT with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions; or xix) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or Attorney Docket No.01245-0062-00PCT xx) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or xxi) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or xxii) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or xxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or xxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or xxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or xxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or xxvii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or xxviii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at Attorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xxix) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xxx) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xxxi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xxxii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xxxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xxxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xxxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xxxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. Attorney Docket No.01245-0062-00PCT Embodiment 35. The conjugate of embodiment 34, wherein the effector molecule comprises a cytotoxic agent. Embodiment 36. The conjugate of embodiment 35, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. Embodiment 37. The conjugate of embodiment 35 or embodiment 36, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). Embodiment 38. The conjugate of any one of embodiments 35-37, wherein the cytotoxic agent is DGN549C. Embodiment 39. The conjugate of any one of embodiments 34-38, wherein the anti-CD74 antibody comprises the isolated antibody of any one of claims 1, 3-12 and 16-26. Embodiment 40. A composition comprising the antibody of any one of embodiments 1-33 and a pharmaceutically acceptable carrier. Embodiment 41. A method of conditioning a subject to reduce an endogenous population of hematopoietic stem cells in the subject comprising administering an anti-CD74 antibody to the subject, the anti-CD74 antibody comprising the isolated antibody of any one of embodiments 1-13 and 16-26. Embodiment 42. The method of embodiment 41, further comprising an effector molecule conjugated to the antibody. Embodiment 43. The method of embodiment 42, wherein the effector molecule comprises a cytotoxic agent. Embodiment 44. The method of embodiment 43, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. Embodiment 45. The method of embodiment 43 or embodiment 44, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). Embodiment 46. The method of any one of embodiments 43-45, wherein the cytotoxic agent is DGN549C. Embodiment 47. The method of any one of embodiments 41-46, wherein the anti-CD74 antibody is internalized by the endogenous population of hematopoietic stem cells. Attorney Docket No.01245-0062-00PCT Embodiment 48. The method of any one of embodiments 41-47, wherein the anti-CD74 antibody comprises an effector silencing modification. Embodiment 49. The method of any one of embodiments 41-48, wherein the hematopoietic stem cells are reduced in bone marrow. Embodiment 50. The method of any one of embodiments 41-49, wherein the hematopoietic stem cells are CD34+ cells. Embodiment 51. The method of any one of embodiments 41-50, wherein the hematopoietic stem cells are human cells. Embodiment 52. The method of any one of embodiments 41-51, comprising administering a composition comprising cells following the conditioning of the subject to reduce the endogenous population of hematopoietic stem cells. Embodiment 53. The method of any one of embodiments 41-52, comprising administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs). Embodiment 54. The method of any one of embodiments 41-53, comprising administering a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs) that comprise a genetic modification. Embodiment 55. The method of any one of embodiments 41-54, wherein the subject has a hemoglobinopathy. Examples of a hemoglobinopathy include, for example, sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Embodiment 56. A nucleic acid encoding the antibody of any one of embodiments 1-26. Embodiment 57. A host cell comprising the nucleic acid of embodiment 56. Embodiment 58. A method of producing the antibody of any one of embodiments 1-26 comprising culturing the host cell of embodiment 57 under conditions wherein the antibody is expressed. Embodiment 59. The method of embodiment 58, further comprising purifying the antibody. BRIEF DESCRIPTION OF THE FIGURES [0008] FIG.1 depicts an exemplary anti-CD74 antibody conjugated to an exemplary effector molecule. [0009] FIGS.2A-2D show the binding of anti-CD74 antibodies from clone 1 (FIG.2A), clone 22 (FIG.2B), and clone 41 (FIG.2C) to primary human bone marrow CD34+ cells. FIG. 2D shows the antibody EC50 for each of the clones.  Attorney Docket No.01245-0062-00PCT [0010] FIGS.3A-3B show the binding of clone 3 anti-CD74 antibody to all CD34+CD90+ cells (FIG.3A), and FIG.3B shows the antibody EC50 comparison of clone 1 to clone 3. [0011] FIGS.4A-4D show binding of anti-CD74 antibody and ADC equivalent binding to primary human bone marrow CD34+ cells for clones 1, 3, 22, and 41. [0012] FIGS.5A-5C show the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells for each of clones 1, 22, and 41. FIG.5A shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ CD90+ cells. FIG.5B shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ CD90- cells. FIG.5C shows the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells. [0013] FIGS.6A-6B show the internalization of anti-CD74 antibodies into primary human bone marrow CD34+ cells. FIG.6A shows the internalization of anti-CD74 antibodies into primary human bone marrow CD34+CD90+ cells. FIG.6B shows the internalization of anti- CD74 antibodies into primary human bone marrow CD34+CD90 - cells. [0014] FIG.7 shows effector silencing of anti-CD74 antibodies. [0015] FIGS.8A-8B show the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells. FIG.8A shows the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells by cell number. FIG.8B shows the cytotoxic effect of anti- CD74 ADCs on primary human bone marrow CD34+ cells by percent. [0016] FIG.9 shows the cytotoxic effect of anti-CD74 ADCs on primary human bone marrow CD34+ cells for clone 3. [0017] FIGS.10A-10B show the cytotoxic effect of anti-CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells. FIG.10A shows the cytotoxic effect of anti- CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells by cell number. FIG. 10B shows the cytotoxic effect of anti-CD74 ADCs on primary cynomolgus monkey bone marrow CD34+ cells by percent. [0018] FIGS.11A-11B show the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line. FIG.11A shows the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line by cell number. FIG.11B shows the cytotoxic effect of anti-CD74 ADCs on a CD74 expressing cell line by percent. [0019] FIG.12A-12B show the lack of cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line. FIG.12A shows the cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line by cell number. FIG.12B shows the cytotoxic effect of anti-CD74 ADCs on a CD74 knockout cell line by percent. Attorney Docket No.01245-0062-00PCT [0020] FIG.13A-13C show evaluation of anti-CD74 antibody in Fc-dependent functional assays. FIG.13A shows ADCC. FIG.13B shows ADCP. FIG.13C shows CDC. [0021] FIG.14A-14B show CD74 copy expression on cryopreserved human (FIG.14A) and NHP (FIG.14B) CD34+ bone marrow cell subsets. [0022] FIG.15 shows CD74 expression on peripheral blood leukocyte subsets of human healthy donors, human subjects with SCD, and NHPs. [0023] FIGS.16A-16B show bone marrow hematopoietic stem cell and progenitor cell depletion following a single IV administration of anti-CD74-DGN549c in humanized mice. FIG.16A shows administration of V-003-0105-001 and FIG.16B shows administration of anti- CD74 ADC. [0024] FIGS.17A-17B show bone marrow hematopoietic stem cell and progenitor cell depletion following a single IV administration of anti-CD74-ADC in nonhuman primates at day 7 (FIG.17A) and day 21 (FIG.17B). [0025] FIGS.18A-18B show kinetics of neutrophil (FIG.18A) and platelet (FIG, 18B) depletion following a single IV administration of anti-CD74-ADC in nonhuman primates. [0026] FIGS.19A-19B show neutrophil (FIG.19A) and neutrophil (FIG.19B) engraftment following conditioning with a single IV administration of anti-CD74 ADC compared to a 4-day regimen of busulfan in nonhuman primates. [0027] FIG.20 shows gene-edited chimerism following conditioning with a single IV administration of anti-CD74 ADC compared to a 4-day regimen of busulfan in nonhuman primates. [0028] FIGS.21A-21B show plasma PK profiles of total ADC (FIG.21A) and total antibody (FIG.21B) in cynomolgus monkeys following single IV administration of anti-CD74 ADC. [0029] FIG.22A-22B show individual plasma concentration-time profile of total antibody (FIG.22A) and total ADC (FIG.22B) following single IV administration of anti-CD74 ADC in cynomolgus monkeys. [0030] FIG.23 shows individual plasma concentration-time profile of free payload FGN849 following single IV administration of anti-CD74 ADC in cynomolgus monkeys. DETAILED DESCRIPTION I. DEFINITIONS [0031] In this application, the use of “or” means “and/or” unless stated otherwise. In the context of a multiple dependent claim, the use of “or” refers back to more than one preceding Attorney Docket No.01245-0062-00PCT independent or dependent claim in the alternative only. The terms “comprising,” “including,” and “having” can be used interchangeably herein. [0032] The terms “CD74,” “DHLAG,” “CLIP,” “CD74 Antigen (Invariant Polypeptide Of Major Histocompatibility Complex, Class II Antigen-Associated),” “Poliovirus Receptor Related Immunoglobulin Domain Containing,” “CD74 Molecule, Major Histocompatibility Complex, Class II Invariant Chain,” “HLA Class II Histocompatibility Antigen Gamma Chain,” “Class II MHC-Associated Invariant Chain Peptide,” “HLA-DR Antigens-Associated Invariant Chain,” “Gamma Chain Of Class II Antigens,” “Ia-Associated Invariant Chain,” “MHC HLA- DR Gamma Chain,” “HLA-DR-Gamma,” “Ia Antigen-Associated Invariant Chain,” “CD74 Antigen,” “Ia-GAMMA,” “HLADG,” “P33,” “II,” and “Ii” are all used interchangeably and refer to a native, human CD74, unless otherwise specifically indicated (e.g. mouse CD74, cynomolgus CD74, etc.). The term includes full-length, unprocessed CD74 as well as any form of CD74 that results from processing in a cell. The term encompasses naturally occurring variants of human CD74, e.g., splice variants or allelic variants. External ID’s for CD74 gene include HGNC: 1697, NCBI Gene: 972, Ensembl: ENSG00000019582, OMIM: 142790, and UniProtKB: P04233. [0033] “Affinity” refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following. [0034] An “affinity matured” antibody refers to an antibody with one or more alterations in one or more hypervariable regions (HVRs), compared to a parent antibody which does not possess such alterations, such alterations optionally resulting in an improvement in the affinity of the antibody for antigen. [0035] The term “antibody” herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity. [0036] An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab’-SH, Attorney Docket No.01245-0062-00PCT F(ab')2; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments. [0037] The term “block,” “crossblock,” or “cross-block,” in the context of an interaction between two or more molecules, is used herein to refer to inhibition or prevention of said interaction between the two or more molecules, wherein the inhibition or prevention of said interaction between the two or more molecules is complete or nearly complete under at least one condition. A “nearly complete” inhibition is a percent inhibition of about 70 - 99.9 %, and a “complete” inhibition is 100%. For example, a molecule is said to “block” an interaction between two or more other molecules if it completely or nearly completely inhibits such interaction at certain concentrations in a dose dependent manner. [0038] The term “cancer” is used herein to refer to a group of cells that exhibit abnormally high levels of proliferation and growth. A cancer may be benign (also referred to as a benign tumor), pre-malignant, or malignant. Cancer cells may be solid cancer cells or leukemic cancer cells. The term “tumor” is used herein to refer to a cell or cells that comprise a cancer. The term “tumor growth” is used herein to refer to proliferation or growth by a cell or cells that comprise a cancer that leads to a corresponding increase in the size or extent of the cancer. [0039] The term “chimeric” antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species. [0040] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called ^, ^, ^, ^, and ^, respectively. [0041] Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive (sequential) administration in any order. [0042] The term “conjugate,” “immunoconjugate,” or “antibody drug conjugate” as used herein refers to the linkage of an antibody or an antigen binding fragment thereof with another effector molecule, such as a cytotoxic agent, an immunotherapeutic agent, an imaging probe, and the like. The linkage can be covalent bonds, or non-covalent interactions such as through electrostatic forces. Various linkers, known in the art, can be employed in order to form the conjugate. Additionally, the conjugate can be provided in the form of a fusion protein that may be expressed from a polynucleotide encoding the conjugate. As used herein, “fusion protein” refers to proteins created through the joining of two or more genes or gene fragments which Attorney Docket No.01245-0062-00PCT originally coded for separate proteins (including peptides and polypeptides). Translation of the fusion gene results in a single protein with functional properties derived from each of the original proteins. [0043] The term “cytotoxic agent” as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamicin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such as small molecule toxins (e.g., DNA inhibitors, topoisomerase inhibitors, or a tubulin inhibitors) or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof. [0044] “Effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation. [0045] An “effective amount” of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result. [0046] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In some embodiments, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present (numbering in this paragraph is according to the EU numbering system, also called the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991). [0047] “Framework,” “framework region,” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3- H3(L3)-FR4. Attorney Docket No.01245-0062-00PCT [0048] The terms “full length antibody,” “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein. [0049] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell and may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. [0050] A “human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non- human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues. [0051] As used herein, the term "humanized" refers to an antibody in which some, most or all of the amino acids outside the CDR domains of a non-human antibody are replaced with corresponding amino acids derived from human immunoglobulins. In some embodiments of a humanized form of an antibody, some, most or all of the amino acids outside the CDR domains have been replaced with amino acids from human immunoglobulins, whereas some, most or all amino acids within one or more CDR regions are unchanged. Small additions, deletions, insertions, substitutions or modifications of amino acids are permissible as long as they do not abrogate the ability of the antibody to bind to a particular antigen. A "humanized" antibody retains an antigenic specificity similar to that of the original antibody. [0052] The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al., J. Immunol.150:880-887 (1993); Clarkson et al., Nature 352:624-628 (1991). Attorney Docket No.01245-0062-00PCT [0053] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91-3242, Bethesda MD (1991), vols.1-3. In some embodiments, for the VL, the subgroup is subgroup kappa I as in Kabat et al., supra. In some embodiments, for the VH, the subgroup is subgroup III as in Kabat et al., supra. [0054] The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). The CDRs are the target protein-binding site of the antibody chains that harbors specificity for such target protein. There are three CDRs (CDR1-3, numbered sequentially from the N-terminus) in each human VL or VH, constituting about 15-20% of the variable domains. CDRs can be referred to by their region and order. For example, “VHCDR1” or “HCDR1” both refer to the first CDR of the heavy chain variable region. The CDRs are structurally complementary to the epitope of the target protein and are thus directly responsible for the binding specificity. The remaining stretches of the VL or VH, the so-called framework regions, exhibit less variation in amino acid sequence (Kuby, Immunology, 4th ed., Chapter 4. W.H. Freeman & Co., New York, 2000). The amino acid sequence boundaries of a given CDR can be determined using any of a number of well-known schemes, including those described by Kabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (“Kabat” numbering scheme), Al-Lazikani et al., (1997) JMB 273, 927-948 (“Chothia” numbering scheme) and ImMunoGenTics (IMGT) numbering (Lefranc, M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003) (“IMGT” numbering scheme). [0055] An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to an effector molecule, such as a cytotoxic agent. [0056] An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human. Attorney Docket No.01245-0062-00PCT [0057] An “isolated” antibody is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC). For review of methods for assessment of antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007). [0058] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present disclosure may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein. [0059] A “naked antibody” refers to an antibody that is not conjugated to a heterologous moiety (e.g., a cytotoxic moiety) or radiolabel. The naked antibody may be present in a pharmaceutical formulation. [0060] “Native antibodies” refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain. Attorney Docket No.01245-0062-00PCT [0061] “Percent (%) amino acid sequence identity” with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary. [0062] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program’s alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program. Attorney Docket No.01245-0062-00PCT [0063] The term “pharmaceutical formulation” or “pharmaceutical composition” refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. [0064] A “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation or composition, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. [0065] As used herein, “treatment” (and grammatical variations thereof such as “treat” or “treating”) refers to clinical intervention in an attempt to alter the natural course of the individual being treated and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the disclosure are used to delay development of a disease or to slow the progression of a disease. [0066] The term “vector,” as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as “expression vectors.” II. COMPOSITIONS AND METHODS [0067] Anti-CD74 antibodies, anti-CD74 antibody conjugates, compositions comprising the described antibodies, and methods of their use are provided. A. Exemplary Anti-CD74 Antibodies [0068] The Sequence Table below provides the sequences of certain embodiments of the antibodies disclosed and claimed herein. [0069] In some embodiments, antibodies are provided that bind to CD74. [0070] In some embodiments, the antibodies bind to human CD74. In some embodiments, the antibodies bind to human and/or cynomolgus CD74. [0071] In certain embodiments, an anti-CD74 antibody comprises a heavy chain variable region (“VH”) comprising VH CDR1, CDR2 and/or CDR3 of any of the anti-CD74 antibodies Attorney Docket No.01245-0062-00PCT provided herein (i.e., antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56). [0072] In certain embodiments, an anti-CD74 antibody comprises a VH comprising VH CDR1, CDR2 and/or CDR3 of any of the anti-CD74 antibodies provided herein and a VL comprising CDR1, CDR2 and/or CDR3 of any of the CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH comprising VH CDR1, CDR2 and/or CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, and a VL comprising VL CDR1, CDR2, and/or CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, optionally wherein the VH and VL CDRs are from the same antibody clone. [0073] In some embodiments, antibodies comprising the following are provided: (a) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or (b) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or Attorney Docket No.01245-0062-00PCT LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or (c) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; or (d) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or (e) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or (f) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or (g) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or (h) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or (i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or (j) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or Attorney Docket No.01245-0062-00PCT LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or (k) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or (l) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or (m) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or (n) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or (o) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or (p) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or (q) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or (r) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or Attorney Docket No.01245-0062-00PCT LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions. [0074] In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [0075] In some embodiments, antibodies comprising the following are provided: (a) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or (b) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or (c) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or (d) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or (e) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:; or (f) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO:603; with or without (d) LCDR1 comprising the amino acid sequence Attorney Docket No.01245-0062-00PCT of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or (g) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or (h) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or (i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or (j) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or (k) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO:; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or (l) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or (m) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; with or without (d) LCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or (n) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or (o) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO:1506; or (p) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or (q) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or (r) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; with or without (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. [0076] In certain embodiments, an anti-CD74 antibody comprises a VL comprising VL CDR1, CDR2 and CDR3 of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising VL CDR1, CDR2 and CDR3 of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [0077] In some embodiments, an anti-CD74 antibody may comprise: Attorney Docket No.01245-0062-00PCT (a) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 22 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 22; or (b) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 3 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 3; or (c) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 1 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 1; or (d) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 41 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 41; or (e) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 93 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 93; or (f) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 95 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 95; or (g) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 41 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 4; or (h) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 7 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 7; or (i) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 53 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 53; or (j) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 66 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 66; or (k) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 68 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 68; or Attorney Docket No.01245-0062-00PCT (l) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 76 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 76; or (m) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 77 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 77; or (n) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 60 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 60; or (o) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 61 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 61; or (p) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 33 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 33; or (q) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 49 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 49; or (r) a VH comprising the amino acid sequence of the VH CDR1, CDR2 and CDR3 of antibody clone number 56 and a VL comprising the VL CDR1, CDR2 and CDR3 of antibody clone number 56. [0078] The Sequence Table below provides the heavy and light chain variable region sequences of certain disclosed antibodies. [0079] In certain embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any of the CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any one of the antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [0080] In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions. In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions. Attorney Docket No.01245-0062-00PCT [0081] In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions outside the complementarity determining regions (CDRs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions outside the CDRs. In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions outside the complementarity determining regions (CDRs). [0082] In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions. In some embodiments, an anti-CD74 antibody comprises the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, or 5 reversion substitutions in the framework regions of the VH sequence. [0083] In some embodiments, an anti-CD74 antibody comprises the VH and VL CDRs of any of the anti-CD74 antibodies described herein, wherein each CDR comprises 0, 1, 2 or 3 amino acid additions, substitutions (e.g., conservative substitutions), or deletions. [0084] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, a CD74 antibody comprises a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of any one of the anti-CD74 antibodies provided herein. [0085] In some embodiments, an isolated antibody that binds human CD74 is provided, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: a) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or b) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, Attorney Docket No.01245-0062-00PCT 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or c) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or d) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or e) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or f) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or g) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or h) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or j) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or Attorney Docket No.01245-0062-00PCT k) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or l) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or m) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or n) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or o) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or p) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or q) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or r) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. [0086] In some embodiments, the isolated antibody comprises: a) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL is at least 90%, 91%, 92%, Attorney Docket No.01245-0062-00PCT 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or b) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or c) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or d) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or e) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the Attorney Docket No.01245-0062-00PCT amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or f) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or g) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or h) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or i) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or Attorney Docket No.01245-0062-00PCT j) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or k) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or l) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or m) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or n) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ Attorney Docket No.01245-0062-00PCT ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or o) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or p) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or q) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or r) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of Attorney Docket No.01245-0062-00PCT SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. [0087] In certain embodiments, an anti-CD74 antibody comprises a VH CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VH CDRs of any of the anti-CD74 antibodies provided herein and comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, a CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. In certain embodiments, the VH of the antibody differs from that of the VH sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions. In certain embodiments, the VH of the antibody differs from that of the VH sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 reversion substitutions in the framework regions of the VH sequence. [0088] In certain embodiments, an anti-CD74 antibody comprises a VH consisting of the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH that consists of the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [0089] In certain embodiments, an anti-CD74 antibody comprises a VL comprising the amino acid sequence of the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [0090] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of the corresponding anti-CD74 antibody. In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VH of any one of Attorney Docket No.01245-0062-00PCT antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, respectively (i.e., the VH and VL of clone 22, the VH and VL of clone 3, the VH and VL of clone 1, the VH and VL of clone 41, the VH and VL of clone 93, the VH and VL of clone 95, the VH and VL of clone 4, the VH and VL of clone 7, the VH and VL of clone 53, the VH and VL of clone 66, the VH and VL of clone 68, the VH and VL of clone 76, the VH and VL of clone 77, the VH and VL of clone 60, the VH and VL of clone 61, the VH and VL of clone 33, the VH and VL of clone 49, the VH and VL of clone 56). [0091] In certain embodiments, an anti-CD74 antibody comprises a VH consisting of the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and a VL comprising the amino acid sequence of the VL of the corresponding anti-CD74 antibody. In certain embodiments, an anti-CD74 antibody comprises a VH that consists of the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL that consists of the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, respectively (i.e., the VH and VL of clone 22, the VH and VL of clone 3, the VH and VL of clone 1, the VH and VL of clone 41, the VH and VL of clone 93, the VH and VL of clone 95, the VH and VL of clone 4, the VH and VL of clone 7, the VH and VL of clone 53, the VH and VL of clone 66, the VH and VL of clone 68, the VH and VL of clone 76, the VH and VL of clone 77, the VH and VL of clone 60, the VH and VL of clone 61, the VH and VL of clone 33, the VH and VL of clone 49, the VH and VL of clone 56). [0092] In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, deletions, and/or insertions. In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions. [0093] In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions outside the complementarity determining regions (CDRs), such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions outside the CDRs. In some embodiments, an anti-CD74 antibody comprises the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 but Attorney Docket No.01245-0062-00PCT with 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions outside the complementarity determining regions (CDRs). [0094] In certain embodiments, an anti-CD74 antibody comprises a VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VL CDRs of any of the anti-CD74 antibodies provided herein and comprises a VL that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. In certain embodiments, the VL of the antibody differs from that of the VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VL sequence, such as 1, 2, 3, 4, or 5 conservative substitutions. In certain embodiments, the VL of the antibody differs from that of the VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 reversion substitutions. [0095] In certain embodiments, an anti-CD74 antibody comprises a VL consisting of the amino acid sequence of the VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VL that consists of the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1,41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [0096] In certain embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any of the anti-CD74 antibodies provided herein and comprises a VL comprising the amino acid sequence of the VL of any of the same anti-CD74 antibodies provided herein. In certain of these embodiments, an anti-CD74 antibody comprises a VH comprising the amino acid sequence of the VH of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56 and a VL comprising the amino acid sequence of the VL of any one of antibody clone numbers 22, 3, 1, or 41, optionally wherein the VH and VL are from the same antibody clone number. [0097] In certain embodiments, the VH of the antibody is that of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, but with 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the VH sequence, such as 1, 2, 3, 4, or 5 conservative substitutions, and the VL is that of any one of the same antibody from the list above. In certain embodiments, however, the VH of the antibody is that of any one of antibody Attorney Docket No.01245-0062-00PCT clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56, but with 1, 2, 3, 4, or 5 substitutions in the framework regions of the VH sequence. [0098] In certain embodiments, an anti-CD74 antibody comprises a VH and a VL comprising the amino acid sequences of the VH and VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [0099] In certain embodiments, an anti-CD74 antibody comprises a VH CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VH CDRs of any of the anti-CD74 antibodies provided herein as well as a VL CDR1, CDR2, and CDR3 comprising the amino acid sequences of the VL CDRs of any of the anti-CD74 antibodies provided herein, and also comprises a VH and a VL that are each at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the corresponding VH and VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, the VH and the VL of the antibody differ from the VH and VL sequences shown in the Sequence Table due to 1, 2, 3, 4, or 5 amino acid substitutions in the framework regions of the sequences, such as 1, 2, 3, 4, or 5 conservative substitutions, or such as 1, 2, 3, 4 or 5 reversion substitutions. [00100] In certain embodiments, an anti-CD74 antibody comprises a VH and a VL consisting of the amino acid sequence of the VH and VL of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a VH and a VL that each consist of the amino acid sequences of the VH and VL of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [00101] An anti-CD74 antibody may comprise: (a) a VH comprising the amino acid sequence of the VH of antibody clone number 22 and a VL comprising the amino acid sequence of the VL of antibody clone number 22; or (b) a VH comprising the amino acid sequence of the VH of antibody clone number 3 and a VL comprising the amino acid sequence of the VL of antibody clone number 3; or (c) a VH comprising the amino acid sequence of the VH of antibody clone number 1 and a VL comprising the amino acid sequence of the VL of antibody clone number 1; or (d) a VH comprising the amino acid sequence of the VH of antibody clone number 41 and a VL comprising the amino acid sequence of the VL of antibody clone number 41; or (e) a VH comprising the amino acid sequence of the VH of antibody clone number 93 and a VL comprising the amino acid sequence of the VL of antibody clone number 93; or (f) a VH comprising the amino acid sequence of the VH of antibody clone number 95 and a VL comprising the amino acid sequence of the VL of antibody clone number 95; or Attorney Docket No.01245-0062-00PCT (g) a VH comprising the amino acid sequence of the VH of antibody clone number 4 and a VL comprising the amino acid sequence of the VL of antibody clone number 4; or (h) a VH comprising the amino acid sequence of the VH of antibody clone number 7 and a VL comprising the amino acid sequence of the VL of antibody clone number 7; or (i) a VH comprising the amino acid sequence of the VH of antibody clone number 53 and a VL comprising the amino acid sequence of the VL of antibody clone number 53; or (j) a VH comprising the amino acid sequence of the VH of antibody clone number 66 and a VL comprising the amino acid sequence of the VL of antibody clone number 66; or (k) a VH comprising the amino acid sequence of the VH of antibody clone number 68 and a VL comprising the amino acid sequence of the VL of antibody clone number 68; or (l) a VH comprising the amino acid sequence of the VH of antibody clone number 76 and a VL comprising the amino acid sequence of the VL of antibody clone number 76; or (m) a VH comprising the amino acid sequence of the VH of antibody clone number 77 and a VL comprising the amino acid sequence of the VL of antibody clone number 77; or (n) a VH comprising the amino acid sequence of the VH of antibody clone number 60 and a VL comprising the amino acid sequence of the VL of antibody clone number 60; or (o) a VH comprising the amino acid sequence of the VH of antibody clone number 61 and a VL comprising the amino acid sequence of the VL of antibody clone number 61; or (p) a VH comprising the amino acid sequence of the VH of antibody clone number 33 and a VL comprising the amino acid sequence of the VL of antibody clone number 33; or (q) a VH comprising the amino acid sequence of the VH of antibody clone number 49 and a VL comprising the amino acid sequence of the VL of antibody clone number 49; or (r) a VH comprising the amino acid sequence of the VH of antibody clone number 56 and a VL comprising the amino acid sequence of the VL of antibody clone number 56. [00102] An anti-CD74 antibody may comprise: (a) a VH comprising the VH CDRs of the VH of antibody clone number 22, and a VL comprising the VL CDRs of antibody clone number 22, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 22; or (b) a VH comprising the VH CDRs of the VH of antibody clone number 3, and a VL comprising the VL CDRs of antibody clone number 3, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 3; or Attorney Docket No.01245-0062-00PCT (c) a VH comprising the VH CDRs of the VH of antibody clone number 1, and a VL comprising the VL CDRs of antibody clone number 1, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 1; or (d) a VH comprising the VH CDRs of the VH of antibody clone number 41, and a VL comprising the VL CDRs of antibody clone number 41, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 41; or (e) a VH comprising the VH CDRs of the VH of antibody clone number 93, and a VL comprising the VL CDRs of antibody clone number 93, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 93; or (f) a VH comprising the VH CDRs of the VH of antibody clone number 95, and a VL comprising the VL CDRs of antibody clone number 95, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 95; or (g) a VH comprising the VH CDRs of the VH of antibody clone number 4, and a VL comprising the VL CDRs of antibody clone number 4, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 4; or (h) a VH comprising the VH CDRs of the VH of antibody clone number 7, and a VL comprising the VL CDRs of antibody clone number 7, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 7; or (i) a VH comprising the VH CDRs of the VH of antibody clone number 53, and a VL comprising the VL CDRs of antibody clone number 53, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 53; or Attorney Docket No.01245-0062-00PCT (j) a VH comprising the VH CDRs of the VH of antibody clone number 66, and a VL comprising the VL CDRs of antibody clone number 66, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 66; or (k) a VH comprising the VH CDRs of the VH of antibody clone number 67, and a VL comprising the VL CDRs of antibody clone number 68, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 68; or (l) a VH comprising the VH CDRs of the VH of antibody clone number 76, and a VL comprising the VL CDRs of antibody clone number 76, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 76; or (m) a VH comprising the VH CDRs of the VH of antibody clone number 77, and a VL comprising the VL CDRs of antibody clone number 77, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 77; or (n) a VH comprising the VH CDRs of the VH of antibody clone number 60, and a VL comprising the VL CDRs of antibody clone number 60, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 60; or (o) a VH comprising the VH CDRs of the VH of antibody clone number 61, and a VL comprising the VL CDRs of antibody clone number 61, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 61; or (p) a VH comprising the VH CDRs of the VH of antibody clone number 33, and a VL comprising the VL CDRs of antibody clone number 33, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 33; or Attorney Docket No.01245-0062-00PCT (q) a VH comprising the VH CDRs of the VH of antibody clone number 49, and a VL comprising the VL CDRs of antibody clone number 49, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 49; or (r) a VH comprising the VH CDRs of the VH of antibody clone number 56, and a VL comprising the VL CDRs of antibody clone number 56, and VH and VL amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the VH and VL of antibody clone number 56. [00103] In some of the above embodiments, the VH and/or VL may differ from the sequence of each of the species by the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, and/or insertions, and/or deletions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions. In some embodiments, the VH may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions. [00104] An anti-CD74 antibody may comprise: (a) a VH consisting of the amino acid sequence of the VH of antibody clone number 22 and a VL consisting of the VL of antibody clone number 22; or (b) a VH consisting of the amino acid sequence of the VH of antibody clone number 3 and a VL consisting of the VL of antibody clone number 3; or (c) a VH consisting of the amino acid sequence of the VH of antibody clone number 1 and a VL consisting of the VL of antibody clone number 1; or (d) a VH consisting of the amino acid sequence of the VH of antibody clone number 41 and a VL consisting of the VL of antibody clone number 41; or (e) a VH consisting of the amino acid sequence of the VH of antibody clone number 93 and a VL consisting of the VL of antibody clone number 93; or (f) a VH consisting of the amino acid sequence of the VH of antibody clone number 95 and a VL consisting of the VL of antibody clone number 95; or (g) a VH consisting of the amino acid sequence of the VH of antibody clone number 4 and a VL consisting of the VL of antibody clone number 4; or (h) a VH consisting of the amino acid sequence of the VH of antibody clone number 7 and a VL consisting of the VL of antibody clone number 7; or (i) a VH consisting of the amino acid sequence of the VH of antibody clone number 53 and a VL consisting of the VL of antibody clone number 53; or Attorney Docket No.01245-0062-00PCT (j) a VH consisting of the amino acid sequence of the VH of antibody clone number 66 and a VL consisting of the VL of antibody clone number 66; or (k) a VH consisting of the amino acid sequence of the VH of antibody clone number 68 and a VL consisting of the VL of antibody clone number 68; or (l) a VH consisting of the amino acid sequence of the VH of antibody clone number 76 and a VL consisting of the VL of antibody clone number 76; or (m) a VH consisting of the amino acid sequence of the VH of antibody clone number 77 and a VL consisting of the VL of antibody clone number 77; or (n) a VH consisting of the amino acid sequence of the VH of antibody clone number 60 and a VL consisting of the VL of antibody clone number 60; or (o) a VH consisting of the amino acid sequence of the VH of antibody clone number 61 and a VL consisting of the VL of antibody clone number 61; or (p) a VH consisting of the amino acid sequence of the VH of antibody clone number 33 and a VL consisting of the VL of antibody clone number 33; or (q) a VH consisting of the amino acid sequence of the VH of antibody clone number 49 and a VL consisting of the VL of antibody clone number 49; or (r) a VH consisting of the amino acid sequence of the VH of antibody clone number 56 and a VL consisting of the VL of antibody clone number 56. [00105] In certain embodiments, an anti-CD74 antibody comprises any of the variable regions and/or variable region CDRs 1-3 of the antibodies described above and elsewhere herein, such as in the Sequence Table. [00106] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 12 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 18. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the Attorney Docket No.01245-0062-00PCT amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 12 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 18; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00107] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 22 and a VL comprising an Attorney Docket No.01245-0062-00PCT amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 22. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 22 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 22; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 22; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 22. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 22 or HCDR1 of clone 22 with one or two amino acid substitutions, HCDR2 of clone 22 or HCDR2 of clone 22 with one or two amino acid substitutions, HCDR3 of clone 22 or HCDR3 of clone 22 with one or two amino acid substitutions, LCDR1 of clone 22 or LCDR1 of clone 22 with one or two amino acid substitutions, LCDR2 of clone 22 or LCDR2 of clone 22 with one or two amino acid substitutions, and LCDR3 of clone 22 or LCDR3 of clone 22 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00108] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 118. In certain embodiments, an anti- Attorney Docket No.01245-0062-00PCT CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative Attorney Docket No.01245-0062-00PCT amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00109] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 3 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 3. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 3 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 3; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 3; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 3. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 3 or HCDR1 of clone 3 with one or two amino acid substitutions, HCDR2 of clone 3 or HCDR2 of clone 3 with one or two amino acid substitutions, HCDR3 of clone 3 or HCDR3 of clone 3 with one or two amino acid substitutions, LCDR1 of clone 3 or LCDR1 of clone 3 with one or two amino acid substitutions, LCDR2 of clone 3 or LCDR2 of clone 3 with one or two amino acid substitutions, and LCDR3 of clone 3 or LCDR3 of clone 3 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00110] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% Attorney Docket No.01245-0062-00PCT identical to the amino acid sequence of SEQ ID NO: 218. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 218. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00111] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 1 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 1. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 1 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 1; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 1; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 1. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 1 or HCDR1 of clone 1 with one or two amino acid substitutions, HCDR2 of clone 1 or HCDR2 of clone 1 with one or two amino acid substitutions, HCDR3 of clone 1 or HCDR3 of clone 1 with one or two amino acid substitutions, LCDR1 of clone 1 or LCDR1 of clone 1 with one or two amino acid substitutions, LCDR2 of clone 1 or LCDR2 of clone 1 with one or two amino acid substitutions, and LCDR3 of clone 1 or LCDR3 of clone 1 with one or two amino acid substitutions. In some embodiments, the one or Attorney Docket No.01245-0062-00PCT two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00112] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 318. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00113] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 41 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 41. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 41 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 41; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 41; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 41. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 41 or HCDR1 of clone Attorney Docket No.01245-0062-00PCT 41 with one or two amino acid substitutions, HCDR2 of clone 41 or HCDR2 of clone 41 with one or two amino acid substitutions, HCDR3 of clone 41 or HCDR3 of clone 41 with one or two amino acid substitutions, LCDR1 of clone 41 or LCDR1 of clone 41 with one or two amino acid substitutions, LCDR2 of clone 41 or LCDR2 of clone 41 with one or two amino acid substitutions, and LCDR3 of clone 41 or LCDR3 of clone 41 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00114] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 518. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00115] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 93 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 93. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 93 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 93; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 93; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 93. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 93 or HCDR1 of clone 93 with one or two amino acid substitutions, HCDR2 of clone 93 or HCDR2 of clone 93 with one or two amino acid substitutions, HCDR3 of clone 93 or HCDR3 of clone 93 with one or two amino acid substitutions, LCDR1 of clone 93 or LCDR1 of clone 93 with one or two amino acid substitutions, LCDR2 of clone 93 or LCDR2 of clone 93 with one or two amino acid substitutions, and LCDR3 of clone 93 or LCDR3 of clone 93 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00116] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 618. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 618; and (a) Attorney Docket No.01245-0062-00PCT HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00117] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 95 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 95. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 95 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions Attorney Docket No.01245-0062-00PCT compared to the amino acid sequence of clone 95. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 95 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 95; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 95 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 95; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 95. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 95 or HCDR1 of clone 95 with one or two amino acid substitutions, HCDR2 of clone 95 or HCDR2 of clone 95 with one or two amino acid substitutions, HCDR3 of clone 95 or HCDR3 of clone 95 with one or two amino acid substitutions, LCDR1 of clone 95 or LCDR1 of clone 95 with one or two amino acid substitutions, LCDR2 of clone 95 or LCDR2 of clone 95 with one or two amino acid substitutions, and LCDR3 of clone 95 or LCDR3 of clone 95 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00118] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 718. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00119] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 4 and a VL comprising an amino Attorney Docket No.01245-0062-00PCT acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 4. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 4 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 4; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 4; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 4. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 4 or HCDR1 of clone 4 with one or two amino acid substitutions, HCDR2 of clone 4 or HCDR2 of clone 4 with one or two amino acid substitutions, HCDR3 of clone 4 or HCDR3 of clone 4 with one or two amino acid substitutions, LCDR1 of clone 4 or LCDR1 of clone 4 with one or two amino acid substitutions, LCDR2 of clone 4 or LCDR2 of clone 4 with one or two amino acid substitutions, and LCDR3 of clone 4 or LCDR3 of clone 4 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00120] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 818. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, Attorney Docket No.01245-0062-00PCT 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative Attorney Docket No.01245-0062-00PCT amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00121] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 7 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 7. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 7 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 7; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 7; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 7. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 7 or HCDR1 of clone 7 with one or two amino acid substitutions, HCDR2 of clone 7 or HCDR2 of clone 7 with one or two amino acid substitutions, HCDR3 of clone 7 or HCDR3 of clone 7 with one or two amino acid substitutions, LCDR1 of clone 7 or LCDR1 of clone 7 with one or two amino acid substitutions, LCDR2 of clone 7 or LCDR2 of clone 7 with one or two amino acid substitutions, and LCDR3 of clone 7 or LCDR3 of clone 7 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00122] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% Attorney Docket No.01245-0062-00PCT identical to the amino acid sequence of SEQ ID NO: 918. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 912 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 918. In certain embodiments, an anti- CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 912 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 918; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00123] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 53 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 53. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 53 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 53; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 53; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 53. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 53 or HCDR1 of clone 53 with one or two amino acid substitutions, HCDR2 of clone 53 or HCDR2 of clone 53 with one or two amino acid substitutions, HCDR3 of clone 53 or HCDR3 of clone 53 with one or two amino acid substitutions, LCDR1 of clone 53 or LCDR1 of clone 53 with one or two amino acid substitutions, LCDR2 of clone 53 or LCDR2 of clone 53 with one or two amino acid substitutions, and LCDR3 of clone 53 or LCDR3 of clone 53 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative Attorney Docket No.01245-0062-00PCT amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00124] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1012 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1018. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1012 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1018; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence Attorney Docket No.01245-0062-00PCT of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00125] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 66 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 66. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 66 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 66; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 66; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 66. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 66 or HCDR1 of clone Attorney Docket No.01245-0062-00PCT 66 with one or two amino acid substitutions, HCDR2 of clone 66 or HCDR2 of clone 66 with one or two amino acid substitutions, HCDR3 of clone 66 or HCDR3 of clone 66 with one or two amino acid substitutions, LCDR1 of clone 66 or LCDR1 of clone 66 with one or two amino acid substitutions, LCDR2 of clone 66 or LCDR2 of clone 66 with one or two amino acid substitutions, and LCDR3 of clone 66 or LCDR3 of clone 66 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00126] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1118. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1112 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1118; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00127] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 68 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 68. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 68 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 68; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 68; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 68. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 68 or HCDR1 of clone 68 with one or two amino acid substitutions, HCDR2 of clone 68 or HCDR2 of clone 68 with one or two amino acid substitutions, HCDR3 of clone 68 or HCDR3 of clone 68 with one or two amino acid substitutions, LCDR1 of clone 68 or LCDR1 of clone 68 with one or two amino acid substitutions, LCDR2 of clone 68 or LCDR2 of clone 68 with one or two amino acid substitutions, and LCDR3 of clone 68 or LCDR3 of clone 68 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00128] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1218. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1212 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of Attorney Docket No.01245-0062-00PCT SEQ ID NO: 1218; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00129] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 76 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 76. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 76 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions Attorney Docket No.01245-0062-00PCT compared to the amino acid sequence of clone 76. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 76 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 76; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 76 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 76; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 76. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 76 or HCDR1 of clone 76 with one or two amino acid substitutions, HCDR2 of clone 76 or HCDR2 of clone 76 with one or two amino acid substitutions, HCDR3 of clone 76 or HCDR3 of clone 76 with one or two amino acid substitutions, LCDR1 of clone 76 or LCDR1 of clone 76 with one or two amino acid substitutions, LCDR2 of clone 76 or LCDR2 of clone 76 with one or two amino acid substitutions, and LCDR3 of clone 76 or LCDR3 of clone 76 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00130] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1318. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1312 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1318; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00131] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 77 and a VL comprising an Attorney Docket No.01245-0062-00PCT amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 77. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 77 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 77; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 77; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 77. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 77 or HCDR1 of clone 77 with one or two amino acid substitutions, HCDR2 of clone 77 or HCDR2 of clone 77 with one or two amino acid substitutions, HCDR3 of clone 77 or HCDR3 of clone 77 with one or two amino acid substitutions, LCDR1 of clone 77 or LCDR1 of clone 77 with one or two amino acid substitutions, LCDR2 of clone 77 or LCDR2 of clone 77 with one or two amino acid substitutions, and LCDR3 of clone 77 or LCDR3 of clone 77 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00132] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1412 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1418. In certain Attorney Docket No.01245-0062-00PCT embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1412 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1418; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are Attorney Docket No.01245-0062-00PCT conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00133] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 60 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 60. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 60 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 60; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 60; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 60. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 60 or HCDR1 of clone 60 with one or two amino acid substitutions, HCDR2 of clone 60 or HCDR2 of clone 60 with one or two amino acid substitutions, HCDR3 of clone 60 or HCDR3 of clone 60 with one or two amino acid substitutions, LCDR1 of clone 60 or LCDR1 of clone 60 with one or two amino acid substitutions, LCDR2 of clone 60 or LCDR2 of clone 60 with one or two amino acid substitutions, and LCDR3 of clone 60 or LCDR3 of clone 60 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00134] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1518. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1512 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1518; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid Attorney Docket No.01245-0062-00PCT sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00135] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 61 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 61. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 61 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 61; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 61; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 61. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 61 or HCDR1 of clone 61 with one or two amino acid substitutions, HCDR2 of clone 61 or HCDR2 of clone 61 with one or two amino acid substitutions, HCDR3 of clone 61 or HCDR3 of clone 61 with one or two amino acid substitutions, LCDR1 of clone 61 or LCDR1 of clone 61 with one or two amino acid substitutions, LCDR2 of clone 61 or LCDR2 of clone 61 with one or two amino acid substitutions, and LCDR3 of clone 61 or LCDR3 of clone 61 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00136] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1618. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1612 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1618; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising Attorney Docket No.01245-0062-00PCT the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00137] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 33 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 33. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 33 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 33; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 33. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 33; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 33. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 33. In Attorney Docket No.01245-0062-00PCT certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 33 or HCDR1 of clone 33 with one or two amino acid substitutions, HCDR2 of clone 33 or HCDR2 of clone 33 with one or two amino acid substitutions, HCDR3 of clone 33 or HCDR3 of clone 33 with one or two amino acid substitutions, LCDR1 of clone 33 or LCDR1 of clone 33 with one or two amino acid substitutions, LCDR2 of clone 33 or LCDR2 of clone 33 with one or two amino acid substitutions, and LCDR3 of clone 33 or LCDR3 of clone 33 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00138] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1718. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1712 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1718; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706. In certain Attorney Docket No.01245-0062-00PCT embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00139] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 49 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 49. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 49 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 49; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 49. In certain Attorney Docket No.01245-0062-00PCT embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 49; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 49. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 49. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 49 or HCDR1 of clone 49 with one or two amino acid substitutions, HCDR2 of clone 49 or HCDR2 of clone 49 with one or two amino acid substitutions, HCDR3 of clone 49 or HCDR3 of clone 49 with one or two amino acid substitutions, LCDR1 of clone 49 or LCDR1 of clone 49 with one or two amino acid substitutions, LCDR2 of clone 49 or LCDR2 of clone 49 with one or two amino acid substitutions, and LCDR3 of clone 49 or LCDR3 of clone 49 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00140] In certain embodiments, an anti-CD74 antibody comprises a VH that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. In certain embodiments, an anti- CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1818. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1812 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 Attorney Docket No.01245-0062-00PCT amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of SEQ ID NO: 1818; and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. In certain embodiments, an anti-CD74 antibody comprises (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non-conservative amino acid substitutions. [00141] In certain embodiments, an anti-CD74 antibody comprises a VH comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VH of clone number 56 and a VL comprising an amino acid sequence that is at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 100% identical to the amino acid sequence of the VL of clone number 56. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56 and a VL Attorney Docket No.01245-0062-00PCT comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56. In certain embodiments, an anti-CD74 antibody comprises a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 56 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of clone 56; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 56. In certain embodiments, an anti-CD74 antibody comprises a VH comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56 and a VL comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to the amino acid sequence of clone 56; and HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 56. In certain embodiments, an anti-CD74 antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of clone 56. In certain embodiments, an anti-CD74 antibody comprises HCDR1 of clone 56 or HCDR1 of clone 56 with one or two amino acid substitutions, HCDR2 of clone 56 or HCDR2 of clone 56 with one or two amino acid substitutions, HCDR3 of clone 56 or HCDR3 of clone 56 with one or two amino acid substitutions, LCDR1 of clone 56 or LCDR1 of clone 56 with one or two amino acid substitutions, LCDR2 of clone 56 or LCDR2 of clone 56 with one or two amino acid substitutions, and LCDR3 of clone 56 or LCDR3 of clone 56 with one or two amino acid substitutions. In some embodiments, the one or two amino acid substitutions are conservative amino acid substitutions. In some embodiments, the one or two amino acid substitutions are non- conservative amino acid substitutions. [00142] In some embodiments, the anti-CD74 antibody is an IgG antibody, such as IgG1, IgG2, IgG3 or IgG4 antibody or a modified form thereof as described in the section below. In some embodiments, the constant region has effector function, and in some embodiments, the constant region is effectorless. [00143] In certain embodiments, an anti-CD74 antibody comprises a heavy chain (HC) comprising the amino acid sequence of the heavy chain of any of the anti-CD74 antibodies provided herein. In certain embodiments, an anti-CD74 antibody comprises a heavy chain comprising the amino acid sequence of the heavy chain of any one of antibody clone numbers 22, 3, 1, 41, 93, 95, 4, 7, 53, 66, 68, 76, 77, 60, 61, 33, 49, or 56. [00144] In some embodiments, an anti-CD74 antibody may comprise: (a) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 22 and a light chain comprising the light chain amino acid sequence of antibody clone number 22; or Attorney Docket No.01245-0062-00PCT (b) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 3 and a light chain comprising the light chain amino acid sequence of antibody clone number 3; or (c) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 1 and a light chain comprising the light chain amino acid sequence of antibody clone number 1; or (d) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 41 and a light chain comprising the light chain amino acid sequence of antibody clone number 41; or (e) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 93 and a light chain comprising the light chain amino acid sequence of antibody clone number 93; or (f) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 95 and a light chain comprising the light chain amino acid sequence of antibody clone number 95; or (g) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 4 and a light chain comprising the light chain amino acid sequence of antibody clone number 4; or (h) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 7 and a light chain comprising the light chain amino acid sequence of antibody clone number 7; or (i) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 53 and a light chain comprising the light chain amino acid sequence of antibody clone number 53; or (j) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 66 and a light chain comprising the light chain amino acid sequence of antibody clone number 66; or (k) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 68 and a light chain comprising the light chain amino acid sequence of antibody clone number 68; or (l) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 76 and a light chain comprising the light chain amino acid sequence of antibody clone number 76; or Attorney Docket No.01245-0062-00PCT (m) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 77 and a light chain comprising the light chain amino acid sequence of antibody clone number 77; or (n) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 60 and a light chain comprising the light chain amino acid sequence of antibody clone number 60; or (o) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 61 and a light chain comprising the light chain amino acid sequence of antibody clone number 61; or (p) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 33 and a light chain comprising the light chain amino acid sequence of antibody clone number 33; or (q) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 49 and a light chain comprising the light chain amino acid sequence of antibody clone number 49; or (r) a heavy chain comprising the amino acid sequence of the heavy chain of antibody clone number 56 and a light chain comprising the light chain amino acid sequence of antibody clone number 56. [00145] An anti-CD74 antibody may comprise: (a) a heavy chain (HC) comprising the HC CDRs of the HC of antibody clone number 22 and a light chain (LC) comprising the LC CDRs of antibody clone number 22 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 22, respectively; or (b) a HC comprising the HC CDRs of the HC of antibody clone number 3, and a light chain (LC) comprising the LC CDRs of antibody clone number 3 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 3, respectively; or (c) a HC comprising the HC CDRs of the HC of antibody clone number 1, and a light chain (LC) comprising the LC CDRs of antibody clone number 1 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 1, respectively; or Attorney Docket No.01245-0062-00PCT (d) a HC comprising the HC CDRs of the HC of antibody clone number 41, and a light chain (LC) comprising the LC CDRs of antibody clone number 41 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 41, respectively; or (e) a HC comprising the HC CDRs of the HC of antibody clone number 93, and a light chain (LC) comprising the LC CDRs of antibody clone number 93 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 93, respectively; or (f) a HC comprising the HC CDRs of the HC of antibody clone number 95, and a light chain (LC) comprising the LC CDRs of antibody clone number 95 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 95, respectively; or (g) a HC comprising the HC CDRs of the HC of antibody clone number 4, and a light chain (LC) comprising the LC CDRs of antibody clone number 4 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 4, respectively; or (h) a HC comprising the HC CDRs of the HC of antibody clone number 7, and a light chain (LC) comprising the LC CDRs of antibody clone number 7 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 7, respectively; or (i) a HC comprising the HC CDRs of the HC of antibody clone number 53, and a light chain (LC) comprising the LC CDRs of antibody clone number 53 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 54, respectively; or (j) a HC comprising the HC CDRs of the HC of antibody clone number 66, and a light chain (LC) comprising the LC CDRs of antibody clone number 66 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 66, respectively; or Attorney Docket No.01245-0062-00PCT (k) a HC comprising the HC CDRs of the HC of antibody clone number 68, and a light chain (LC) comprising the LC CDRs of antibody clone number 68 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 68, respectively; or (l) a HC comprising the HC CDRs of the HC of antibody clone number 76, and a light chain (LC) comprising the LC CDRs of antibody clone number 76 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 76, respectively; or (m) a HC comprising the HC CDRs of the HC of antibody clone number 77, and a light chain (LC) comprising the LC CDRs of antibody clone number 77 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 77, respectively; or (n) a HC comprising the HC CDRs of the HC of antibody clone number 60, and a light chain (LC) comprising the LC CDRs of antibody clone number 60 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 60, respectively; or (o) a HC comprising the HC CDRs of the HC of antibody clone number 61, and a light chain (LC) comprising the LC CDRs of antibody clone number 61 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 61, respectively; or (p) a HC comprising the HC CDRs of the HC of antibody clone number 33, and a light chain (LC) comprising the LC CDRs of antibody clone number 33 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 33, respectively; or (q) a HC comprising the HC CDRs of the HC of antibody clone number 49, and a light chain (LC) comprising the LC CDRs of antibody clone number 49 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 49, respectively; or Attorney Docket No.01245-0062-00PCT (r) a HC comprising the HC CDRs of the HC of antibody clone number 56, and a light chain (LC) comprising the LC CDRs of antibody clone number 56 and HC and LC amino acid sequences that are at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the HC and LC of antibody clone number 56, respectively. [00146] In some of the above embodiments, the HC and/or LC may differ from the sequence of each of the species by the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, or deletions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 conservative substitutions. In some of the above embodiments, the HC and/or LC may differ from the sequence of each of the species by the presence of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 reversion substitutions. [00147] In any of the embodiments having one or more amino acid substitutions, the amino acid substitutions may be conservative amino acid substitutions or non-conservative amino acid substitutions. 1. Antibody Fragments [00148] In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab’, Fab’-SH, F(ab’)2, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson et al. Nat. Med.9:129-134 (2003). For a review of scFv fragments, see, e.g., Pluckthün, in The Pharmacology of Monoclonal Antibodies, vol.113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp.269-315 (1994); see also WO 93/16185; and U.S. Patent Nos.5,571,894 and 5,587,458. For discussion of Fab and F(ab')2 fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No.5,869,046. [00149] Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404,097; WO 1993/01161; Hudson et al., Nat. Med.9:129-134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat. Med.9:129-134 (2003). [00150] Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No.6,248,516 B1). Attorney Docket No.01245-0062-00PCT [00151] Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein. 2. Multispecific Antibodies [00152] In certain embodiments, an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for CD74 and the other is for any other antigen. In certain embodiments, bispecific antibodies may bind to two different epitopes of CD74. Bispecific antibodies may also be used to localize cytotoxic agents to cells which express CD74. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments. [00153] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al., EMBO J.10: 3655 (1991)), and “knob-in-hole” engineering (see, e.g., U.S. Patent No.5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross- linking two or more antibodies or fragments (see, e.g., US Patent No.4,676,980, and Brennan et al., Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using “diabody” technology for making bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444- 6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g. Gruber et al., J. Immunol., 152:5368 (1994)); and preparing trispecific antibodies as described, e.g., in Tutt et al. J. Immunol.147: 60 (1991). [00154] Engineered antibodies with three or more functional antigen binding sites, including “Octopus antibodies,” are also included herein (see, e.g. US 2006/0025576A1). [00155] The antibody or fragment herein also includes a “Dual Acting Fantibody” or “DAF” comprising an antigen binding site that binds to CD74 as well as another, different antigen (see, US 2008/0069820, for example). 3. Antibody Variants [00156] In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such modifications include, for example, Attorney Docket No.01245-0062-00PCT deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding. 4. Substitution, Insertion, and Deletion Variants [00157] In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Conservative substitutions are shown in Table 1 as are “exemplary substitutions. Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g., retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC. [00158] TABLE 1 Attorney Docket No.01245-0062-00PCT Amino acids may be grouped according to common side-chain properties: (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influence chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe. [00159] Non-conservative substitutions will entail exchanging a member of one of these classes for another class. [00160] Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, Methods Mol. Biol.207:179-196 (2008)), and/or residues that contact antigen, with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom et al. in Methods in Molecular Biology 178:1-37 (O’Brien et al., ed., Human Press, Totowa, NJ, (2001).) In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted. [00161] In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may, for example, be outside of antigen contacting residues in the HVRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions. [00162] A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called “alanine scanning mutagenesis” as described by Cunningham and Wells (1989) Science, 244:1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and Attorney Docket No.01245-0062-00PCT replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties. [00163] Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody. 5. Glycosylation variants [00164] In certain embodiments, an antibody provided herein is altered to increase or decrease the extent to which the antibody is glycosylated. Addition or deletion of glycosylation sites to an antibody may be conveniently accomplished by altering the amino acid sequence such that one or more glycosylation sites is created or removed. [00165] Where the antibody comprises an Fc region, the carbohydrate attached thereto may be altered. Native antibodies produced by mammalian cells typically comprise a branched, biantennary oligosaccharide that is generally attached by an N-linkage to Asn297 of the CH2 domain of the Fc region. See, e.g., Wright et al. TIBTECH 15:26-32 (1997). The oligosaccharide may include various carbohydrates, e.g., mannose, N-acetyl glucosamine (GlcNAc), galactose, and sialic acid, as well as a fucose attached to a GlcNAc in the “stem” of the biantennary oligosaccharide structure. In some embodiments, modifications of the oligosaccharide in an antibody of the disclosure may be made in order to create antibody variants with certain improved properties. [00166] In some embodiments, antibody variants are provided having a carbohydrate structure that lacks fucose attached (directly or indirectly) to an Fc region. For example, the amount of fucose in such antibody may be from 1% to 80%, from 1% to 65%, from 5% to 65% or from 20% to 40%. The amount of fucose is determined by calculating the average amount of fucose within the sugar chain at Asn297, relative to the sum of all glycostructures attached to Asn 297 (e. g. complex, hybrid and high mannose structures) as measured by MALDI-TOF mass spectrometry, as described in WO 2008/077546, for example. Attorney Docket No.01245-0062-00PCT Asn297 refers to the asparagine residue located at about position 297 in the Fc region (Eu numbering of Fc region residues); however, Asn297 may also be located about ± 3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300, due to minor sequence variations in antibodies. Such fucosylation variants may have improved ADCC function. See, e.g., US Patent Publication Nos. US 2003/0157108 (Presta, L.); US 2004/0093621 (Kyowa Hakko Kogyo Co., Ltd). Examples of publications related to “defucosylated” or “fucose-deficient” antibody variants include: US 2003/0157108; WO 2000/61739; WO 2001/29246; US 2003/0115614; US 2002/0164328; US 2004/0093621; US 2004/0132140; US 2004/0110704; US 2004/0110282; US 2004/0109865; WO 2003/085119; WO 2003/084570; WO 2005/035586; WO 2005/035778; WO2005/053742; WO2002/031140; Okazaki et al. J. Mol. Biol.336:1239-1249 (2004); Yamane-Ohnuki et al. Biotech. Bioeng.87: 614 (2004). Examples of cell lines capable of producing defucosylated antibodies include Lec13 CHO cells deficient in protein fucosylation (Ripka et al. Arch. Biochem. Biophys.249:533-545 (1986); US Pat Appl No US 2003/0157108 A1, Presta, L; and WO 2004/056312 A1, Adams et al., especially at Example 11), and knockout cell lines, such as alpha-1,6-fucosyltransferase gene, FUT8, knockout CHO cells (see, e.g., Yamane-Ohnuki et al. Biotech. Bioeng.87: 614 (2004); Kanda, Y. et al., Biotechnol. Bioeng., 94(4):680-688 (2006); and WO2003/085107). [00167] Antibodies variants are further provided with bisected oligosaccharides, e.g., in which a biantennary oligosaccharide attached to the Fc region of the antibody is bisected by GlcNAc. Such antibody variants may have reduced fucosylation and/or improved ADCC function. Examples of such antibody variants are described, e.g., in WO 2003/011878 (Jean- Mairet et al.); US Patent No.6,602,684 (Umana et al.); and US 2005/0123546 (Umana et al.). Antibody variants with at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function. Such antibody variants are described, e.g., in WO 1997/30087 (Patel et al.); WO 1998/58964 (Raju, S.); and WO 1999/22764 (Raju, S.). 6. Fc region variants [00168] In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions. [00169] In certain embodiments, the disclosure contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector Attorney Docket No.01245-0062-00PCT functions (such as complement and ADCC) are unnecessary or deleterious. In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks Fc^R binding (hence likely lacking ADCC activity), but retains FcRn binding ability. The primary cells for mediating ADCC, NK cells, express Fc^RIII only, whereas monocytes express Fc^RI, Fc^RII and Fc^RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol.9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in U.S. Patent No.5,500,362 (see, e.g. Hellstrom, I. et al. Proc. Nat’l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I et al., Proc. Nat’l Acad. Sci. USA 82:1499-1502 (1985); 5,821,337 (see Bruggemann, M. et al., J. Exp. Med.166:1351-1361 (1987)). Alternatively, non-radioactive assays methods may be employed (see, for example, ACTI™ non- radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96® non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al. Proc. Nat’l Acad. Sci. USA 95:652-656 (1998). C1q binding assays may also be carried out to confirm that the antibody is unable to bind C1q and hence lacks CDC activity. See, e.g., C1q and C3c binding ELISA in WO 2006/029879 and WO 2005/100402. To assess complement activation, a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, M.S. et al., Blood 101:1045-1052 (2003); and Cragg, M.S. and M.J. Glennie, Blood 103:2738-2743 (2004)). FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (see, e.g., Petkova, S.B. et al., Int’l. Immunol.18(12):1759-1769 (2006)). [00170] In some embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which reduce Fc receptor binding, e.g. substitutions at positions 234, 235, and/or 329 of the Fc region (EU numbering of residues). [00171] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid deletions which reduce heterogeneity, e.g., deletion at 447 of the Fc region (EU numbering of residues). [00172] Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No.6,737,056; WO 2004/056312, and Shields et al., J. Biol. Chem.9(2): 6591-6604 (2001).) Attorney Docket No.01245-0062-00PCT [00173] In certain embodiments, an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g., substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues). [00174] In some embodiments, alterations are made in the Fc region that result in altered (i.e., either improved or diminished) C1q binding and/or Complement Dependent Cytotoxicity (CDC), e.g., as described in US Patent No.6,194,551, WO 99/51642, and Idusogie et al. J. Immunol.164: 4178-4184 (2000). [00175] Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer et al., J. Immunol.117:587 (1976) and Kim et al., J. Immunol.24:249 (1994)), are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 252, 254, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (e.g., US Patent No.7,371,826). [00176] See also Duncan & Winter, Nature 322:738-40 (1988); U.S. Patent No. 5,648,260; U.S. Patent No.5,624,821; and WO 94/29351 concerning other examples of Fc region variants. [00177] In some embodiments, an antibody is provided according to the Table of Sequences, wherein the isotype is human IgG1. In some embodiments, an antibody is provided according to the Table of Sequences, wherein the isotype is human IgG4. 7. Cysteine engineered antibody variants [00178] In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., “thioMantibodies,” in which one or more residues of an antibody are substituted with cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; S239 (EU numbering) of the heavy chain Fc region; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent Nos.7,521,541 and 8,455,622. Attorney Docket No.01245-0062-00PCT 8. Antibody Derivatives [00179] In certain embodiments, an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, prolypropylene oxide/ethylene oxide co-polymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc. [00180] In another embodiment, conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided. In some embodiments, the nonproteinaceous moiety is a carbon nanotube (Kam et al., Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody- nonproteinaceous moiety are killed. B. Recombinant Methods [00181] Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No.4,816,567. In some embodiments, isolated nucleic acid encoding an anti-CD74 antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the Attorney Docket No.01245-0062-00PCT antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In some embodiments, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In some embodiments, a method of making an anti-CD74 antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium). [00182] For recombinant production of an anti-CD74 antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody). [00183] Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., U.S. Patent Nos. 5,648,237, 5,789,199, and 5,840,523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp.245-254, describing expression of antibody fragments in E. coli.) After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified. [00184] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech.22:1409-1414 (2004), and Li et al., Nat. Biotech.24:210-215 (2006). [00185] Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells. [00186] Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants). Attorney Docket No.01245-0062-00PCT [00187] Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al., J. Gen Virol.36:59 (1977)); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.23:243-251 (1980)); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather et al., Annals N.Y. Acad. Sci.383:44-68 (1982); MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR- CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki and Wu, Methods in Molecular Biology, Vol.248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ), pp.255-268 (2003). C. Immunoconjugates [00188] The disclosure also provides immunoconjugates comprising an anti-CD74 antibody herein conjugated to one or more effector molecules. [00189] In some embodiments, the effector molecules comprise cytotoxic agents. In some embodiments, the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor, but not limited thereto. Examples of DNA inhibitors include, but are not limited to, monoimine indolinobenzodiazepenes (e.g., DGN549C), tesirine, talirine, duocarmycins (e.g., seco-DUBA), pyrrolobenzodiazepine (PBD), and anthracyclines (e.g., NMS249, PNU-159682). Examples of topoisomerase inhibitors include, but are not limited to, exatecans (e.g., Dxd). Examples of tubulin inhibitors include, but are not limited to, auristatins (e.g., monomethyl auristatin F, monomethyl auristatin E) and maytansinoids (e.g., ravtansine). In some embodiments, the cytotoxic agent is selected from Table 2. In some embodiments, the cytotoxic agent is a monoimine indolinobenzodiazepene (e.g., FGN849). (See, e.g., U.S. Patent No.10,898,579.) In some embodiments, the cytotoxic agent is DGN549C. In some embodiments, DGN549C may be conjugated to the CD74 antibody at an S239C substitution of an IgG heavy chain constant region. Attorney Docket No. 01245-0062-00PCT Table 2. Attorney Docket No. 01245-0062-00PCT
Attorney Docket No. 01245-0062-00PCT
Attorney Docket No. 01245-0062-00PCT Attorney Docket No. 01245-0062-00PCT [00190] Drug to antibody ratio (DAR) is used herein to describe the average number of effector molecules conjugated to each antibody. Methods of measuring DAR are known in the art, and include liquid chromatography mass spectrometry, for example. Any suitable DAR can be used with the disclosures described herein. In some embodiments, DAR is from about 2 to about 4. In some embodiments, DAR is about 2. In some embodiments, the DAR is about 3. In some embodiments, the DAR is about 4. [00191] Methods of conjugating one or more effector molecules to an antibody are known in the art. For example, an antibody, e.g., an antibody described herein, can be directly conjugated to one or more effector molecules, including any of the effector molecules described herein, such as a cytotoxic agent in Table 2, to produce an immunoconjugate. Alternatively, an antibody, e.g., an antibody described herein, can be conjugated to one or more effector molecules, including any of the effector molecules described herein, such as a cytotoxic agent in Table 2, using a linker or bifunctional protein coupling agent to produce an immunoconjugate. Attorney Docket No.01245-0062-00PCT [00192] Conjugates of an antibody may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)- ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). A linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase- sensitive linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari et al., Cancer Res.52:127-131 (1992); U.S. Patent No.5,208,020) may be used. [00193] The immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A). D. Pharmaceutical Formulations and Compositions [00194] Pharmaceutical formulations or compositions of an anti-CD74 antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers, diluents, and/or excipients (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers, diluents, and excipients are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: sterile water, buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as Attorney Docket No.01245-0062-00PCT sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include insterstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rHuPH20 (HYLENEX®, Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rHuPH20, are described in US Patent Publication Nos.2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases. [00195] Exemplary lyophilized antibody formulations are described in US Patent No.6,267,958. Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO2006/044908, the latter formulations including a histidine-acetate buffer. [00196] The formulation or composition herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended. [00197] Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980). [00198] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g. films, or microcapsules. [00199] The formulations or compositions to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g., by filtration through sterile filtration membranes. E. Therapeutic Methods [00200] Any of the anti-CD74 antibodies provided herein may be used in therapeutic methods. Throughout, where an “antibody” is discussed, it should also be appreciated that a composition comprising the antibody is also encompassed. [00201] In one aspect, an anti-CD74 antibody for use as a medicament is provided. In some embodiments, an anti-CD74 antibody for use in conditioning a subject to reduce an Attorney Docket No.01245-0062-00PCT endogenous population of hematopoietic stem cells in the subject is provided. In some embodiments, an effector molecule is conjugated to the antibody. In some embodiments, the antibodies or immunoconjugates of the present disclosure are useful in a variety of applications including, but not limited to, for reducing an endogenous population of hematopoietic stem cells in a subject in need thereof, e.g., a hematopoietic stem cell transplantation recipient. Provided herein are methods of reducing an endogenous population hematopoietic stem cells in a subject in need thereof by administering to the subject an effective amount of any of the antibodies and/or immunoconjugates described herein. In some embodiments, methods of reducing an endogenous population of hematopoietic stem cells includes reducing a population of cells in bone marrow and/or CD34+ cells but not all immune cells. Provided herein are also methods of conditioning a hematopoietic stem cell transplantation subject (e.g., a transplant subject) by administering to the subject an effective amount of any of the antibodies and/or immunoconjugates described herein, and allowing a sufficient period of time for the antibodies and/or immunoconjugates to clear from the subject’s circulation before performing a hematopoietic stem cell transplantation on the subject. Also provided are use of any of the antibodies, immunoconjugates, or pharmaceutical compositions described herein for reducing an endogenous population hematopoietic stem cells in a subject in need thereof. Further provided are use of any of the antibodies, immunoconjugates or pharmaceutical compositions described herein in the manufacture of a medicament for reducing an endogenous population hematopoietic stem cells in a subject in need thereof. [00202] Provided herein are methods of reducing an endogenous population of hematopoietic stem cells in a pre-treatment/conditioning of the subject before a hematopoietic stem cell transplantation. By way of non-limiting example, the antibodies and/or immunoconjugates herein could be used to condition a subject having any non-malignant condition/disorder wherein stem cell transplantation could be beneficial, such as Adrenoleukodystrophy (ALD), Severe aplastic anemia (SAA), Severe immunodeficiency syndrome (SCID), Wiskott Aldrich Syndrome, Hurler Syndrome, familial haemophagocytic lymphohistiocytosis (FHL), Krabbe disease (Globoid-Cell Leukodystrophy), Metachromatic Leukodystrophy (MLD), Sickle cell disease (SCD), transfusion-dependent beta thalassemia (TDT), Chronic granulomatous disease (CGD), Kostmanns syndrome, other autoimmune disorders such as SLE, Multiple sclerosis, IBD, Crohns Disease, Ulcerative colitis, Sjogrens syndrome, vasculitis, Lupus, Myasthenia Gravis, Wegeners disease, inborn errors of metabolism and/or other immunodeficiencies. [00203] The antibodies and/or immunoconjugates herein could be used to condition a subject having any malignant condition/disorder wherein stem cell transplantation Attorney Docket No.01245-0062-00PCT could be beneficial, such as hematologic diseases, hematological malignancies or solid tumors (e.g., renal cancer, hepatic cancer, pancreatic cancer). Common types of hematological diseases/malignancies that could be pretreated or conditioned with the claimed methods include, but are not limited to hematologic malignancies derived from either of the two major blood cell lineages, i.e., the myeloid cell line (which produces granulocytes, erythrocytes, thrombocytes, macrophages and mast cells) or lymphoid cell line (which produces B, T, NK and plasma cells), such as all types of leukemias, lymphomas, and myelomas, e.g., acute, chronic, lymphocytic and/or myelogenous leukemias, such as acute leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), and chronic myelogenous leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (Ml), myeloblastic leukemia (M2; with cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 variant with eosinophilia [M4E]), monocytic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), isolated granulocytic sarcoma, and chloroma; lymphomas, such as Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), B cell hematologic malignancy, e.g., B cell lymphomas, T cell lymphomas, lymphoplasmacytoid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., Ki 1+) large-cell lymphoma, adult T cell lymphoma/leukemia, mantle cell lymphoma, angio immunoblastic T cell lymphoma, angiocentric lymphoma, intestinal T cell lymphoma, primary mediastinal B-cell lymphoma, precursor T-lymphoblastic lymphoma, T- lymphoblastic; and lymphoma/leukaemia (T-Lbly/T-ALL), peripheral T cell lymphoma, lymphoblastic lymphoma, post-transplantation lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, B cell lymphoma, lymphoblastic lymphoma (LBL), hematopoietic tumors of lymphoid lineage, acute lymphoblastic leukemia, diffuse large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B -lymphoblastic lymphoma, cutaneous T cell lymphoma (CTLC) (also called mycosis fungoides or Sezary syndrome), and lymphoplasmacytoid lymphoma (LPL) with Waldenstrom's macroglobulinemia; myelomas, such as IgG myeloma, light chain myeloma, nonsecretory myeloma, smoldering myeloma (also called indolent myeloma), solitary plasmocytoma, and multiple myelomas, chronic lymphocytic leukemia (CLL), hairy cell lymphoma; hematopoietic tumors of myeloid lineage; hematopoietic tumors of lymphoid lineage, for example T cell and B cell tumors, including but not limited to T cell disorders such as T-prolymphocytic leukemia (T- PLL), including of the small cell and cerebriform cell type; large granular lymphocyte leukemia (LGL) of the T cell type; a/d T-NHL hepatosplenic lymphoma; peripheral/post-thymic T cell lymphoma (pleomorphic and immunoblastic subtypes); angiocentric (nasal) T cell lymphoma; Attorney Docket No.01245-0062-00PCT cancer of the head or neck, renal cancer, rectal cancer, cancer of the thyroid gland; acute myeloid lymphoma, as well as any combinations of these cancers. [00204] In some embodiments, the antibodies and/or immunoconjugates described herein can be used to condition a subject in preparation for a transplant of an engineered cell. For example, the antibodies and/or immunoconjugates described herein can be used to condition a subject prior to transplanting an engineered cell for treatment of a disease. In some embodiments, the antibodies and/or immunoconjugates described herein can be used to condition a subject in preparation for administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs). In some embodiments, the antibodies and/or immunoconjugates described herein can be used to condition a subject in preparation for administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs) that comprise a genetic modification. In some embodiments, the subject has a hemoglobinopathy. Non-limiting, exemplary diseases include sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). In some embodiments, following conditioning as described herein, the cells, compositions, and/or methods can be used for treatment as described in WO 2019/113149, WO 2020/257325, and/or WO 2022/133246, which are incorporated by reference herein in their entirety for any purpose. F. Combinations [00205] Antibodies of the invention can be used either alone or in combination with other agents in a therapy. For instance, an antibody or immunoconjugate of the disclosure may be used in combination with at least one additional therapeutic agent (e.g., further comprising administering a second therapy). In some embodiments, the antibody or immunoconjugate may be used with a second conditioning therapy such as radiation therapy or chemotherapy. [00206] The antibodies or immunoconjugates herein may be provided before, substantially contemporaneous with, or after other modes of treatment, for example, surgery, chemotherapy, radiation therapy, or the administration of a biologic, such as another therapeutic antibody or an engineered cell type. In some embodiments, the cancer has recurred or progressed following a therapy selected from surgery, chemotherapy, and radiation therapy, or a combination thereof. [00207] For treatment of cancer, the combinations may be administered in conjunction with one or more additional anti-cancer agents, such as a chemotherapeutic agent, growth inhibitory agent, anti-cancer vaccine such as a gene therapy vaccine, anti-angiogenesis agent and/or anti-neoplastic composition. Attorney Docket No.01245-0062-00PCT [00208] In some embodiments, an anti-inflammatory drug may be administered with the combination, such as a steroid or a non-steroidal anti-inflammatory drug (NSAID). In cases where it is desirable to render aberrantly proliferative cells quiescent in conjunction with or prior to treatment with CD74 antibodies described herein, hormones and steroids (including synthetic analogs), such as 17a-Ethinylestradiol, Diethylstilbestrol,Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyl-testosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, ZOLADEX®, can also be administered to the subject. When employing the methods or compositions described herein, other agents used in the modulation of tumor growth or metastasis in a clinical setting, such as antimimetics, can also be administered as desired. [00209] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations or compositions), and separate administration, in which case, administration of the antibody of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent or agents. In some embodiments, administration of the anti- CD74 antibody and administration of an additional therapeutic agent occur within about one month, or within about one, two or three weeks, or within about one, two, three, four, five, or six days, of each other. [00210] An antibody of the disclosure (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein. [00211] Antibodies of the disclosure can be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual subject, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. As used herein, a “split dose” is the division of single unit dose or total daily dose Attorney Docket No.01245-0062-00PCT into two or more doses, e.g., two or more administrations of the single unit dose. The antibody may be administered as “split dose.” [00212] The antibody need not be but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation or composition, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate. In some embodiments, the antibody is provided in a formulation for immediate release and the other agent is formulated for extended release or vice versa. G. Articles of Manufacture [00213] In another aspect of the disclosure, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the disclosure. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the disclosure; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the disclosure may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes. [00214] It is understood that any of the above articles of manufacture may include an immunoconjugate of the disclosure in place of or in addition to an anti-CD74 antibody. Attorney Docket No.01245-0062-00PCT III. EXAMPLES Example 1. Anti-CD74 Antibody Generation [00215] Materials and methods [00216] Antigen preparation [00217] Antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit (Thermo Scientific, Cat #21425). [00218] The antigens were concentrated to ~1mg/mL and buffer exchanged into PBS before addition of 1:7.5 molar ration biotinylation reagent. The mixture was held at 4C overnight prior to another buffer exchange to remove free biotin in the solution. Biotinylation was confirmed through streptavidin sensor binding of the labeled proteins on a ForteBio. [00219] Naïve Library Selections [00220] For the first two rounds of selection, a magnetic bead sorting technique utilizing the Miltenyi MACS system was performed, as previously described (see, e.g., Siegel et al, J Immunol Methods 286(1-2), 141-153 (2004).) Briefly, yeast cells (~1010 cells/library) were incubated with biotinylated human CD74 for 30 min at 30°C in wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing once with 40 mL ice-cold wash buffer, the cell pellet was resuspended in 20 mL wash buffer, and Streptavidin MicroBeads (500 μl) were added to the yeast and incubated for 15 min at 4°C. Next the yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL were loaded, the column was washed 3 times with 3 mL wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight. [00221] For the first two rounds of selection, a magnetic bead sorting technique utilizing the Miltenyi MACS system was performed, as previously described (see, e.g., Siegel et al, J Immunol Methods 286(1-2), 141-153 (2004).) Briefly, yeast cells (~1010 cells/library) were incubated with biotinylated human CD74 for 30 min at 30°C in wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing once with 40 mL ice-cold wash buffer, the cell pellet was resuspended in 20 mL wash buffer, and Streptavidin MicroBeads (500 μl) were added to the yeast and incubated for 15 min at 4°C. Next the yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL were loaded, the column was washed 3 times with 3 mL wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight. Attorney Docket No.01245-0062-00PCT [00222] The following rounds of selection were performed using flow cytometry (FACS). Yeast were pelleted, washed three times with wash buffer, and incubated at 30°C with decreasing concentrations of biotinylated p33 and p41 human CD74 (100 to 1 nM) under equilibrium conditions, 100 nM biotinylated cyno CD74 in order to obtain species cross- reactivity, or with a polyspecificity reagent (PSR) to remove non-specific antibodies from the selection. For the PSR depletion, the libraries were incubated with a 1:10 dilution of biotinylated PSR reagent as previously described (see, e.g., Y. Xu et al, PEDS 26(10), 663-70 (2013).) Yeast were then washed twice with wash buffer and stained with goat F(ab’)2 anti-human kappa-FITC (LC-FITC) diluted 1:100 (Southern Biotech, Cat # 2062-02) and either Streptavidin-AF633 (SA- 633) diluted 1:500 (Life Technologies, Cat # S21375) or Extravidin- phycoerthyrin (EA-PE) diluted 1:50 (Sigma-Aldrich, Cat # E4011), secondary reagents for 15 min at 4°C. After washing twice with ice-cold wash buffer, the cell pellets were resuspended in 0.3 mL wash buffer and transferred to strainer-capped sort tubes. Sorting was performed using a FACS ARIA sorter (BD Biosciences) and sort gates were determined to select for antibodies with desired characteristics. Selection rounds were repeated until a population with all of the desired characteristics was obtained. After the final round of sorting, yeast were plated and individual colonies were picked for characterization. [00223] Light chain batch shuffle diversification [00224] Heavy chains from naïve output were used to prepare light chain diversification libraries used for additional selection rounds. Selections were performed on these libraries as described above, i.e., with one round of MACS and four rounds of FACS. In the different FACS selection rounds, the libraries were evaluated for, e.g., PSR binding, species cross-reactivity, and affinity pressure by antigen titration. Sorting was performed in order to obtain a population with the desired characteristics. Individual colonies from each terminal FACS selection round were picked for sequencing and characterization. [00225] Affinity maturation [00226] Optimization of parent clones was carried out utilizing two maturation strategies: diversification of CDRH1 and CDRH2 and diversification of CDRL1, CDRL2, CDRL3 and CDRH3. [00227] CDRH1 and CDRH2 selection: The CDRH3s from clones selected from the light chain diversification procedure were recombined into a premade library with CDRH1 and CDRH2 variants of a diversity of 1 x 108 and selections were performed using CD74 antigen. Affinity pressures were applied by using decreasing concentrations of biotinylated CD74 antigen (100 to 1 nM) under equilibrium conditions at room temperature and by preincubating the biotinylated antigen with parental IgG for 30 minutes and then applying that precomplexed mixture Attorney Docket No.01245-0062-00PCT to the yeast library for a length of time which would allow the selection to reach an equilibrium. The higher affinity antibodies were then able to be sorted. [00228] CDRL1, CDRL2, CDRL3 and CDRH3 selection: Oligos were ordered from IDT which comprised the CDRL3 or CDRH3 as well as a flanking region on either sides of the CDR. Amino acid positions in the CDRL3 and CDRH3 were variegated via NNK diversity. Clones obtained from CDRH1 and CDRH2 selection procedure were combined into a premade library with CDRL1 and CDRL2 diversity and the CDRL3 and CDRH3 oligo. Selections were performed using biotinylated CD74 as antigen generally as described above. [00229] Antibody production and purification [00230] Yeast clones were grown to saturation and then induced for 48 h at 30°C with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. IgGs were purified using a Protein A column and eluted with acetic acid, pH 3.5. Fab fragments were generated by papain digestion and purified over KappaSelect (GE Healthcare LifeSciences).  [00231] ForteBio KD measurements [00232] ForteBio affinity measurements were performed on an Octet HTX generally as previously described (see, e.g., Estep et al, Mabs 5(2), 270-278 (2013)). Briefly, ForteBio affinity measurements were performed by loading IgGs on-line onto AHC sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 3 minutes, and afterwards were transferred to assay buffer for 3 min for off-rate measurement. For monovalent affinity assessment Fabs were used instead of IgGs. For this assessment the unbiotinylated Fc fusion antigen was loaded on-line onto the AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 min and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded antigen were exposed to 100 nM Fab for 3 minutes, and afterwards they were transferred to assay buffer for 10 min for off-rate measurement. All kinetics were analyzed using the 1:1 binding model. [00233] ForteBio Epitope Binning [00234] Epitope binning was performed using a standard sandwich format cross- blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc- binding sites on the sensor were blocked with an irrelevant human IgG1 antibody. The sensors were then exposed to 100 nM human CD74 antigen followed by a second anti-CD74 antibody. Additional binding by the second antibody or ligands after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking). Attorney Docket No.01245-0062-00PCT [00235] Cell Binding Analysis [00236] Approximately 200,000 cells overexpressing human CD74 antigen were washed with wash buffer and incubated with 100 ul of 100-10 nM IgG or Fab for 15 minutes at room temperature. Cells were then washed twice with wash buffer and incubated with 100 ul of 1:100 anti-Human IgG R-PE (Southern Biotech Cat #2040-09) or anti-Human F(ab’)2 Alexa Fluor 647 (Jackson Immunoresearch Cat #109-605-006) for 15 minutes on ice. Cells were then washed twice with wash buffer and analyzed on a FACS Canto II analyzer (BD Biosciences.) [00237] Dynamic Scanning Fluorimetry [00238] 10 uL of 20x Sypro Orange is added to 20 uL of 0.2-1mg/mL mAb or Fab solution. A RT-PCR instrument (BioRad CFX96 RT PCR) is used to ramp the sample plate temperature from 40 to 95 C at 0.5C increment, with 2min equilibrate at each temperature. The negative of first derivative for the raw data is used to extract Tm. Example 2. Anti-CD74 Antibody Binding [00239] From the analyses in Example 1, 3 sequences (clone 1, clone 22, and clone 41) bound comparably to human and cynomolgus CD74. Clone 3 was a variant identified by affinity maturation of Clone 1 and exhibited improved affinity relative to it’s parental lineage. Table 3 lists the measured avid binding kinetics for Clones 1, 3, 22, and 41 to human and cynomolgus CD74. Antibody binding studies were performed at 25 degrees Celsius in 1xPBS supplemented with 0.1% w/v bovine serum albumin with a Sartorious Octet biolayer interferometry (BLI) instrument. For avid kinetics, the indicated antibody was immobilized onto anti-human Fc biosensors (AHC; Sartorious 18-5060) and incubated with 100 nM of purified human or cynomolgus CD74 p33 ectodomain. The apparent affinity KD was determined by global full fitting with a 1:1 binding model as calculated by ForteBio data analysis software. Table 4 lists the measured avid binding kinetics for Clones 1, 3, 22, and 41 to human CD74 p33 and p41. Table 3: Human and Cynomolgus CD74 Binding Attorney Docket No.01245-0062-00PCT Screening for avid binding to human and cynomolgus recombinant CD74 as determined by bio-layer interferometry. Table 4: p33 and p41 Human CD74 Binding Table 5: Epitope Identification [00240] Clone 22 was determined to bind to CD74 in a unique epitope, where it did not cross-block with Clone 1, Clone 41, or any other selected antibody. Table 5 shows epitope binning by bio-layer interferometry. Briefly, antibody in the first column is loaded onto an instrument sensor followed by human CD74. Next, antibody from the first row is loaded on the antigen-loaded sensor. If the second antibody can bind, it does not cross-block the first antibody and will result in a positive binding value. Non-crossblocking interactions are highlighted in bold. Crossblocking interactions are underlined. Self-self blocking is italicized. [00241] Antibody binding studies were performed at 25 degrees Celsius in 1xPBS supplemented with 0.1% w/v bovine serum albumin with a Sartorious Octet biolayer interferometry (BLI) instrument. For binning, the indicated antibody was immobilized onto anti- human Fc biosensors (AHC; Sartorious 18-5060). A second binding step was performed with saturating amounts of a non-specific isotype control antibody. Following a wash in binding Attorney Docket No.01245-0062-00PCT buffer, sensors were incubated with saturating amounts of recombinant human CD74 p41 ectodomain followed by the second indicated antibody. Cross-blocking interactions were assessed relative to the corresponding self-self blocking and buffer only controls. [00242] In Tables 6 and 7, detailed monovalent kinetics of Clones 1, 3, 22, and 41 were assessed by Bio-Layer Interferometry (BLI). The indicated cynomolgus p33 or p41 recombinant ectodomains were biotinylated using standard methods known in the art. Biotinylated antigen was immobilized onto streptavidin biosensors (SA; Sartorious 18-5057) and incubated with 100 nM of indicated Fab. Fab was generated from the indicated antibody using papain digestion and standard methods known in the art. The resulting binding intervals are represented with association and dissociation curves in the sensorgram. The apparent affinity (KD), apparent association rate (kON) and apparent dissociation rate (kOFF) were determined by global full fitting with a 1:1 binding model as calculated by ForteBio data analysis software. Based on response values and corresponding 1:1 kinetics, clones 1, 3, 22, and 41 exhibited comparable binding to both p33 and p41isoforms. In addition, clones 1, 3, 22, and 41 demonstrated comparable monovalent kinetics to both human and cynomolgus CD74. Clone 3 is an affinity maturation variant of Clone 1 and exhibits a resultant improvement in monovalent affinity to both human p33 and p41 isoforms as well as the cynomolgus counterparts.
Attorney Docket No.01245-0062-61US -E -E -E b s / 0- 0 0 0 3 8 1 a 1 ( E - - - 8 . 3 1 . 5 1 . 1 F, f r f 0 E2 E E o o 1 5 7 2 8 0 s k . . . n 1 3 5 . 1 e s A 5 5 5 S mr e t o c n o f f O M y l 7 o . l e t 7 8 9 . s 1 9 . 0 5 . 0 i 3 ) ) e a d u o q e 3 M p n mn m d a 4 0 ( 0 e s 3 7 1 ( n 1 5 . 4 6 . 6 5 . 4 g . n i e b n o 0 1 0 0 d n o t 3 0 3 - 0 3 0 D C o i p t s e i b e l b E - - u l 0 E5 E4 o o R 1 : a S 1 n 4 . 5 3 3 . 4 . 9 n y C n i a o u t t u d b e a i F ) s / 3 0 3 0 3 t i f b , y f i , r r o 1 ( - s E - 0 E -E a t a s n f f o 3 6 . 7 7 . 7 1 . a D s a 5 0 5 + 0 5 0 u P e s k 3 5 1 . ) s i h E + + A n t S o f 1 E E o t n k / o 3 . 6 2 3 . 4 1 1 . 1 g n o f f i o s n d 3 3 ) n i p s 5 5 5 k o i 4 M 0 0 0 = ti B 7 / D 1 + + + d ( E G C n 2 E3 E D n o g o o 6 . 2 3 . 6 1 0 . K 1 ( c e I n k t y n h t 8 0 8 8 d C a t s n r e - 0 E - 0- e i f d e t o c d n u 7 E 4. 5 E 3 1 . 6 i 1 r a l y ) t n 3 . 8 u P n : i t o t M ( e l 8 n 8 7 o i g 7 i n D a . 0- 0- 0- t n a i i d Be l e a Kv o F . E8 4 3 E1 c n i l : t v b eo bn P o 3 . . 4 1 . o s B. a t c n a 1 1 o F M s i d tiF T O M mu r i o o 3 2 1 e r n b il P 2 4 o l 1 3 2 1 i = C 2 4 u q . F E . P Attorney Docket No.01245-0062-00PCT Example 3. Analytical Characterization of Clones 1, 22, and 41 [00243] Clones 1, 22, and 41 were subjected to a variety of stressors in a short forced degradation study. The following conditions were evaluated: 1) a stock 1 mg/ml antibody solution was buffer exchanged to pH 3.7 and incubated for 1 hour at room temperature; 2) a stock 1 mg/ml antibody solution was buffer exchanged into Tris pH 8.0 and incubated for 7 days at 40oC; 3) a stock 1 mg/ml antibody solution was buffer exchanged into acetate pH 5.0 and incubated for 7 days at 40oC; 4) a stock 1 mg/ml antibody solution was incubated for 7 or 14 days at 50oC; 5) a stock 1 mg/ml antibody solution was cycled through 6 freeze/thaw cycles (- 80oC to room temperature); 6) a stock 1 mg/ml antibody solution was incubated with 0.02% hydrogen peroxide and incubated at room temperature for 2 hours or 16 hours. [00244] Samples taken from a zero hour or terminal time point were assessed in a variety of standard analytical methods known in the art, including size exclusion chromatography (SEC) to assess impact of stress on aggregation, capillary electrophoresis SDS- PAGE (CE-SDS) to assess the impact of stress on fragmentation, and reduced peptide mapping by LC-MS to assess the impact of stress on chemical modification (deamidation, oxidation). Based on the results highlighted in Tables 8, 9, 10, Clones 1, 22, and 41 demonstrated resistance to the stressors evaluated in this study. Table 8: Forced Degradation of Clone 1 Antibody SEC: % high molecular weight species relative to untreated control Attorney Docket No.01245-0062-00PCT CE-SDS: % total fragments relative to corresponding intact antibody (non-reduced; NR) or HC/LC (reduced; RD) relative to untreated control LC-MS: %Oxidation and %Deamidation detected within CDR peptides relative to untreated control. <1.0% isomerization observed. N.D.: not determined Table 9: Forced Degradation of Clone 22 Antibody SEC: % high molecular weight species relative to untreated control CE-SDS: % total fragments relative to corresponding intact antibody (non-reduced; NR) or HC/LC (reduced; RD) relative to untreated control LC-MS: %Isomerization detected within CDR peptides relative to untreated control. <1.0% deamidation and oxidation observed. N.D.: not determined Table 10: Forced Degradation of Clone 41 Antibody Attorney Docket No.01245-0062-00PCT SEC: % high molecular weight species relative to untreated control CE-SDS: % total fragments relative to corresponding intact antibody (non-reduced; NR) or HC/LC (reduced; RD) relative to untreated control LC-MS: %Oxidation detected within CDR peptides relative to untreated control. <1.0% deamidation and isomerization observed. N.D.: not determined Example 4. Binding of Anti-CD74 Antibodies to Human Bone Marrow CD34+ Cells. [00245] Binding was performed on primary human bone marrow CD34+ cells (AllCells). Cryopreserved cells were rapidly thawed, washed, and incubated with antibody (Clones 1, 3, 22, and 41) at the indicated concentrations on ice for 4 hours in triplicate. Unbound antibody was washed out and cells were stained with fluorescently-labeled anti-human IgG secondary antibody and surface marker antibodies according to methods known in the art. Data were read out by flow cytometry and are expressed as the geometric mean fluorescent intensity (gMFI) of the labeled secondary antibody on viable CD34+ cells. EC50 values were calculated using a four-parameter non-linear regression curve fit with no constraints in GraphPad Prism software. [00246] FIGS.2A-2C show the binding of anti-CD74 clone 1, clone 22, and clone 41 antibodies to primary human bone marrow CD34+ cells and the corresponding EC50 values are reported in FIG.2D. The antibodies demonstrated binding to human bone marrow CD34+ cells relative to the isotype control. To assess the binding of the affinity maturation variant clone 3, binding under identical conditions was evaluated. FIG.3A shows binding to primary human bone marrow CD34+ cells. In addition, clone 3 shows marked improvement in EC50 on primary human bone marrow CD34+ cells relative to its parental clone 1 as shown in FIG.3B. [00247] To determine the impact of linker payload conjugation on antibody binding to primary bone marrow CD34+ cells, binding was performed using clone 1, 3, 22, and 41 conjugated with the linker payload DGN549C. Antibodies and antibody drug conjugates were incubated with primary human bone marrow CD34+ cells prepared as described previously. Unbound antibody and ADC were washed out and cells were stained with fluorescently-labeled Attorney Docket No.01245-0062-00PCT anti-human IgG secondary antibody and surface marker antibodies as previously described. Data was read out by flow cytometry and expressed as gMFI of the labeled secondary antibody on viable CD34+ cells. As shown in FIGS.4A-4D, antibody and ADC showed equivalent binding to primary human bone marrow CD34+ cells for clones 1, 3, 22, and 41. Example 5. Binding of Anti-CD74 Antibodies to Cyno Bone Marrow CD34+ Cells. [00248] Binding was performed on primary cynomolgus monkey bone marrow CD34+ cells (Worldwide Primates, Inc.). Cryopreserved cells were rapidly thawed, washed, and expanded in culture for 7 days prior to binding. Cells were incubated with antibody at the indicated concentrations on ice for two hours in technical triplicate. Unbound antibody was washed out and cells were stained with fluorescently-labeled anti-human IgG secondary antibody and surface marker antibodies. Fluorescence was measured by flow cytometry and are expressed as the geometric mean fluorescent intensity (gMFI) of the labeled secondary antibody on CD34+CD90+, CD34+CD90-, and all CD34+ cells. EC50 values were calculated using a four- parameter non-linear regression curve fit with no constraints in GraphPad Prism 10. [00249] FIGS.5A-5C show the binding of anti-CD74 antibodies to primary cynomolgus monkey bone marrow CD34+ cells. Table 11 shows the EC50 values for clones 1, 22, and 41 binding to CD34+CD90+, CD34+CD90-, and all CD34+ cells. Table 11: EC50 [nM] Cyno Bone Marrow CD34+ Cells Example 6. Internalization of Anti-CD74 Antibodies into Human Bone Marrow CD34+ Cells. [00250] To assess the internalization capabilities of the antibodies, such as for use as an antibody drug conjugate, anti-CD74 antibodies were conjugated to the pH-sensitive fluorophore, pHAb (Promega, catalog # G9835). Primary human bone marrow CD34+ cells (AllCells) were incubated in the presence of a fixed 50 nM concentration of the pHAb- conjugated anti-CD74 antibody overnight at 37°C in growth culture media. After overnight incubation, cells were stained with a panel of cell surface markers, and fluorescence was Attorney Docket No.01245-0062-00PCT measured by flow cytometry. Data are expressed as the geometric mean fluorescence intensity (gMFI) of the pH-sensitive fluorophore on CD34+CD90+ and CD34+CD90- cells. [00251] FIGS.6A-6B show the internalization of anti-CD74 antibodies into primary human bone marrow CD34+ cells. Table 12 shows the gMFI values for clones 1, 3, 22, and 41 for internalization on bone marrow CD34+ cells. Based on these findings a rank order can be applied based on internalization capability. Amongst these clones, Clone 3 exhibited the greatest capacity to internalize on primary bone marrow CD34+ cells. Table 12: gMFI values for internalization of anti-CD74 antibodies on CD34+ cells. Example 7. Effector Silencing of Anti-CD74 Antibodies. [00252] Monocyte-derived macrophages (MDM) were derived from primary human monocytes (AllCells) after culture for 5 days in growth media with recombinant human M-CSF (R&D Systems). Adherent cells were detached and plated overnight in growth media with M-CSF. Fluorescently-labeled primary human bone marrow CD34+ cells (AllCells) were incubated in the presence of MDM for 2 hours in the presence of effector-silenced or wild-type anti-CD74 antibody. After incubation, a fluorescently labeled cell surface marker specific to MDM cells was added. Cells were then washed, and fluorescence was measured by flow cytometry. Co-expression of the MDM-specific marker and the fluorescence associated to the CD34+ was used to quantify phagocytosis. [00253] FIG.7 shows effector silencing of anti-CD74 antibodies. Example 8. Cytotoxicity of Anti-CD74 ADCs on Human Bone Marrow CD34+ Cells. [00254] Primary human bone marrow CD34+ cells (AllCells) were incubated in the presence of a titration of anti-CD74 antibody or antibody-drug-conjugate (ADC) prepared with DGN549C for 5 days. Cells were stained for cell surface markers and viability, and fluorescence was measured by flow cytometry. Viable CD34+ were quantified in each well and curves were generated using a four-parameter non-linear regression curve fit with no constraints in GraphPad Prism 10. Attorney Docket No.01245-0062-00PCT [00255] FIGS.8A-8B shows the cytotoxic effect of anti-CD74 antibodies and ADCs on primary human bone marrow CD34+ cells. As shown, clone 1, 22, and 41 antibodies had no impact on primary human CD34+ cell viability whereas the ADCs of the corresponding clones were highly potent cytotoxic agents relative to the isotype control ADC. In this assay, the rank order of cytotoxicity was Clone 41>Clone 1>Clone 22. In a similar cytotoxicity assay, the affinity maturation variant clone 3 showed highly potent cytotoxicity of primary human CD34+ cells relative to isotype control ADC as shown in FIG.9. Example 9. Cytotoxicity of Anti-CD74 ADCs on Cyno Bone Marrow CD34+ Cells. [00256] Similar to Example 8, primary cynomolgus monkey bone marrow CD34+ cells (Worldwide Primates, Inc.) were incubated in the presence of a titration of anti-CD74 antibody or antibody-drug-conjugate (ADC) prepared with DGN549C for 5 days. Cells were stained for cells surface markers and fluorescence was measured by flow cytometry. Viable CD34+ were quantified in each well and curves were generated using a four-parameter non- linear regression curve fit with no constraints in GraphPad Prism 10. [00257] FIGS.10A-10B show the cytotoxic effect of anti-CD74 antibodies and ADCs on primary cynomolgus monkey bone marrow CD34+ cells. As shown, clone 1, 22, and 41 antibodies had no impact on primary cynomolgus CD34+ cell viability whereas the ADCs of the corresponding clones were highly potent cytotoxic agents relative to the isotype control ADC. In this assay, the rank order of cytotoxicity was Clone 41=Clone 1>Clone 22. Example 10. Cytotoxicity of Anti-CD74 ADCs on CD74 Expressing Cell line and CD74 Knockout. [00258] Raji (ATCC) and Raji CD74 knockout cells generated by CRISPR/Cas9 editing were incubated in the presence of a titration of anti-CD74 antibody or antibody-drug- conjugate (ADC) prepared with DGN549C for 5 days. Cell viability was measured by CellTiter- Glo (Promega) as relative luminescence using a SpectraMax plate reader (Molecular Devices). Curves were generated using a four-parameter non-linear regression curve fit with no constraints in GraphPad Prism 10. [00259] FIGS.11A-11B show the cytotoxic effect of anti-CD74 antibodies and ADCs on CD74 expressing cell line and FIGS.12A-12B show the lack of cytotoxic effect of anti-CD74 ADCs on the CD74 knockout cell line. As shown, clone 1, 22, and 41 antibodies had no impact on Raji cell viability whereas the ADCs of the corresponding clones were highly potent cytotoxic agents relative to the isotype control ADC. Cytotoxicity was target dependent, as the ADCs exhibited marked reduction in cytotoxicity in the Raji CD74 knockout cells. Attorney Docket No.01245-0062-00PCT Example 11. Kinetic Parameters and Binding Affinity of anti-CD74 Antibodies and ADCs to Human, Mouse, Rat, and NHP CD74. [00260] Antibody specificity for binding to target cells expressing CD74 was tested using biolayer interferometry (BLI) as described above. The amino acid sequence identity for CD74 is 96% between human and NHP but <80% relative to mouse, rat, and rabbit. Consistent with the amino acid sequence homology, BLI studies demonstrated that binding of anti-CD74 antibody and ADC (clone 22) to human and NHP recombinant CD74 extracellular domain is comparable; however, no binding is observed for recombinant mouse or rat CD74 (Table 13). Comparable binding between anti-CD74 antibody and ADC demonstrate the conjugation of DGN549c does not disrupt CD74 binding (Table 13, Table 16). Further, no differences between the binding affinity of anti-CD74 antibody and ADC to either human or NHP CD74-expressing cells were observed, while no binding was evident on rodent or rabbit primary CD74+ cells as measured by flow cytometry (Table 14, Table 15). Collectively, these data support the CD74 epitope for anti-CD74 antibody and ADC, is shared between human and NHP, but not shared with mouse, rat, or rabbit. Table 13: Kinetic Parameters and Binding Affinity of anti-CD74 Antibody and ADC to BLI: bio-layer interferometry; ka: association rate constant, on-rate; Kd: dissociation rate constant, off-rate; K D : equilibrium dissociation constant; ND: not determined: NHP: non- human primate Notes: Values are the geometric means across 9 replicates. Brackets denote the lower and upper 95% confidence interval, respectively. Attorney Docket No.01245-0062-00PCT Table 14: Binding Affinity of anti-CD74 Antibody and ADC on Human and NHP BM-Derived HSPCs in Culture BM: bone marrow; HSPCs: hematopoietic stem and progenitor cells; NHP: non-human primate Notes: Binding affinity assessed on primary human (defined as CD34+ CD90+ cells) and NHP (defined as CD90+ CD45RA- cells) HSPCs by flow cytometry. Data reflect n=5 unique human donors and n=3 unique NHP donors and are expressed as the geometric mean EC 50 values and 95% confidence interval calculated for each cell type. Binding curves were generated using non- linear regression, 4-parameter curve fitting. Table 15: Binding Affinity of anti-CD74 Antibody and ADC on Mouse, Rat, and Rabbit Bone Marrow-Derived Hematopoietic Cells in Culture Notes: Binding affinity assessed on primary mouse, rat, and rabbit hematopoietic cells by flow cytometry. Data reflect 3 biological replicates per species. Table 16: Binding Affinity of anti-CD74 Antibody and ADC on CD74-Expressing and CD74- Knockout Raji Cells in Culture Notes: Binding affinity assessed on Raji cells by flow cytometry. Data reflect n=4 independent experiments. Values reported as the geometric mean. Binding curves were generated using non- linear regression, 4-parameter curve fitting. Example 12: Fc-dependent Functional Testing [00261] Anti-CD74 antibody (clone 22) was engineered with Fc silencing mutations to diminish antibody binding to CD74 negative cells that express Fc receptors. Surface plasmon resonance (SPR) studies showed that the anti-CD74 antibody maintained binding to only the neonatal Fc receptor (FcRn) and the high affinity Fc receptor (FCGRI) amongst a panel of Fc receptors maintaining the ability of cells to recycle anti-CD74 ADC of cells after nonspecific uptake (Table 17). Orthogonal BLI binding studies demonstrate that anti-CD74 ADC maintains the pH-dependent binding to FcRn (Table 18). The potency of the anti-CD74 antibody was evaluated by flow cytometry in a trio of Fc-dependent functional assays. Consistent with loss of Attorney Docket No.01245-0062-00PCT Fc receptor binding, anti-CD74 antibody did not show activity in Fc-dependent functional assays (FIGS.13A-13C). Data reflect n = 3 independent experiments. Each line represents a unique CD34+ cell donor. An effector enhanced anti-CD74 antibody was used as positive control in the (A) antibody-dependent cellular cytotoxicity (ADCC) and (B) antibody-dependent cellular phagocytosis (ADCP) assays. An effector enhanced anti-CD43 antibody was used as positive control in the (C) complement-dependent cytotoxicity CDC assay. Table 17: Fc Receptor Binding by Surface Plasmon Resonance Anti-CD74 antibody Positive Control Ligand KD (nM) KD (nM) FCGRI, CD64 201.5a 0.106 FCGRIIA, CD32a (R131) NA 999.3 FCGRIIA, CD32a (H131) NA 802.3 FCGRIIB/C, C32b/c NA 4933.3 FCGRIIIA, CD16a (V158) NA 101.3 FCGRIIIA, CD16a (F158) NA 702.67 FCGRIIB, CD16b (NA1) NA 6300 FCGRIIB, CD16b (NA2) NA 4066.7 FcRn pH 7.4 NA NA FcRn pH 6.0 0.605a 11 NA: no at applicable Notes: Fit was generated using a bulk shift term
Attorney Docket No.01245-0062-61US Table 18: Kinetic Parameters and Binding Affinity of Anti-CD74 Antibody and Control Antibodies to Human FcRn at pH 6 and 7 as Measured by BLI Receptor Capture Notes: Values are the geometric mean across 3 replicates. Brackets denote the lower and upper 95% confidence interval, respectively. ND = no detectable binding. Example 13: CD74 Copy Expression [00262] The CD74 copy number on hematopoietic cells was quantified and found comparable between healthy humans, people with SCD, and NHP supporting the potential translatability of the non-clinical findings to the clinic. Expression of CD74 on human (FIG. 14A) versus NHP (FIG.14B) CD34+ HSPC subsets was quantified by flow cytometry based on geometric mean fluorescence intensity following staining with a PE-conjugated anti-CD74 antibody and interpolated based on a standard curve produced with PE-conjugated beads. [00263] Each symbol represents an individual donor. Bars represent mean values. Analysis of cryopreserved bone marrow-derived CD34+ cell subsets from healthy human donors and NHPs showed the cell surface CD74 copy number was in the same range between human and NHP (FIGS.14A, 14B). The cell surface CD74 copy number was also comparable on peripheral blood cells from healthy human donors, donors with SCD, and NHPs as assessed by flow cytometry. Each symbol represents an individual donor. Bars indicate mean values. Data represent n= 10 (human healthy and SCD) versus n=5 (NHP) unique donors. # below limit of quantitation; * subset not characterized. (FIG.15). Example 14: Cytotoxicity of anti-CD74 Antibody and ADC, Isotype-DGN549c, and FGN849 on Cells in Culture. [00264] The in vitro cytotoxic activity of anti-CD74 ADC (clone 22) to Raji CD74+ and CD74- cells, as well as primary human and NHP CD34+ cells, was shown to be target- and payload-dependent. The Raji cell line is a lymphoblast-like cell that expresses CD74. anti-CD74 ADC was >90-fold more potent on Raji CD74+ cells compared to Raji CD74- cells (Table 19). Attorney Docket No.01245-0062-00PCT In contrast, the potency of the active catabolite, FGN849, and isotype-DGN549c conjugate were similar between CD74+ and CD74- cells indicating the expression of the target drives increased potency with anti-CD74 ADC. No cytotoxicity was observed with the antibody alone, demonstrating that the anti-CD74 antibody needs to be conjugated to the linker payload to be cytotoxic. Similar to the cytotoxicity on Raji cells, anti-CD74 ADC was more cytotoxic to primary human (77-fold) and NHP (150-fold) CD34+ HSPCs compared to isotype-DGN549c conjugate (Table 20 and Table 21), respectively. Importantly, the cytotoxic activity of anti-CD74 ADC was similar on the phenotypic subset of CD34+ cells that has been reported to be enriched for long-term HSCs, the CD34+ CD90+ population. Pre-incubation with plasma led to a <2-fold shift in cytotoxic activity, suggesting the conjugation of anti-CD74 antibody to DGN549c is stable in human, NHP, and mouse plasma for at least up to 48 hours (Table 22). Table 19: Cytotoxicity of anti-CD74 Antibody and ADC, Isotype-DGN549c, and FGN849 on CD74- Expressing and CD74-Knockout Raji Cells in Culture Notes: CD74 dependent cytotoxicity was evaluated on CD74-expressing versus CD74-knockout Raji cell lines. Data reflect 2 independent experiments. Values reported as the geometric mean and range across all experimental replicates. The number of replicates per condition is shown. Table 20: Cytotoxicity of anti-CD74 Antibody and ADC, Isotype-DGN549c, FGN849, and DGN549c on Human CD34 + Versus CD34 + CD90 + HSPCs in Culture HSPCs: hematopoietic stem and progenitor cells Notes: Cytotoxicity was evaluated on primary human HSPCs. Data reflect over 50 experiments and include 23 unique human donors and 17 different batches of anti-CD74 ADC. Values reported as the geometric mean and 95% confidence interval across all experimental replicates. The number of replicates per condition is shown. Table 21: Cytotoxicity of anti-CD74 Antibody and ADC, Isotype- DGN549c, and FGN849 on NHP CD34+ and CD34+ CD90+ HSPCs in Culture Attorney Docket No.01245-0062-00PCT HSPCs: hematopoietic stem and progenitor cells; NHP: non-human primate Notes: Cytotoxicity was evaluated on primary NHP HSPCs. Data reflect 4 independent experiments and include 4 unique NHP donors and 1 batch of anti-CD74 ADC. Values reported as the geometric mean and 95% confidence interval across all experimental replicates. The number of replicates per condition is shown. Table 22: Plasma Stability Analysis N: total sample size; NHP: non-human primate Notes: Data reflect 2 independent experiments. Values reported as the geometric mean and range across all experimental replicates. The number of replicates per condition is shown. Example 15: Bone Marrow Hematopoietic Stem and Progenitor Cell Depletion in Mice [00265] The effect of anti-CD74-DGN549c on HSPC depletion was evaluated in humanized NOD/scid/IL2Rγnull (NSG) mice in two independent experiments. In the first study, humanized mice received a single IV administration of V-003-0105- 001, an anti-CD74 antibody with a different Fc allotype but the same variable domains as clone 22 conjugated to DGN549c, unconjugated CD74 mAb, isotype-DGN549c, or PBS vehicle. Bone marrow was collected from the femur of euthanized mice on Day 21 post-dose administration and the depletion of human hematopoietic stem and progenitor cells (identified as CD34+ CD38- cells) was assessed by flow cytometry. Results are shown in FIG.16A. In a second study, the results were reproduced with anti-CD74 ADC (clone 22, DGN549c). Results are shown in FIG.16 B. Data represent n=5 mice/group and are plotted as geometric mean +/- standard deviation. Symbols represent individual animals. * Adjusted P value < 0.05 based on the exact Mann-Whitney U test, adjusted for multiple comparisons. Only V-003—0105—001 or anti-CD74 ADC were compared to PBS treatment in statistical analysis. In humanized mice, a single dose of anti-CD74-DGN549c down to 0.1 mg/kg depleted >95% human CD34+ HSPCs (FIG.16A-16B). Antibody alone or isotype- DGN549c had no effect, indicating that human CD34+ HSPC depletion by anti-CD74-DGN549c was target- and payload-dependent. Example 16: Overview of Non-Human Primate Pharmacology Models [00266] anti-CD74 ADC (clone 22) was evaluated in 2 different non-GLP pharmacology models in NHPs (Table 23). The first model monitored HSPC depletion to identify the minimum dose of anti-CD74 ADC that causes myeloablation. The second model was Attorney Docket No.01245-0062-00PCT to determine if the identified myeloablative doses are sufficient to enable autologous gene-edited HSCT. Table 23: Overview of NHP Pharmacology Models BM: bone marrow; HSPCs: hematopoietic stem and progenitor cells; HSCT: hematopoietic stem cell transplant; NHP: non-human primate [00267] In the depletion model, myeloablation was defined as BM HSPC depletion below the limit of quantitation and sustained neutropenia (<500/µL) at day 21 post-dose administration. NHPs received a single administration of anti-CD74 ADC versus a 4-day regimen of myeloablative busulfan (6 mg/kg/day) and were monitored for 20-24 days. Animals were supported with blood transfusions and antibiotics to mitigate risk of serious complications related to sustained thrombocytopenia and neutropenia, which are expected sequelae of myeloablation. FIGS.17A and 17B show the results where NHPs received a 4-day regimen of busulfan (6 mg/kg/day) or a single IV administration of anti-CD74 ADC at the doses indicated, and the number of BM HSPCs (defined as CD34+ CD90+ CD45RA- cells) per mL of BM aspirate was quantified at 7 (17A) versus 21 (17B) days post-dose administration. Data reflect 2- 4 NHP per dose cohort and are expressed as the geometric mean. Symbols represent individual animals. Untreated reflects BM aspirates collected from n=16 treatment-naïve NHPs. Terminal BM aspirates for animals treated with busulfan were collected on day 20 post-final dose administration due to dosing error. Terminal BM aspirates for animal treated with 0.2 mg/kg anti-CD74 ADC collected on day 24 post-dose administration. Calculated values equal to zero are plotted as 10 for visualization on a logarithmic scale. FIGS.18A and 18B show the kinetics of neutrophil and platelet depletion following a 4-day regimen of busulfan (6 mg/kg/day) compared to a single IV administration of 0.05, 0.1, 0.2, 0.3, and 0.4 mg/kg anti-CD74 ADC in Attorney Docket No.01245-0062-00PCT NHPs measured by hematology analyzer. Data reflect 2- 4 NHPs per dose cohort and are expressed as the geometric mean +/- standard deviation. [00268] In the depletion model, single doses of anti-CD74 ADC (0.1, 0.2, 0.3, and 0.4 mg/kg) are myeloablative and comparable to a myeloablative busulfan 4-day QD regimen (FIGS. 17A, 17B, 18A, 18B). A single dose of anti-CD74 ADC (0.05 mg/kg) resulted in similar CD34+ HSPC depletion at 7 days after treatment compared to higher doses; however, the CD34+ HSPCs recovered by Day 21. Therefore, 0.05 mg/kg anti-CD74 ADC is non-myeloablative. A monitoring duration of 21 days was selected because myelosuppression with 1020 gray total body irradiation, resulting in an absolute neutrophil count <500/µL for 19 days, is sufficient to enable successful autologous gene-edited hematopoietic stem cell transplant in NHPs. [00269] In the transplant model, NHPs went through ≤2 cycles of HSPC mobilization, collection via leukapheresis, ex vivo editing with CRISPR/Cas9 at the CCR5 locus, and cryopreservation of the edited HSPCs. Animals that achieved a cumulative dose of ≥2 × 106 CD34+ cells/kg were conditioned with a single administration of anti-CD74 ADC or a 4-day regimen of myeloablative busulfan (6 mg/kg/day) prior to infusion of the edited CD34+ cell product. Post-transplant, animals were monitored for signs of neutrophil and platelet engraftment, and samples were collected to assess chimerism of gene-edited cells in peripheral blood and bone marrow. Prior to engraftment, NHPs were supported with anti-infectives (antibiotics, antivirals, and antifungals) and blood transfusion. [00270] FIGS.19A and 19B show NHPs transplanted 6 days (0.2 or 0.3 mg/kg) or 10 days (0.1 mg/kg) after anti-CD74 ADC administration versus 2 days after the final administration of busulfan (6 mg/kg/day), and the kinetics of neutrophil (19A) and platelet (19B) engraftment measured by hematology analyzer. Animals were supported with G-CSF (up to 25µg/kg/day) and whole blood transfusions (up to daily) until achievement of ANC > 500/µL and PLT > 100,000/µL, respectively. Each line represents an individual animal. † One animal treated with 0.1 mg/kg anti-CD74 ADC was electively euthanized at day 36 post-transplant after testing positive for plasmodium. †† One animal treated with 0.3 mg/kg anti-CD74 ADC was electively euthanized at day 69 post-transplant after developing complications associated with thrombocytopenia. [00271] As shown in FIG.20, Peripheral myeloid chimerism (circles) was assessed monthly following transplant. Myeloid cells (CD11b+) were isolated from peripheral blood, and genomic DNA was isolated for next-generation sequencing analysis to determine indel frequency at the CCR5 locus. The editing efficiency for each post-transplant sample is expressed relative to the editing efficiency in the drug product. Bone marrow aspirates were collected bi-monthly beginning 4 months post-transplant, and editing efficiency was measured in bone marrow Attorney Docket No.01245-0062-00PCT CD34+ cells (squares). Each colored line represents an individual animal. The expected stable editing interval for myeloid chimerism following myeloablative busulfan conditioning (highlighted in gray) was determined based on the 95% confidence interval of the arithmetic mean of stable editing results from n=5 NHP (n=4 published37 and n=1 internal) that underwent autologous CCR5-edited HSCT following myeloablative busulfan. † One animal treated with 0.3 mg/kg anti-CD74 ADC was electively euthanized at day 69 post-transplant after developing complications associated with thrombocytopenia. In the transplant model, successful multilineage engraftment and stable gene edited chimerism was achieved with anti-CD74 ADC conditioning at 0.2 and 0.1 mg/kg with 8 and 5 months follow up, respectively (FIGS.19A, 19B, 20). Three animals treated with anti-CD74 ADC (0.3 mg/kg) did not meet success criteria. Additional dose levels of anti-CD74 ADC and different dosing intervals between anti-CD74 ADC dosing and graft infusion will be evaluated to characterize the therapeutic dose range and the sufficiency of clearance of anti-CD74 ADC and its active catabolites to enable autologous gene-edited HSCT. Example 17: Drug Metabolism and Pharmacokinetics [00272] Pharmacokinetics (PK) and biodistribution of anti-CD74 ADC (clone 22) were evaluated in NHPs using sensitive and selective bioanalytical methods (total ADC/total antibody by ligand binding assays, unconjugated payload by LC-MS/MS). Following a single IV administration, anti-CD74 ADC exhibits a short residence time in circulation (effective T 1/2 2-5 hours) due to rapid target-mediated distribution into CD74-expressing tissues including bone marrow as the pharmacological site of action. Results showing mean plasma pharmacokinetic parameters of total ADC and total antibody following a single intravenous administration of anti-CD74 ADC to cynomolgus monkeys are in Table 24 and FIGS.21A, 21B. FIG.21A shows plasma PK profiles of total ADC and FIG.21B shows plasma PK profiles of total antibody with 2-4 NHPs per dose cohort and results are expressed as the arithmetic mean +/- standard deviation. N =2 for 0.05, 0.1, 0.2, and 0.4 mg/kg dose level; N = 4 for 0.3 mg/kg. Table 25 shows individual and mean plasma toxicokinetic parameters of total antibody following a single intravenous administration of antiCD74ADC in cynomolgus monkeys. FIGS.22A and 22B show individual plasma concentration-time profile of total ADC and total antibody following a single intravenous administration of anti-CD74ADC in cynomolgus monkeys. Table 26 shows individual and mean plasma toxicokinetic parameters of free FGN849 following a single intravenous administration of anti-CD74 ADC in cynomolgus monkeys. FIG.23 shows the individual plasma concentration-time profile of free FGN849 following a single intravenous administration of anti-CD74 ADC in cynomolgus monkeys. Attorney Docket No.01245-0062-00PCT Table 24: Mean Plasma Pharmacokinetic Parameters of Total ADC and Total Antibody Following a Single Intravenous Administration of anti-CD74 ADC to Cynomolgus Monkeys C0: back extrapolated concentration at time 0 for IV bolus administration; AUCinf: area under the concentration vs. time curve extrapolated from time zero to infinity; CL: clearance; Vss: volume of distribution at steady state; Tlast: time of last measurable concentration; T1/2: time required for the concentration to decrease by half. Table 25: Individual and Mean Plasma Toxicokinetic Parameters of Total Antibody Following a Single Intravenous Administration of anti-CD74 ADC in Cynomolgus Monkeys * Animal 3501B showed unexpected TK profiles. Dose proportionality analysis at the 0.4 mg/kg dose only included 3001B. Table 26: Individual and Mean Plasma Toxicokinetic Parameters of Free FGN849 Following a Single Intravenous Administration of BIO-111 in Cynomolgus Monkeys Attorney Docket No.01245-0062-00PCT * Animal 3501B showed unexpected TK profiles. Dose proportionality analysis at the 0.4 mg/kg dose only included 3001B. [00273] Upon internalization with the target, anti-CD74 ADC undergoes linker cleavage via intracellular metabolism and releases FGN849 as the active catabolite that drives HSPC depletion in the bone marrow. Systemic exposure of total ADC, total antibody, and FGN849 increased with escalating doses in an approximately dose-proportional manner. The rapid clearance of anti-CD74 ADC provides the desired candidate profile for this indication so that HSCT can be performed 7-10 days following myeloablative conditioning. At doses of ≤ 0.2 mg/kg, total ADC, total antibody, and unconjugated FGN849 in circulation all fell below the in vitro cytotoxicity EC50 within 7 days post-dose. At higher doses, more extended ADC exposure was observed that could compromise the successful engraftment of the stem cell transplant. [00274] Preliminary biodistribution data following a single 0.2 mg/kg IV dose of anti- CD74 ADC indicate that highest exposure to the intact ADC occurred in plasma, followed by spleen (a CD74 expressing tissue), which likely indicates target-mediated uptake of the ADC. Selective ADC distribution into spleen is consistent with this being a target organ for toxicity. In other tissues, including the bone marrow and gonads, the ADC exposure was approximately 4-60 fold and 2-30 fold lower than plasma and spleen, respectively. Comparative exposure data of the payload FGN849 in bone marrow versus other tissues are pending. Current human efficacious dose prediction is based on allometric scaling of anti-CD74 ADC systemic exposure in NHPs. This approach assumes that 1) exposure of the active entity FGN849 in the bone marrow will also follow the same allometric relationship across species, and 2) the PK/PD relationship directly translates from NHP to human. Using these assumptions and 0.1 mg/kg single IV dose as the preliminary efficacious dose in NHPs, the human efficacious dose is predicted to be 0.03 mg/kg single IV dose. [00275] Preliminary NHP data indicated low risk of immunogenicity following a single IV dose of anti-CD74 ADC at 0.2 – 1.0 mg/kg. Anti-CD74 ADC has a low risk of drug interactions via effects on cytochrome P450 enzymes or drug transporters because of the ADC modality and the very low systemic exposure of FGN849. [00276] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, the descriptions and examples should not be construed as limiting the scope of the invention. The disclosures of all patent and scientific literature cited herein are expressly incorporated in their entirety by reference. Attorney Docket No.01245-0062-00PCT Table of Sequences Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT Attorney Docket No.01245-0062-00PCT

Claims

Attorney Docket No.01245-0062-00PCT WHAT IS CLAIMED IS: 1. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino Attorney Docket No.01245-0062-00PCT acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or Attorney Docket No.01245-0062-00PCT xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. 2. An isolated antibody that binds human CD74, the antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or Attorney Docket No.01245-0062-00PCT iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; or iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or Attorney Docket No.01245-0062-00PCT viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or Attorney Docket No.01245-0062-00PCT xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 Attorney Docket No.01245-0062-00PCT comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or Attorney Docket No.01245-0062-00PCT xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions. 3. The isolated antibody of claim 1 or claim 2, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a heavy chain variable region (VH) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of claim 1.ii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of claim 1.iii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of claim 1.iv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of claim 1.v) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of claim 1.vi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of claim 1.vii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 712; or viii) the CDRs of claim 1.viii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of claim 1.ix) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 912; or x) the CDRs of claim 1.x) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1012; or Attorney Docket No.01245-0062-00PCT xi) the CDRs of claim 1.xi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of claim 1.xii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of claim 1.xiii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of claim 1.xiv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of claim 1.xv) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of claim 1.xvi) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of claim 1.xvii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of claim 1.xviii) and further comprises a VH that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1812. 4. The isolated antibody of any one of claims 1-3, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 12; or ii) the CDRs of claim 1.ii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 112; or iii) the CDRs of claim 1.iii) and further comprises a comprising the amino acid sequence of SEQ ID NO: 212; or iv) the CDRs of claim 1.iv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 312; or v) the CDRs of claim 1.v) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 512; or vi) the CDRs of claim 1.vi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 612; or vii) the CDRs of claim 1.vii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 712; or viii) the CDRs of claim 1.viii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 812; or ix) the CDRs of claim 1.ix) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 912; or Attorney Docket No.01245-0062-00PCT x) the CDRs of claim 1.x) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1012; or xi) the CDRs of claim 1.xi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1112; or xii) the CDRs of claim 1.xii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1212; or xiii) the CDRs of claim 1.xiii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1312; or xiv) the CDRs of claim 1.xiv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1412; or xv) the CDRs of claim 1.xv) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1512; or xvi) the CDRs of claim 1.xvi) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1612; or xvii) the CDRs of claim 1.xvii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1712; or xviii) the CDRs of claim 1.xviii) and further comprises a VH comprising the amino acid sequence of SEQ ID NO: 1812. 5. The isolated antibody of any one of claims 1-4, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a light chain variable region (VL) that is at least 90% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of claim 1.ii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of claim 1.iii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of claim 1.iv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of claim 1.v) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of claim 1.vi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of claim 1.vii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the CDRs of claim 1.viii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 818; or Attorney Docket No.01245-0062-00PCT ix) the CDRs of claim 1.ix) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of claim 1.x) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of claim 1.xi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of claim 1.xii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of claim 1.xiii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of claim 1.xiv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of claim 1.xv) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of claim 1.xvi) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of claim 1.xvii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the CDRs of claim 1.xviii) and further comprises a VL that is at least 90% identical to the amino acid sequence of SEQ ID NO: 1818. 6. The isolated antibody of any one of claims 1-5, wherein the antibody comprises: i) the CDRs of claim 1.i) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 18; or ii) the CDRs of claim 1.ii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 118; or iii) the CDRs of claim 1.iii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 218; or iv) the CDRs of claim 1.iv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 318; or v) the CDRs of claim 1.v) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 518; or vi) the CDRs of claim 1.vi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 618; or vii) the CDRs of claim 1.vii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 718; or Attorney Docket No.01245-0062-00PCT viii) the CDRs of claim 1.viii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 818; or ix) the CDRs of claim 1.ix) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 918; or x) the CDRs of claim 1.x) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1018; or xi) the CDRs of claim 1.xi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1118; or xii) the CDRs of claim 1.xii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1218; or xiii) the CDRs of claim 1.xiii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1318; or xiv) the CDRs of claim 1.xiv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1418; or xv) the CDRs of claim 1.xv) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1518; or xvi) the CDRs of claim 1.xvi) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1618; or xvii) the CDRs of claim 1.xvii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1718; or xviii) the CDRs of claim 1.xviii) and further comprises a VL comprising the amino acid sequence of SEQ ID NO: 1818. 7. The isolated antibody of any one of claims 1-6, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at Attorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or Attorney Docket No.01245-0062-00PCT xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. 8. The isolated antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: i) the VH comprises the amino acid sequence of SEQ ID NO: 12 and the VL comprises the amino acid sequence of SEQ ID NO: 18; or ii) the VH comprises the amino acid sequence of SEQ ID NO: 112 and the VL comprises the amino acid sequence of SEQ ID NO: 118; or Attorney Docket No.01245-0062-00PCT iii) the VH comprises the amino acid sequence of SEQ ID NO: 212 and the VL comprises the amino acid sequence of SEQ ID NO: 218; or iv) the VH comprises the amino acid sequence of SEQ ID NO: 312 and the VL comprises the amino acid sequence of SEQ ID NO: 318; or v) the VH comprises the amino acid sequence of SEQ ID NO: 512 and the VL comprises the amino acid sequence of SEQ ID NO: 518; or vi) the VH comprises the amino acid sequence of SEQ ID NO: 612 and the VL comprises the amino acid sequence of SEQ ID NO: 618; or vii) the VH comprises the amino acid sequence of SEQ ID NO: 712 and the VL comprises the amino acid sequence of SEQ ID NO: 718; or viii) the VH comprises the amino acid sequence of SEQ ID NO: 812 and the VL comprises the amino acid sequence of SEQ ID NO: 818; or ix) the VH comprises the amino acid sequence of SEQ ID NO: 912 and the VL comprises the amino acid sequence of SEQ ID NO: 918; or x) the VH comprises the amino acid sequence of SEQ ID NO: 1012 and the VL comprises the amino acid sequence of SEQ ID NO: 1018; or xi) the VH comprises the amino acid sequence of SEQ ID NO: 1112 and the VL comprises the amino acid sequence of SEQ ID NO: 1118; or xii) the VH comprises the amino acid sequence of SEQ ID NO: 1212 and the VL comprises the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH comprises the amino acid sequence of SEQ ID NO: 1312 and the VL comprises the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH comprises the amino acid sequence of SEQ ID NO: 1412 and the VL comprises the amino acid sequence of SEQ ID NO: 1418; or xv) the VH comprises the amino acid sequence of SEQ ID NO: 1512 and the VL comprises the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH comprises the amino acid sequence of SEQ ID NO: 1612 and the VL comprises the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH comprises the amino acid sequence of SEQ ID NO: 1712 and the VL comprises the amino acid sequence of SEQ ID NO: 1718; or xviii) the VH comprises the amino acid sequence of SEQ ID NO: 1812 and the VL comprises the amino acid sequence of SEQ ID NO: 1818. 9. An isolated antibody that binds human CD74, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein: Attorney Docket No.01245-0062-00PCT i) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or ii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or iii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or iv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or v) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or vi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or vii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or viii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or ix) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and the VL is at Attorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or x) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xiii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xiv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xv) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xvi) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or xvii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or Attorney Docket No.01245-0062-00PCT xviii) the VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and the VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. 10. The isolated antibody of claim 9, wherein the antibody comprises: i) the VH and VL of claim 8.i) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6; or ii) the VH and VL of claim 8.ii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106; or iii) the VH and VL of claim 8.iii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206; or iv) the VH and VL of claim 8.iv) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306; or v) the VH and VL of claim 8.v) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506; or Attorney Docket No.01245-0062-00PCT vi) the VH and VL of claim 8.vi) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606; or vii) the VH and VL of claim 8.vii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706; or viii) the VH and VL of claim 8.viii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806; or ix) the VH and VL of claim 8.ix) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906; or x) the VH and VL of claim 8.x) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006; or xi) the VH and VL of claim 8.xi) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: Attorney Docket No.01245-0062-00PCT 1104; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106; or xii) the VH and VL of claim 8.xii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206; or xiii) the VH and VL of claim 8.xiii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306; or xiv) the VH and VL of claim 8.xiv) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406; xv) or the VH and VL of claim 8.xv) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506; or xvi) the VH and VL of claim 8.xvi) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606; or xvii) the VH and VL of claim 8.xvii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702; (c) HCDR3 comprising the amino acid sequence Attorney Docket No.01245-0062-00PCT of SEQ ID NO: 1703; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706; or xviii) the VH and VL of claim 8.xviii) and (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806. 11. The isolated antibody of claim 9 or claim 10, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 12, 112, 212, 312, 512, 612, 712, 812, 912, 1012, 1112, 1212, 1312, 1412, 1512, 1612, 1712, or 1812. 12. The isolated antibody of any one of claims 9-11, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, insertions, and/or deletions compared to an amino acid sequence chosen from any one of SEQ ID NOs: 18, 118, 218, 318, 518, 618, 718, 818, 918, 1018, 1118, 1218, 1318, 1418, 1518, 1618, 1718, or 1818. 13. The isolated antibody of any one of the preceding claims, wherein the antibody is a monoclonal antibody. 14. The isolated antibody of any one of the preceding claims, wherein the antibody is an antibody fragment. 15. The isolated antibody of claim 14, wherein the fragment is a Fab, Fab’, Fv, scFv or (Fab’)2. 16. The isolated antibody of any one of claims 1-13, wherein the antibody is a full- length antibody. 17. The isolated antibody of any one of claims 1-13, wherein an Fc region of the antibody comprises IgG1, IgG2, IgG3, or IgG4. 18. The isolated antibody of any one of claims 1-13, wherein the antibody comprises a human IgG1 heavy chain constant region. 19. The isolated antibody of any one of claims 1-13, wherein the antibody comprises a human IgG4 heavy chain constant region. 20. The isolated antibody of claim 18, wherein the antibody comprises a mutant human IgG1 heavy chain constant region. Attorney Docket No.01245-0062-00PCT 21. The isolated antibody of claim 20, wherein the mutant IgG1 heavy chain constant region comprises a mutation selected from a substitution at L234, a substitution at L235, a substitution at P329, or a combination thereof, according to EU numbering. 22. The isolated antibody of claim 21, wherein the mutant IgG1 heavy chain constant region comprises an L234A substitution, an L234A substitution, and a P329A substitution or a combination thereof, according to EU numbering. 23. The isolated antibody of any one of claims 20-22, wherein the mutant IgG1 heavy chain constant region comprises a deletion of K447, according to EU numbering. 24. The isolated antibody of any one of claims 20-23, wherein the mutant IgG heavy chain constant region comprises a substitution at S239, according to EU numbering. 25. The isolated antibody of any one of claims 20-24, wherein the mutant IgG heavy chain constant region comprises an S239C substitution, according to EU numbering. 26. The isolated antibody of any one of claims 1-13 and 16-25, wherein the antibody comprises a human IgG kappa light chain constant region. 27. The isolated antibody of any one of claims 1-26, further comprising an effector molecule conjugated to the antibody. 28. The isolated antibody of claim 27, wherein the effector molecule comprises a cytotoxic agent. 29. The isolated antibody of claim 28, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. 30. The isolated antibody of claim 28 or claim 29, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). 31. The isolated antibody of any one of claims 28-30, wherein the cytotoxic agent is DGN549C. 32. The isolated antibody of claim 31, wherein the DGN549C is conjugated to the antibody at an S239C substitution of a IgG heavy chain constant region. 33. A humanized or fully human version of the antibody of any one of the preceding claims. 34. A conjugate comprising an anti-CD74 antibody and an effector molecule conjugated to the antibody, the anti-CD74 antibody comprising: i) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1 with one or two amino Attorney Docket No.01245-0062-00PCT acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 2 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 3 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 4 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 5 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 6 with one or two amino acid substitutions; or ii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 101 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 106 with one or two amino acid substitutions; or iii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 206 with one or two amino acid substitutions; iv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 304 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 306 with one or two amino acid substitutions; or v) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 506 with one or two amino acid substitutions; or vi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 601 with one or two amino Attorney Docket No.01245-0062-00PCT acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 606 with one or two amino acid substitutions; or vii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 706 with one or two amino acid substitutions; or viii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 804 with one or two amino acid Attorney Docket No.01245-0062-00PCT substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 806 with one or two amino acid substitutions; or ix) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 901 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 902 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 903 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 904 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 905 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 906 with one or two amino acid substitutions; or x) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1001 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1002 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1003 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1004 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1005 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1006 with one or two amino acid substitutions; or xi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1101 with one or two amino Attorney Docket No.01245-0062-00PCT acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1102 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1103 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1104 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1105 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1106 with one or two amino acid substitutions; or xii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1201 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1202 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1203 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1204 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1205 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1206 with one or two amino acid substitutions; or xiii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1301 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1302 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1303 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1304 with one or two amino Attorney Docket No.01245-0062-00PCT acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1305 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1306 with one or two amino acid substitutions; or xiv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1401 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1402 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1403 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1404 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1405 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1406 with one or two amino acid substitutions; or xv) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1501 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1502 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1503 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1504 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1505 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1506 with one or two amino acid substitutions; or xvi) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1601 with one or Attorney Docket No.01245-0062-00PCT two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1602 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1603 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1604 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1605 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1606 with one or two amino acid substitutions; or xvii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1701 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1702 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1703 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1704 with one or two amino acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1705 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1706 with one or two amino acid substitutions; or xviii) (a) HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 or HCDR1 comprising the amino acid sequence of SEQ ID NO: 1801 with one or two amino acid substitutions; (b) HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 or HCDR2 comprising the amino acid sequence of SEQ ID NO: 1802 with one or two amino acid substitutions; (c) HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 or HCDR3 comprising the amino acid sequence of SEQ ID NO: 1803 with one or two amino acid substitutions; (d) LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 or LCDR1 comprising the amino acid sequence of SEQ ID NO: 1804 with one or two amino Attorney Docket No.01245-0062-00PCT acid substitutions; (e) LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 or LCDR2 comprising the amino acid sequence of SEQ ID NO: 1805 with one or two amino acid substitutions; and (f) LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 or LCDR3 comprising the amino acid sequence of SEQ ID NO: 1806 with one or two amino acid substitutions; or xix) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 12 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 18; or xx) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 112 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 118; or xxi) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 212 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 218; or xxii) a VH that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 312 and a VL that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 318; or xxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 518; or xxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 618; or xxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 718; or xxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 812 and a VL is at Attorney Docket No.01245-0062-00PCT least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 818; or xxvii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 912 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 918; or xxviii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1012 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1018; or xxix) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1112 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1118; or xxx) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1212 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1218; or xxxi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1312 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1318; or xxxii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1412 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1418; or xxxiii) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1512 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1518; or xxxiv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1612 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1618; or Attorney Docket No.01245-0062-00PCT xxxv) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1712 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1718; or xxxvi) a VH is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1812 and a VL is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence of SEQ ID NO: 1818. 35. The conjugate of claim 34, wherein the effector molecule comprises a cytotoxic agent. 36. The conjugate of claim 35, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. 37. The conjugate of claim 35 or claim 36, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). 38. The conjugate of any one of claims 35-37, wherein the cytotoxic agent is DGN549C. 39. The conjugate of any one of claims 34-38, wherein the anti-CD74 antibody comprises the isolated antibody of any one of claims 1, 3-12 and 16-26. 40. A composition comprising the antibody of any one of claims 1-33 and a pharmaceutically acceptable carrier. 41. A method of conditioning a subject to reduce an endogenous population of hematopoietic stem cells in the subject comprising administering an anti-CD74 antibody to the subject, the anti-CD74 antibody comprising the isolated antibody of any one of claims 1-13 and 16-26. 42. The method of claim 41, wherein the anti-CD74 antibody is conjugated to an effector molecule. 43. The method of claim 42, wherein the effector molecule comprises a cytotoxic agent. 44. The method of claim 43, wherein the cytotoxic agent is selected from a DNA inhibitor, a topoisomerase inhibitor, or a tubulin inhibitor. 45. The method of claim 43 or claim 44, wherein the cytotoxic agent is selected from Monoimine indolinobenzodiazepene (DGN549C), Tesirine, Talirine, Duocarmycin (secoDUBA Attorney Docket No.01245-0062-00PCT prodrug), NMS249 (anthracycline), PNU (anthracycline), Dxd (exatecan), Monomethyl auristatin F (MMAF), Monomethyl auristatin E (MMAE), Ravtansine (DM4), and Pyrrolobenzodiazepine (PBD). 46. The method of any one of claims 43-45, wherein the cytotoxic agent is DGN549C. 47. The method of any one of claims 41-46, wherein the anti-CD74 antibody is internalized by the endogenous population of hematopoietic stem cells. 48. The method of any one of claims 41-47, wherein the anti-CD74 antibody comprises an effector silencing modification. 49. The method of any one of claims 41-48, wherein the hematopoietic stem cells are reduced in bone marrow. 50. The method of any one of claims 41-49, wherein the hematopoietic stem cells are CD34+ cells. 51. The method of any one of claims 41-50, wherein the hematopoietic stem cells are human cells. 52. The method of any one of claims 41-51, comprising administering a composition comprising cells following conditioning of the subject to reduce the endogenous population of hematopoietic stem cells. 53. The method of any one of claims 41-52, comprising administering to the subject a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs). 54. The method of any one of claims 41-53, comprising administering a composition comprising CD34+ human hematopoietic stem and/or progenitor cells (hHSPCs) that comprise a genetic modification. 55. The method of any one of claims 41-54, wherein the subject has a hemoglobinopathy. 56. A nucleic acid encoding the antibody of any one of claims 1-26. 57. A host cell comprising the nucleic acid of claim 56. 58. A method of producing the antibody of any one of claims 1-26 comprising culturing the host cell of claim 57 under conditions wherein the antibody is expressed. 59. The method of claim 58, further comprising purifying the antibody.
PCT/US2025/031700 2024-05-31 2025-05-30 Anti-cd74 antibodies, conjugates and uses thereof Pending WO2025250969A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202463654412P 2024-05-31 2024-05-31
US63/654,412 2024-05-31
US202563787525P 2025-04-11 2025-04-11
US63/787,525 2025-04-11

Publications (1)

Publication Number Publication Date
WO2025250969A1 true WO2025250969A1 (en) 2025-12-04

Family

ID=96356512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/031700 Pending WO2025250969A1 (en) 2024-05-31 2025-05-30 Anti-cd74 antibodies, conjugates and uses thereof

Country Status (1)

Country Link
WO (1) WO2025250969A1 (en)

Citations (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0404097A2 (en) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
WO1993001161A1 (en) 1991-07-11 1993-01-21 Pfizer Limited Process for preparing sertraline intermediates
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5648237A (en) 1991-09-19 1997-07-15 Genentech, Inc. Expression of functional antibody fragments
WO1997030087A1 (en) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation of glycosylated antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO2000061739A1 (en) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Method for controlling the activity of immunologically functional molecule
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2001029246A1 (en) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
US6420548B1 (en) 1999-10-04 2002-07-16 Medicago Inc. Method for regulating transcription of foreign genes
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
WO2003074567A2 (en) * 2002-03-01 2003-09-12 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20050014934A1 (en) 2002-10-15 2005-01-20 Hinton Paul R. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005035586A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
US20050260186A1 (en) 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060025576A1 (en) 2000-04-11 2006-02-02 Genentech, Inc. Multivalent antibodies and uses therefor
WO2006029879A2 (en) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anti-ox40l antibodies
WO2006044908A2 (en) 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
WO2008077546A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US20100074840A1 (en) * 2002-03-01 2010-03-25 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2017062271A2 (en) * 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
WO2018071871A1 (en) * 2016-10-13 2018-04-19 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2019113149A1 (en) 2017-12-05 2019-06-13 Crispr Therapeutics Ag Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
WO2020257325A1 (en) 2019-06-17 2020-12-24 Vertex Pharmaceuticals Inc. Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
US10898579B2 (en) 2015-06-29 2021-01-26 Immunogen, Inc. Conjugates of cysteine engineered antibodies
WO2022133246A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Patent Citations (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5648260A (en) 1987-03-18 1997-07-15 Scotgen Biopharmaceuticals Incorporated DNA encoding antibodies with altered effector functions
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US6248516B1 (en) 1988-11-11 2001-06-19 Medical Research Council Single domain ligands, receptors comprising said ligands methods for their production, and use of said ligands and receptors
EP0404097A2 (en) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispecific and oligospecific, mono- and oligovalent receptors, production and applications thereof
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6417429B1 (en) 1989-10-27 2002-07-09 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1993001161A1 (en) 1991-07-11 1993-01-21 Pfizer Limited Process for preparing sertraline intermediates
US5648237A (en) 1991-09-19 1997-07-15 Genentech, Inc. Expression of functional antibody fragments
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
WO1997030087A1 (en) 1996-02-16 1997-08-21 Glaxo Group Limited Preparation of glycosylated antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
WO1998058964A1 (en) 1997-06-24 1998-12-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
WO1999051642A1 (en) 1998-04-02 1999-10-14 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7371826B2 (en) 1999-01-15 2008-05-13 Genentech, Inc. Polypeptide variants with altered effector function
WO2000061739A1 (en) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US6420548B1 (en) 1999-10-04 2002-07-16 Medicago Inc. Method for regulating transcription of foreign genes
WO2001029246A1 (en) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US20060025576A1 (en) 2000-04-11 2006-02-02 Genentech, Inc. Multivalent antibodies and uses therefor
US20030115614A1 (en) 2000-10-06 2003-06-19 Yutaka Kanda Antibody composition-producing cell
US20020164328A1 (en) 2000-10-06 2002-11-07 Toyohide Shinkawa Process for purifying antibody
WO2002031140A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions
WO2003011878A2 (en) 2001-08-03 2003-02-13 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003074567A2 (en) * 2002-03-01 2003-09-12 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
US20100074840A1 (en) * 2002-03-01 2010-03-25 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
US20040110282A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040109865A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
WO2003085107A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells with modified genome
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
US20050014934A1 (en) 2002-10-15 2005-01-20 Hinton Paul R. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20050260186A1 (en) 2003-03-05 2005-11-24 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005035586A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY USING RNA INHIBITING THE FUNCTION OF α1,6-FUCOSYLTRANSFERASE
US20050123546A1 (en) 2003-11-05 2005-06-09 Glycart Biotechnology Ag Antigen binding molecules with increased Fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
WO2005100402A1 (en) 2004-04-13 2005-10-27 F.Hoffmann-La Roche Ag Anti-p-selectin antibodies
WO2006029879A2 (en) 2004-09-17 2006-03-23 F.Hoffmann-La Roche Ag Anti-ox40l antibodies
US7521541B2 (en) 2004-09-23 2009-04-21 Genetech Inc. Cysteine engineered antibodies and conjugates
WO2006044908A2 (en) 2004-10-20 2006-04-27 Genentech, Inc. Antibody formulation in histidine-acetate buffer
US20080069820A1 (en) 2006-08-30 2008-03-20 Genentech, Inc. Multispecific antibodies
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
WO2008077546A1 (en) 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US10898579B2 (en) 2015-06-29 2021-01-26 Immunogen, Inc. Conjugates of cysteine engineered antibodies
WO2017062271A2 (en) * 2015-10-06 2017-04-13 Merck Sharp & Dohme Corp. Antibody drug conjugate for anti-inflammatory applications
WO2018071871A1 (en) * 2016-10-13 2018-04-19 President And Fellows Of Harvard College Compositions and methods for non-myeloablative conditioning
WO2019113149A1 (en) 2017-12-05 2019-06-13 Crispr Therapeutics Ag Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
WO2020257325A1 (en) 2019-06-17 2020-12-24 Vertex Pharmaceuticals Inc. Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
WO2022133246A1 (en) 2020-12-17 2022-06-23 Vertex Pharmaceuticals Incorporated Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

Non-Patent Citations (51)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1980
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
BRENNAN ET AL., SCIENCE, vol. 229, 1985, pages 81
BRUGGEMANN, M. ET AL., J. EXP. MED., vol. 166, 1987, pages 1351 - 1361
CHARI ET AL., CANCER RES., vol. 52, 1992, pages 127 - 131
CHOWDHURY, METHODS MOL. BIOL., vol. 207, 2008, pages 179 - 196
CHROMATOGR. B, vol. 848, 2007, pages 79 - 87
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
CLYNES ET AL., PROC. NAT'LACAD. SCI. USA, vol. 95, 1998, pages 652 - 656
CRAGG, M.S. ET AL., BLOOD, vol. 101, 2003, pages 1045 - 1052
CRAGG, M.S.M.J. GLENNIE, BLOOD, vol. 103, 2004, pages 2738 - 2743
CRISTINA L. ABRAHAMS ET AL: "Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001", ONCOTARGET, vol. 9, no. 102, 28 December 2018 (2018-12-28), pages 37700 - 37714, XP055725165, DOI: 10.18632/oncotarget.26491 *
CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 1085
DUNCANWINTER, NATURE, vol. 322, 1988, pages 738 - 40
ESTEP ET AL., MABS, vol. 5, no. 2, 2013, pages 270 - 278
GAZZANO-SANTORO ET AL., J. IMMUNOL. METHODS, vol. 202, 1996, pages 163
GERNGROSS, NAT. BIOTECH., vol. 22, 2004, pages 1409 - 1414
GRAHAM ET AL., J. GEN VIROL., vol. 36, 1977, pages 59
GRUBER ET AL., J. IMMUNOL., vol. 152, 1994, pages 5368 - 315
GUYER ET AL., J. IMMUNOL., vol. 117, 1976, pages 587
HAVERKOS BRADLEY M ET AL: "A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies", BLOOD, AMSTERDAM, NL, vol. 124, no. 21, 14 November 2014 (2014-11-14), pages 1168, XP086740352, [retrieved on 20210625], DOI: 10.1182/BLOOD.V124.21.1168.1168 *
HELLSTROM, I ET AL., PROC. NAT'L ACAD. SCI. USA, vol. 82, 1985, pages 1499 - 1502
HELLSTROM, I. ET AL., PROC. NAT'LACAD. SCI. USA, vol. 83, 1986, pages 7059 - 7063
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HUDSON ET AL., NAT. MED., vol. 9, 2003, pages 129 - 134
IDUSOGIE ET AL., J. IMMUNOL., vol. 164, 2000, pages 4178 - 4184
KAM ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, 2005, pages 11600 - 11605
KANDA, Y. ET AL., BIOTECHNOL. BIOENG., vol. 94, no. 4, 2006, pages 680 - 688
KOSTELNY ET AL., J. IMMUNOL., vol. 148, no. 5, 1992, pages 1547 - 1553
LEFRANC, M.-P. ET AL., DEV. COMP. IMMUNOL., vol. 27, 2003, pages 55 - 77
LEFRANC, M.-P., THE IMMUNOLOGIST, vol. 7, 1999, pages 132 - 136
LI ET AL., NAT. BIOTECH., vol. 24, 2006, pages 210 - 215
MATHER ET AL., ANNALS N.Y. ACAD. SCI., vol. 383, 1982, pages 44 - 68
MATHER, BIOL. REPROD., vol. 23, 1980, pages 243 - 251
MILSTEINCUELLO, NATURE, vol. 305, 1983, pages 537
OKAZAKI ET AL., J. MOL. BIOL., vol. 336, 2004, pages 1239 - 1249
PETKOVA, S.B. ET AL., INT'L. IMMUNOL., vol. 18, no. 12, 2006, pages 1759 - 1769
PORTOLANO ET AL., J. IMMUNOL., vol. 150, 1993, pages 880 - 887
RAVETCHKINET, ANNU. REV. IMMUNOL., vol. 9, pages 457 - 492
RIPKA ET AL., ARCH. BIOCHEM. BIOPHYS., vol. 249, 1986, pages 533 - 545
SAHA ASIM ET AL: "Antibody based conditioning for allogeneic hematopoietic stem cell transplantation", FRONTIERS IN IMMUNOLOGY, vol. 13, 1031334, 1 January 2022 (2022-01-01), pages 1 - 12, XP093078897, DOI: 10.3389/fimmu.2022.1031334 *
SHIELDS ET AL., J. BIOL. CHEM., vol. 178, no. 2, 2001, pages 6591 - 6604
SIEGEL ET AL., J IMMUNOL METHODS, vol. 286, no. 1-2, 2004, pages 141 - 153
TRAUNECKER ET AL., EMBO J., vol. 1-3, 1991, pages 3655
TUTT ET AL., J. IMMUNOL., vol. 147, 1991, pages 60
UCHIDA NAOYA ET AL: "Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model", NATURE COMMUNICATIONS, vol. 14, no. 1, 6291, 12 October 2023 (2023-10-12), UK, XP093315175, ISSN: 2041-1723, Retrieved from the Internet <URL:https://www.nature.com/articles/s41467-023-41153-5> DOI: 10.1038/s41467-023-41153-5 *
URLAUB ET AL., PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216
WRIGHT ET AL., TIBTECH, vol. 15, 1997, pages 26 - 32
Y. XU ET AL., PEDS, vol. 26, no. 10, 2013, pages 663 - 70
YAMANE-OHNUKI ET AL., BIOTECH. BIOENG., vol. 87, 2004, pages 614
YAZAKIWU: "Methods in Molecular Biology", vol. 248, 2003, HUMANA PRESS, pages: 255 - 268

Similar Documents

Publication Publication Date Title
US20230279109A1 (en) Anti-tim3 antibodies and methods of use
RU2630296C2 (en) Antibodies to biotin and application methods
JP7248761B2 (en) Anti-BRDU Antibodies and Methods of Use
JP6549278B2 (en) Anti-theophylline antibodies and methods of use
WO2025250969A1 (en) Anti-cd74 antibodies, conjugates and uses thereof
HK1242354B (en) Anti-theophylline antibodies and methods of use
HK1181402B (en) Anti-fap antibodies and methods of use
HK1208235B (en) Anti-biotin antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25737914

Country of ref document: EP

Kind code of ref document: A1